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Synthesis of Novel Cannabinoid Ligands and Their Use as Anti-Glioma and AntiInflammatory Agents
Abstract
Following the discovery of the cannabinoid receptors, research in the field of cannabinoids has grown
exponentially over the last two decades. Cannabinoids have been shown to have tremendous therapeutic
potential in the treatment of several pathological conditions ranging from inflammation to asthma,
multiple sclerosis, Parkinson’s disease, epilepsy, glaucoma, septic shock, hemorrhagic shock, and cancer.
Our research has focused on two major conditions for which cannabinoids hold great promise for drug
development, namely, cancer and inflammation.
Our focus in the field of cancer has been on the devastatingly lethal brain tumor glioblastoma multiforme.
Due to the high expression of the CB2 receptor in human gliomas, we chose to focus on two CB2
selective lead compounds for these studies: KM-233 (CB2 antagonist) and HB-I-172 (CB2 inverse
agonist). Both compounds showed in vitro efficacy against four human glioma cell lines (EC50s = 2.27 ±
0.18µM to 6.34 ± 4.10µM) while HB-I-172 also showed efficacy against prostate, lung, and colorectal
tumor lines (2.38 ± 0.75µM to 5.22 ± 1.2µM). Significant reductions in tumor load were also observed in
vivo in both side flank and intracranial models of glioblastoma. The anti-glioma efficacies of the two lead
compounds were not altered by pharmacologic blockade of the CB1 and CB2 receptors which points to a
non-CB1/CB2 mediated signaling pathway. This pathway was examined in the human glioma line U-87
MG and determined to involve reductions in pMEK1/2, pERK1/2, pAkt, and p-p70S6K with increases in
pGSK3B, p53, and cleaved caspases 3 and 9, and PARP. Immunohistochemical studies revealed loss of
mitochondrial membrane polarization with release of cytochrome-C, DNA fragmentation and
condensation, and alterations in cytoskeletal structure.
The current focus in the field of cannabinoids as anti-inflammatory agents is on CB2 selective
compounds which are devoid of the CNS side-effects which could limit their therapeutic usefulness. We
screened a variety of novel cannabinoids and the CB2 inverse agonist HB-I-172 emerged as a lead. In
vitrotreatment with HB-I-172 caused a significant reduction in a number of proinflammatory cytokines and
chemokines in both neoplastic lung epithelial cell and macrophage models and in primary human lung
epithelial and endothelial cells, macrophages, and microglia. We believe that HB-I-172 and other CB2
selective cannabinoids are promising treatments for a variety of inflammatory conditions from neuroinflammatory disorders such as multiple sclerosis and Huntington’s disease to systemic conditions such
as atherosclerosis and inflammatory pain.
Finally, three new series of heterocyclic cannabinoid ligands were synthesized and screened. The
hexahydro pyrimidine classical, pyrimidine nonclassical, and furanopyrimidine cannabinoids were
designed with CB2 selectivity in mind. After many failed synthetic routes were abandoned, the three new
classes were successfully generated. Many of these compounds showed good CB2 selectivity (77-fold)
and showed efficacy in both anti-glioblastoma and anti-inflammatory studies.
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Abstract
Following the discovery of the cannabinoid receptors, research in the field of
cannabinoids has grown exponentially over the last two decades. Cannabinoids have
been shown to have tremendous therapeutic potential in the treatment of several
pathological conditions ranging from inflammation to asthma, multiple sclerosis,
Parkinson’s disease, epilepsy, glaucoma, septic shock, hemorrhagic shock, and cancer.
Our research has focused on two major conditions for which cannabinoids hold great
promise for drug development, namely, cancer and inflammation.
Our focus in the field of cancer has been on the devastatingly lethal brain tumor
glioblastoma multiforme. Due to the high expression of the CB2 receptor in human
gliomas, we chose to focus on two CB2 selective lead compounds for these studies: KM233 (CB2 antagonist) and HB-I-172 (CB2 inverse agonist). Both compounds showed in
vitro efficacy against four human glioma cell lines (EC50s = 2.27 ± 0.18µM to 6.34 ±
4.10µM) while HB-I-172 also showed efficacy against prostate, lung, and colorectal
tumor lines (2.38 ± 0.75µM to 5.22 ± 1.2µM). Significant reductions in tumor load were
also observed in vivo in both side flank and intracranial models of glioblastoma. The
anti-glioma efficacies of the two lead compounds were not altered by pharmacologic
blockade of the CB1 and CB2 receptors which points to a non-CB1/CB2 mediated
signaling pathway. This pathway was examined in the human glioma line U-87 MG and
determined to involve reductions in pMEK1/2, pERK1/2, pAkt, and p-p70S6K with
increases in pGSK3B, p53, and cleaved caspases 3 and 9, and PARP.
Immunohistochemical studies revealed loss of mitochondrial membrane polarization with
release of cytochrome-C, DNA fragmentation and condensation, and alterations in
cytoskeletal structure.
The current focus in the field of cannabinoids as anti-inflammatory agents is on
CB2 selective compounds which are devoid of the CNS side-effects which could limit
their therapeutic usefulness. We screened a variety of novel cannabinoids and the CB2
inverse agonist HB-I-172 emerged as a lead. In vitro treatment with HB-I-172 caused a
significant reduction in a number of proinflammatory cytokines and chemokines in both
neoplastic lung epithelial cell and macrophage models and in primary human lung
epithelial and endothelial cells, macrophages, and microglia. We believe that HB-I-172
and other CB2 selective cannabinoids are promising treatments for a variety of
inflammatory conditions from neuro-inflammatory disorders such as multiple sclerosis
and Huntington’s disease to systemic conditions such as atherosclerosis and
inflammatory pain.
Finally, three new series of heterocyclic cannabinoid ligands were synthesized
and screened. The hexahydro pyrimidine classical, pyrimidine nonclassical, and
furanopyrimidine cannabinoids were designed with CB2 selectivity in mind. After many
failed synthetic routes were abandoned, the three new classes were successfully
generated. Many of these compounds showed good CB2 selectivity (77-fold) and
showed efficacy in both anti-glioblastoma and anti-inflammatory studies.
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Chapter 1: Introduction
1.1 History
Cannabis sativa (marijuana) is one of the oldest known herbal drugs whose
medicinal value has been exploited for centuries. The use of Cannabis sativa
preparations for treatment of a variety of pathological conditions in ancient Indian,
Chinese, and Egyptian civilizations is well-documented.1 Ancient literature is rich with
therapeutic indications for Cannabis such as its usage as an analgesic,2 an anesthetic,3 an
appetite stimulant,4 an anti-inflammatory agent,5 and as a treatment for hemorrhoids.1
Early in the nineteenth century there was a rapidly increasing interest in research
of natural products, and several alkaloids such as morphine, cocaine, and strychnine were
isolated from plant materials. The search for the psychoactive constituent of marijuana
began during this period of rapid growth in the field of pharmacognosy. It was the
common belief for many years that the principal active constituent of Cannabis sativa
was in fact an alkaloid. In 1896, however, Marshall and coworkers isolated a mixture of
terpenes from an ethereal extract of Indian hemp,6 which produced the same
pharmacological effects that are observed with Cannabis sativa use. This provided the
first evidence that the principal active compound was terpenoid in nature. In the early
1930s Cahn and coworkers isolated cannabinol (Figure 1.1) and determined a partial
structure after conducting extensive chemical degradation studies.7 This discovery was
quickly followed by the synthesis of several derivatives of cannabinol and ∆6a,10a–
tetrahydrocannabinol (∆6a,10a–THC) (Figure 1.1) by the Adams group in the US8 and the
Todd group in Britain.9 The pharmacological activities of cannabinol and ∆6a,10a–THC,
as tested by the Gayer areflexia test for suppression of corneal reflexes in the rabbit, were
observed to be similar to those of the Cannabis extract, but were significantly less potent.
The isolation and structural characterization of the principal active constituent of
Cannabis sativa, ∆9–tetrahydrocannabinol (∆9–THC) (Figure 1.2), was reported in 1964
by Gaoni and Mechoulam.10 The activity of this cannabinoid was subsequently studied in
a number of animal models. These studies ranged from evaluation of the cataleptic
reaction in mice11 to the effects on motor activity and gross behavior in mice and rats.12
There was also extensive experimentation in rhesus monkeys12 which ultimately led to
the pharmacological characterization of cannabinoids.
Following these reports, several other constituents of marijuana such as
cannabidiol, cannabigerol, cannabichromene, cannabicyclol (Figure 1.2) and related
cannabinoid acids were isolated and characterized. The structural characterization of ∆9–
THC provided a springboard to stimulate interest in research on cannabinoids. This
resulted in the design and synthesis of several structurally diverse classes of
cannabinoids. Studies on the effects of various analogues in animal models showed a
positive correlation between structure and biological activity indicating the possible
involvement of a defined receptor for the cannabinoids. This variety of compounds then
aided in the discovery and cloning of the cannabinoid receptors and the subsequent
identification of their endogenous ligands.
1

OH
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Δ6a, 10a-tetrahydrocannabinol (racemic)

Figure 1.1: Structures of cannabinol and ∆6a,10a–tetrahydrocannabinol
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Figure 1.2: Structures of ∆9–THC, cannabidiol, cannabigerol, cannabichromene, and
cannabicyclol
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1.2 Cannabinoid Receptors

The beginning of the exponential growth seen in the field of cannabinoid research
in the last 20 years can be traced to the identification, isolation and cloning of the
cannabinoid receptors. After the discovery of ∆9–THC, but before the discovery of the
cannabinoid receptors, research on cannabinoids in the late 1970s and in the early 1980s
was based on the assumption that the pharmacological effects attributed to cannabinoids
were mediated not through specific receptors but by perturbation of cellular membranes.
Due to their high lipophilicity, it was thought that cannabinoids behaved like general
anesthetics in terms of their mechanism of action.13 However, the highly stereospecific
activity associated with several cannabinoids14 suggested receptor mediated action.
Then, in 1988, Devane and coworkers15 utilized a tritium labeled synthetic cannabinoid to
tag specific sites in the brain and on neuronal cells. This then identified the presence of a
specific cannabinoid receptor in the rat brain. This discovery was finally followed by the
isolation of the cDNA of this receptor, its expression in Chinese hamster ovary (CHO)
cells, and subsequent naming as the cannabinoid receptor type 1 (CB1).16 In 1993, a
second cannabinoid receptor subtype, cannabinoid receptor type 2 (CB2), was isolated
and cloned from the human promyelocytic cell line HL60 by Munro and coworkers.17
An amino terminal variant of the human CB1 receptor has also been reported18 in which,
a 167 base portion of the CB1 coding sequence is spliced out of the mRNA. This amino
terminal variant of the CB1 receptor was named the CB1A receptor.
Whether there are additional cannabinoid receptors is still a hotly debated topic
among several researchers in this field. This is, in part, due to the observation that the
endogenous cannabinoid ligand, anandamide, induces spinal antinociception via a
different mechanism than ∆9–THC.19 In 2000, Di Marzo and coworkers carried out
studies20 using transgenic mice21 that lack the CB1 receptor to evaluate the CB1 mediated
effects of anandamide and ∆9–THC. They found that in these knockout mice anandamide
still produced CB1-like effects such as catalepsy, analgesia, and loss of spontaneous
activity whereas ∆9–THC did not. This suggested the presence of a new cannabinoid
receptor in the brain. Recent studies have also shown that a number of the cannabinoid
ligands bind to the orphan receptor GPR55.22 This receptor is reported to be expressed in
several tissues and might function in regulation of vascular tone and immune-cell
migration.22c Anandamide is also known to act on other classes of receptors such as the
vanilloid receptor TRPV1. Anandamide activates the vanilloid receptor and produces
membrane currents or increases in intracellular calcium levels.23 The presence of these
multiple sites for cannabinoid action (along with the possibility for yet undiscovered
sites) with several signaling pathways and associated second messengers is consistent
with the complex pharmacology associated with cannabinoids.
The cannabinoid receptors belong to the superfamily of G-protein coupled
receptors11 (GPCRs) and are single polypeptides with seven transmembrane α-helices, an
extracellular, glycosylated N-terminus and intracellular C-terminus. The CB1 and CB2
receptor subtypes posses 68% amino acid identity within their transmembrane regions but
only 44% identity throughout the entire peptide. The CB1 receptor is a 52.8 kDa, 472
amino acid polypeptide, which is found in both the CNS and periphery and in both neural
and non-neural tissues. CB1 is coupled to inhibitory Gi/o proteins24 which bind to its
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third intracellular loop and its C-terminus.25 The amino acid residues in transmembrane
regions 3, 5, and 6 of the CB1 receptor are believed to be involved in binding with
cannabinergic ligands.26 Activation of CB1 causes inhibition of adenylate cyclase and a
reduction in cAMP levels. Reduction of cAMP affects phosphorylation by protein kinase
A which causes modulation of ion channels and other second messengers. Activation of
voltage-sensitive outwardly rectifying K+ channels,27 inwardly rectifying K+ channels28
and inhibition of voltage gated N, L, P, and Q-type Ca2+ channels29 are observed in
response to CB1 receptor activation.
The CB1 receptor is also known to regulate different members of the mitogenactivated protein kinase (MAP kinase) family of enzymes such as:
a. extracellular signal-regulated kinase (ERK)30
b. c-Jun N-terminal kinase31
c. p38.31b,32
Activation of MAP kinases is associated with:
a. activation of immediate early genes like c-Fos and Egr1 (Krox-24)30a
b. activation of focal adhesion kinase (important for integrating cytoskeletal changes
associated with signal transduction events)
c. activation of phospholipases (PL), PLA, PLC, and PLD33
d. activation of the Na+/H+ exchanger34
e. activation of phospholipase A2, which in turn causes release of arachidonic acid
leading to the synthesis of prostaglandins.35
There is also evidence of a second pathway initiated by CB1 receptor stimulation
which is coupled with sphingomyelinase activation and subsequent release of
ceramide.30c Ceramide then causes activation of the Raf-1/MAP kinase cascade36 and
also carnitine palmitoyltransferase I in mitochondrial membranes to stimulate ketogenesis
and fatty acid oxidation.37 This elevation in levels of intracellular ceramide have also
been suggested to be one of the possible factors responsible for the apoptotic effects of
cannabinoids seen on glioblastoma cells.38
The CB2 cannabinoid receptor, also referred to as the peripheral cannabinoid
receptor, is a 41 kDa, 360 amino acid polypeptide that is predominantly expressed in the
immune system.39 Its amino acid sequence is quite different from that of CB1, especially
in the amino terminal domain where there is no significant conservation and which is
significantly shorter in the CB2 receptor when compared to the CB1 receptor. The amino
acid residues involved in ligand recognition are also found in the transmembrane domains
3, 5, and 6 for the CB2 receptor.
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Like the CB1 receptor, CB2 is also coupled to the inhibitory Gi/o proteins that bind
to its third intracellular loop and C-terminus. Activation of the CB2 receptor also causes
inhibition of adenylate cyclase and therefore a similar reduction in cAMP levels. Most of
the known signaling pathways of CB2 are identical to those observed with CB1.
However, unlike the CB1 receptor, the CB2 receptor has no effect on ion channels.28
After the discovery of the CB2 receptor it was believed that it was found only in
the immune system and was completely absent from the CNS.40 Recently, however, CB2
expression has been confirmed in the brain on microglia,41 blood vessels,41 and on some
neurons.42 CB2 is, however, expressed in much higher densities than CB1 in the immune
system. The expression level of the CB2 gene in immune tissues is 10-100 times that of
the CB1 gene.43 In fact, the CB2 mRNA content of the spleen and tonsils is almost
equivalent to the CB1 mRNA content in the CNS.43 This first led researchers to suggest
that CB2 receptor might play an important role in immune function. It is no surprise then
that many reports have been made over the years regarding the deleterious effects of
marijuana smoking on host defense mechanisms where marijuana smokers were found to
be more susceptible to bacterial and viral infections.44 Between transmembrane domains
1 and 7, including the loop regions, the CB2 receptor is only 44% identical to the CB1
receptor, making it is possible to develop selective CB2 ligands to specifically target the
immune system.
GPR55 was first identified and cloned by O’Dowd in 1999.45 It was later
identified by an in silico screen as a putative cannabinoid receptor due to an amino acid
sequence in the binding region that is similar. Research groups at the pharmaceutical
companies Glaxo Smith Kline and Astra Zeneca then extensively characterized the
receptor in the hope that it would be responsible for the blood pressure lowering effects
of cannabinoids. GPR55 is indeed activated by endogenous, phyto-, and synthetic
cannabinoids but GPR55 knockout mice generated at Glaxo Smith Kline showed no
alteration in the cannabinoid induced blood pressure regulation after administration of the
GPR55 agonist abnormal cannabidiol.
Many of the known CB1 and CB2 ligands also bind to GPR55. The receptor is
activated by phytocannabinoids such as ∆9–THC and cannabidiol,22c synthetic
cannabinoids such as CP-55,940, and the endocannabinoids anandamide, 2arachidonoylglycerol, and nolandin ether.22c Recent research suggests that
lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous
ligands for GPR5546 and the receptor appears likely to be a possible target for treatment
of inflammation and pain as with the other cannabinoid receptors.47
While the CB1 and CB2 receptors couple to Gαi/o proteins, GPR55 is coupled to
Gα13 and activation of the receptor leads to stimulation of a number of GTPases such as
Ras homolog gene family, member A (RhoA), cell division control protein 42 homolog
(cdc42) and Ras-related C3 botulinum toxin substrate 1 (rac1).22a Members of this
GTPase superfamily appear to regulate a diverse array of cellular events, including the
control of cell growth, cytoskeletal reorganization, and the activation of protein kinases.48
Stimulation of GPR55 induces F-actin formation under the control of Gα13, RhoA and
Rho-associated, coiled-coil containing protein kinase (ROCK).46b GPR55 activation also
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induces intracellular calcium release and activation of the transcription factors nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor of
activated T-cells (NFAT) and cAMP response element-binding (CREB).46b
The physiological role of GPR55 remains unclear. Mice with a target deletion of
the GPR55 gene show no specific phenotype.49 GPR55 is has been found to be widely
expressed in the brain, especially in the cerebellum. It is found in the gastrointestinal
tract in the jejunum and ileum and also in the adrenal glands but is apparently not highly
expressed elsewhere in the periphery.22c Osteoblasts and osteoclasts have also been
shown to express GPR55 and this has been shown to regulate bone cell function.50
1.3 Cannabinoids as Anti-Glioma Agents

Brain tumors are the second and fifth leading causes of cancer-related deaths in
males and females ages 20 to 39, respectively.51 The most prevalent form of adult
primary CNS tumors is collectively referred to as glioma, and the most common,
devastating, and high-grade glioma is glioblastoma multiforme (GBM).51-52 These
tumors are classically thought to originate from supporting or glial cells of the CNS, and
represent roughly fifty percent of all adult primary CNS tumors. Long term survival of
patients with a GBM diagnosis with the best radiological, surgical, and anti-tumor drug
therapy available is extremely rare. The historical median survival for GBM patients is 3
to 12 months depending on age and other prognostic factors.53
1.3.1 Current Standard of Care for Glioblastoma

CNS tumors in general are difficult to treat because of the complexities
associated with removing cancerous cells from a background of normal brain tissue
without introducing considerable neurological damage. Conventional therapy for
malignant glioma consists of complete gross resection followed by radiation, either with
or without chemotherapy. Radiation is indicated because surgical resection misses
micro populations of cells that have migrated from the primary tumor site. However,
currently accepted therapeutic adjuvants to surgery such as radiotherapy and
chemotherapy provide only a minor improvement in the disease course and life
expectancy of patients diagnosed with malignant glioma.54 The blood-brain-barrier
(BBB) prevents the use of most chemotherapeutic agents; those that are available do not
significantly impact the course of disease and often have unacceptable side effect
profiles.55 Therefore, new drugs that adequately treat high-grade glioma of the brain and
spinal cord are desperately needed if these tumors are going to be treated adequately in
the future.
1.3.1.1 Surgical Intervention

Therapeutic treatment patterns for GBM have produced limited increases in
overall survival over the last few decades. The advent of microneurosurgical techniques
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along with improvements in neuroanesthesia and perioperative care has resulted in
remarkable advancement in the management of benign tumors of the brain. However,
current surgical technique cannot adequately rid the surrounding brain tissue of
microscopic foci of high-grade glioma cells that are not visible on the post-operative MRI
scan. Although surgery is not sufficient for cure of glioma, it is a necessary component
of a multi modality approach that includes radiation and chemotherapy in some instances.
Goals of surgery for malignant glioma include: (1) establishment of a histological
diagnosis; (2) reduction in tumor cell load leading to reduced intracranial pressure; and
(3) possibly changing tumor kinetics.
1.3.1.2 Radiotherapy

Surgery alone has fallen short in providing any appreciable long-term increase in
life expectancy for patients with high-grade gliomas. Radiotherapy directed at the
gliomatous area around the surgical cavity is considered beneficial to survival outcome,
and indeed postsurgical radiation has proven to be the most effective treatment currently
available for improving survival. There is also mounting evidence to suggest that
additional radiation, given in the form of brachytherapy or radiosurgery, at initial
diagnosis as a "boost" to standard radiation or at tumor recurrence, may provide added
improvement in survival outcome.56 With advancements in radiotherapy tools and
techniques the practice of whole brain irradiation has somewhat fallen from favor as
radiation therapy results in radionecrosis not only of rapidly dividing tumor cells, but also
of surrounding healthy brain tissue. There are now two main radiotherapy delivery
techniques: (1) external stereotactic radiotherapy (SRT) boost, administered either in one
session or in fractions; and (2) brachytherapy boost by peri- or post-operative
implantation of temporary catheters or permanent isotope seeds.
1.3.1.3 Chemotherapy

At present, most centers in the United States also employ adjuvant chemotherapy
as part of a patient’s initial treatment. Current conventional chemotherapy regimens for
newly diagnosed malignant glioma include single-agent intravenous bis-chloroethylnitrosurea (BCNU; carmustine), single-agent oral procarbazine, or the PCV combination
of procarbazine, chloroethyl-cyclohexylnitrosourea (CCNU) (lomustine), and vincristine.
Since the 1980s, some but not all randomized studies have shown a small survival
advantage for patients receiving one of these chemotherapy regimens in addition to
surgery and RT.54a,b,57 A meta-analysis of published phase III randomized prospective
studies showed a modest overall survival benefit and a higher proportion of long-term (>
24 months in some studies) survivors for patients with GBM who received adjuvant
chemotherapy.58 The toxicity profile varies among these treatments, with
myelosuppression being the most frequent dose-limiting effect.55a,57 Factors limiting the
use of chemotherapy are that there are no strong predictors of chemosensitivity among
individual patients and the proper timing of upfront chemotherapy in relation to SRT for
newly diagnosed tumors has never been studied rigorously. Empirically administered
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adjuvant chemotherapy generally is begun during or shortly after completion of SRT.
Despite a variety of drugs and treatment schedules, the median time to tumor progression
for patients with GBM is 6 to 8 months, and the overall survival remains around 12
months. To date there has been no proven prolongation of time to progression or survival
for patients with malignant glioma when other drugs are added to the "standard" BCNU
or PCV chemotherapeutic regimens, including cisplatin,59 carboplatin,60
dibromodulcitol,61 mercaptopurine,62 or 6-thioguanine.63
1.3.2 Cannabinoids as Chemotherapeutic Agents for the Treatment of HighGrade Gliomas

Investigational research related to the use of cannabinoids in oncology was
primarily restricted to anti-emesis prior to the late 1980s. Although limited studies on
Lewis lung cancer and leukemia predate this time, active research on the antineoplastic
potential of cannabinoids gained increased attention following the discovery of the CB1
and CB2 receptors. Cannabinoids have now been shown to induce apoptosis in
rhabdomyosarcoma,64 colon,65 prostate66 and skin carcinomas,67 glioma,32,68
neuroblastoma,68b and lymphoma/leukemia.69 Furthermore, a decrease in tumor size
and/or cell growth inhibition has been reported in breast,66b,70 uterus,71 and lung
cancers,72 and in thyroid epithelioma.73 The ability of cannabinoids to modulate the cell
survival and death pathways in neoplasia is extremely significant from a drug
development perspective. Specifically, clinically investigated cannabinoids, in contrast
to conventional cancer chemotherapies, do not exhibit the generalized toxic effects, are
well tolerated by patients, and have the ability to penetrate the blood brain barrier. This
fledgling strategy of cancer treatment has the potential of decreasing the often severe side
effects associated with most antineoplastic agents. The future development of
cannabinoids as peripheral antineoplastic agents holds great promise, however possibly
the greatest impact in cancer therapy is the unprecedented opportunity for the
development of antineoplastic agents capable of treating malignancies in the CNS.
The CNS and associated BBB is arguably the most difficult target organ for
which drugs are developed. Despite the development of an arsenal of clinically utilized
CNS drugs, e.g. anti-depressants and anti-psychotics, highly effective chemotherapeutics
for the treatment of brain cancers such as glioblastoma remain elusive. One of the
principle factors hindering this field of drug development is the fact that many of the
otherwise efficacious natural product related antineoplastic agents are substrates for the
anti-porter proteins that are abundant in the CNS microvasculature. The established
permeability of classical cannabinoids (CCBs) through the BBB combined with the
demonstrated in vitro anti-glioma activity of several cannabinoid ligands offers an
unprecedented opportunity for drug development. Often such in vitro data does not
translate to in vivo efficacy; however our lab and others have demonstrated the
therapeutic potential of CCBs. Specifically, KM-233 and JWH-133 were highly effective
in halting the progression of human brain tumors in mice.68a,74 This is significant in that
JWH-133 and, to a lesser extent KM-233, are selective CB2 receptor ligands and a recent
report shows that primary human glioblastomas express significant levels of CB2
receptors.75 This study was conducted prior to the emergence of GPR55 in the CB field
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and as such expression levels of GPR55 were not evaluated. As stated earlier, GPR55 is
widely expressed in the CNS and increased GPR55 expression is consistent with our
Western blot analysis of GBM cell lines (see Chapter 2, Figure 2.8). Validation of
GPR55 as a target for CB based anti-neoplastic agents offers a significant advancement
in therapies targeted at GBM.
Further support for targeting the cannabinoid system comes from a pilot clinical
study using THC, a non-selective partial agonist of the CB receptors; there was a slight
improvement in survival in patients with recurrent brain cancers.76 In this study THC
was administered intratumorally which may have, in part, reduced the overall efficacy of
the treatment. Specifically, in our side flank model, administration of KM-233
intraperitoneally (i.p.) resulted in a greater reduction of tumor load compared to
intratumor injection.74b The development of cannabinoids as anti-glioma agents
represents a promising field of research into the treatment of one of the most malignant
forms of cancer whose current treatment is either ineffective or only palliative.
1.4 Cannabinoids as Anti-Inflammatory Agents

It has been shown over the last forty years, initially by examining marijuana
users, then in animal studies, and finally in cell culture, that cannabinoids are proven
immunomodulators.77 It has been known for a much longer period of time, however,
that marijuana does possess anti-inflammatory properties. In what is perhaps the earliest
literature reference to Cannabis, it is described as an anti-inflammatory agent. The
Chinese emperor Shen-nung (ca. 2000 B.C.), in a work called Pen-ts’ao Ching, noted
many of the effects of Cannabis in humans. Among other properties, he claimed that
Cannabis “undoes rheumatism”, suggesting possible anti-inflammatory effects.78
1.4.1 Cannabinoid Receptors in the Immune System

The presence of a cannabinoid receptor in cells of the immune system was known
before the discovery of CB2. In 1992, Kaminsky et al. reported the presence of the
putative cannabinoid receptor on mouse splenic cells.79 This report was supported by the
evidence of stereoselective immunomodulatory effects of cannabinoids on the splenic
cells, specific binding of tritiated CP-55,940, and by the identification of mRNA for the
receptor in the cells. Shortly after this discovery, the peripheral expression and
distribution of CB1 was examined in human tissues. Messenger RNA for the receptor
was identified in human spleen, tonsil, and peripheral blood leukocytes,80 although at
much lower levels than in the brain. The expression patterns found in the human blood
cells varied significantly by type. The order of expression level was found to be B cells >
natural killer (NK) cells > polymorphonuclear neutrophils > CD8+ T lymphocytes >
monocytes > CD4+ T lymphocytes. CB1 mRNA at varying levels was also found in a
number of monocytic and T and B leukemia cell lines, with the exception of Jurkat cells.
On average, the B cell lines were found to have higher expression levels than the T cells.
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After the discovery of the CB2 receptor in 1993, it was shown to be the dominant
cannabinoid receptor in the immune system with (at that time) no quantifiable expression
in the brain.17,39b Human tissues were examined for expression levels of CB2 and it was
found that levels of CB2 are 10-100X that of CB1 in human immune tissues.42a,81 It was
shown by Galiegue and coworkers that the level of expression of CB2 in the spleen and
tonsils was equivalent to the CB1 expression levels in the brain.43 Knowing the
physiologic function of CB1 in the CNS, the researchers drew the conclusion that the
CB2 receptor must be the major subtype responsible for the immunomodulatory effects
of cannabinoids. The order of expression of CB2 in human blood cells was reported to
be B cells > NK cells > monocytes > polymorphonuclear neutrophils > CD8+ T
lymphocytes > CD4+ T lymphocytes. Human cell lines derived from myeloid,
monocytic, and lymphoid lineages were shown to have the same rank order of CB2
density as determined by mRNA levels. The high level of mRNA in the B lymphocytes
also correlates with receptor expression on the cell surface. This was confirmed by Lynn
and Herkenham using tritiated CP-55,940.82 The CB2 receptor has also been verified to
be present on dendritic cells.83 Its presence on these potent antigen-presenting cells
suggests a possible role for cannabinoids to modulate antigen presentation. More
recently, the presence of CB2 has been reported in the CNS. Here, the CB2 receptor
plays a possible role in inflammation due to the high expression levels found in the
macrophage-like cell type microglia.84
With the recent identification of GPR55 as a putative cannabinoid receptor, its
role in cannabinoid mediated immunomodulatory effects has not been as well established
as with CB1 and CB2. While GPR55 has not been shown to be present in peripheral
blood leukocytes, it has been identified in the spleen.22c One possibly significant role for
GPR55 in immune modulation is in the CNS. In a recent report by Pietr et al., the
authors claim to have discovered the presence of mRNA for GPR55 in a primary culture
of mouse microglia and also in the mouse microglial cell line BV-2.47d,85 The possible
role of this receptor in inflammation in this cell type is supported by the observation of
altered levels of mRNA for the GPR55 receptor upon exposure to various inflammatory
stimuli. Pietr and coworkers reported that stimulation of primary microglia or BV-2 with
lipopolysaccharide (LPS) caused a concentration-dependent decrease in mRNA levels.
Differing results were seen, however, utilizing stimulation with interferon gamma (IFNγ) which caused a slight decrease in GPR55 mRNA levels in primary culture but an
increase in the BV-2 cell line.47d This observation is similar to the reported variation in
CB2 expression on microglia based on activation state.86
1.4.2 Cannabinoid Effects on Immunity

The effects elicited by cannabinoids on the immune system are mediated by the
downstream signaling cascades of the cannabinoid receptors. This is achieved mainly by
the down-regulation of cAMP formation by inhibition of adenylate cyclase (AC)
activity.87 It has been shown that lymphocyte activation and cytokine transcription in
macrophages is regulated by AC activity and the cAMP cascade.88 This is supported by
the fact that cAMP analogs can stimulate or inhibit the immune response and can also
antagonize the anti-inflammatory effects of cannabinoids.87
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The signaling cascade involved in the anti-inflammatory effects of cannabinoids
is probably not simply due to regulation of AC. This would explain why endogenous and
exogenous cannabinoids can elicit different immunomodulatory effects.
Endocannabinoids seem to have effects that are very localized, short lived, and are
stimulatory in nature.89 The endocannabinoid 2-arachidonylglycerol (2-AG), for
example, has been shown to have immunostimulatory actions such as serving as a
chemoattractant to myeloid leukemia cells, splenocytes, and microglia90 and has also
been shown to induce both chemotaxis and chemokinesis on microglia.91 There is some
evidence, however, that certain metabolically stable analogs of endocannabinoids can be
immunosuppressive. An example of this is the anandamide analog 2-methylarachidonyl(2′-fluoroethyl) amide that has been shown to suppress immune response in a model of T
lymphocyte function.92
Exogenous cannabinoids, on the other hand, have effects on the immune system
that are more generalized in nature, persist for longer periods of time, and tend to be
immunosuppressive.93 Both phytocannabinoids and synthetic cannabinoids have been
shown to have immunosuppressive effects. THC, CP-55,940, and the classical
cannabinoid analog HU-210 have all been shown to inhibit cell contact-dependent lysis
of tumor cells by macrophages, to inhibit the ability of macrophages to process antigens,
and to suppress the proliferation of both B and T lymphocytes.94 THC has also been
shown to attenuate the proliferation and maturation of cytotoxic T lymphocytes and to
suppress the activity of NK cells.94a Exogenous cannabinoids have also been reported to
cause a switch in the T helper (Th) cell profile from the Th1 phenotype to the Th2
phenotype by alteration of the cytokine / chemokine network.95 This switching of T
helper function to the anti-inflammatory Th2 phenotype is of particular interest due to the
possible therapeutic implications in autoimmune diseases. For example, blocking the Th1
cytokines and enhancing the Th2 pathways has shown promise in several animal models
of inflammatory diseases such as experimental autoimmune encephalomyelitis,81,96
experimental arthritis,97 and experimental autoimmune hepatitis.98 Exogenous
cannabinoids have also been shown to inhibit immune cell migration and recruitment,99
in contrast to the effects of endocannabinoids such as 2-AG.
The indirect effects that cannabinoids exert on immune function through
alterations in the cytokine / chemokine network have been extensively studied.77
Cytokines and chemokines are a large family of proteins that are produced by various
cells of the immune system. Their function is to alter the state or the activity of other
cells in the immune system or to direct the movement of immune cells to sites where they
are needed. Cytokines and chemokines can be broadly classified as proinflammatory or
anti-inflammatory depending upon whether their overall effect on the immune response is
stimulatory or suppressive, respectively. Much of the original work in this field was with
the classical cannabinoid THC and many results were confounding. For example, THC
has been shown to increase the processing and release of the proinflammatory cytokine
interleukin-1 (IL-1) in vitro100 and IL-1 along with proinflammatory tumor necrosis
factor-alpha (TNF-α) and IL-6 in vivo.101 On the other hand, THC has also been shown
to suppress the acute phase proinflammatory cytokines such as TNF-α, for example, in
both human and mouse macrophage cultures.77
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With the nearly ubiquitous expression of the cannabinoid receptors (especially
CB2) in the immune system it is clear why they are ever increasing targets for the
treatment of inflammatory disorders. Along with the previously mentioned cells,
cannabinoids have also been shown to have immunomodulatory effects on other cell
types such as mast cells,5,102 neutrophils,103 astrocytes,104 glia,95c,105 and neurons.95d,106
Levels of many other cytokines have been reported to be effected by cannabinoids such
as decreases in the proinflammatory proteins IFN-γ, IL-2, and IL-125 and increases in the
anti-inflammatory factors IL-4 and IL-10.107 Much of the current work with
cannabinoids in this field is focused on CB2 selective compounds which are void of the
psychotropic effects mediated by the CB1 receptor which could limit their usefulness.
Current studies on CB2 selective ligands as anti-inflammatory agents will be covered in
Chapter 5.
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Chapter 2: Anti-Glioma Activity of KM-233 and Analogs
2.1 Introduction

Due to the increasing attention given to the endocannabinoid system as a target
for the development of antineoplastic agents, we began to evaluate the anti-cancer
potential of our novel cannabinoid ligands. The initial antineoplastic work performed in
our laboratory was by Dr. Mathangi Krishnamurthy for her doctoral dissertation. She
prepared a novel series of C1'-dimethyl-aryl Δ8-tetrahydrocannabinol analogs and
evaluated the compounds for CB1 and CB2 binding.108 The compound which exhibited
the highest degree of CB2 selectivity was (6aR,10aR)-6,6,9-trimethyl-3-(2-phenylpropan2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol; designated KM-233 1 (Figure
2.1). This classical cannabinoid exhibited high affinity for the CB1 and CB2 receptors
with binding affinity constants of 12.3nM and 0.91nM, respectively. This corresponds to
a CB1/CB2 ratio of 13.5. KM-233 showed higher affinities for both the CB1 and CB2
receptors compared to Δ8-THC (Ki (CB1) = 28.5nM, Ki (CB2) = 25.0nM) with 13-fold
higher selectivity for the CB2 receptor. Introduction of a phenyl ring in the classical
cannabinoid side chain also resulted in an increase in logP from 6.08 for Δ8-THC to 6.27
for KM-233, which suggests improved blood-brain-barrier (BBB) penetrating ability.
Hence, this combination of lipophilicity and high CB2 affinity indicates that this
compound would possess significant permeation through the blood-brain-barrier as well
as good activity at the CB2 receptor and would be a viable candidate to screen for antiglioma activity.
The cytotoxic effects of KM-233 were evaluated against the human glioblastoma
multiforme cell line U-87 MG.109 Cell death was analyzed after 24, 48 and 72 hours of
exposure to the drug. KM-233 effectively killed glioma cells over a 3-day incubation
period with maximum cytotoxic effects occurring at 5µM (concentrations above 5µM not
shown) (Figure 2.2) and with the EC50 at 3.1µM. The cytotoxic effect produced by KM233 was compared with that produced by Δ8-THC (Figure 2.3) using a 5µM dose of each
drug. Although both drugs showed similar cytotoxic effects at the end of 3 days, KM233 was more effective than Δ8-THC over the first 48 hours (data not shown here). In
summary, KM-233 was shown to be as efficacious as Δ8-THC as a chemotherapeutic
agent and may have a more rapid onset of action than Δ8-THC.
Next, the cytotoxic effect of KM-233 was compared with that produced by
BCNU, a standard glioblastoma chemotherapeutic agent. For these experiments, a 5µM
dose of KM-233 was compared with escalating doses of BCNU. A 5µM dose of KM233 was far more cytotoxic than the highest dose of BCNU tested which was 300µM
(well above the typical 5µM blood level following i.v. administration in humans) (Figure
2.4). This led to the conclusion that KM-233 is superior to BCNU as a chemotherapeutic
agent for the treatment of glioblastoma in terms of its in vitro cytotoxic activity.
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Figure 2.1: The structure of KM-233 1
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Figure 2.2: Dose response curve for KM-233 on U-87 MG

C represents untreated control, D represents untreated control with 0.5% DMSO, E
represents drug treatment at concentration 0.1μM, F represents drug treatment at 1μM
concentration, G represents drug treatment at 2μM concentration, H represents drug
treatment at 3μM concentration and I represents drug treatment at 5μM concentration.
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Figure 2.3: Comparison of efficacies of KM-233 and Δ8-THC

B represents untreated control, C represents untreated control with 0.5% DMSO, D
represents effect after 1 day treatment with KM-233, E represents effect after 2 days
treatment with KM-233, F represents effect after 3 days treatment with KM-233 and G
represents effect after 3 days treatment with Δ8-THC.
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Figure 2.4: Comparison of efficacies of KM-233 and BCNU

B represents untreated control, C represents untreated control with 0.5% DMSO, D
represents treatment with 5μM KM-233, E represents treatment with 100μM BCNU, F
represents treatment with 200μM BCNU and G represents treatment with 300μM BCNU.
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2.2 Murine Flank Model

The in vitro efficacy of KM-233 was then translated into an animal model of
glioblastoma to further evaluate its potential as a chemotherapeutic agent. The first in
vivo model performed was a mouse flank model. The flank model was performed by the
Duntsch group in the Department of Neurosurgery at the University of Tennessee Health
Science Center.109 The mouse xenograft subcutaneous model was created by suspending
2 x 106 glioblastoma multiforme cells in PBS and injecting them subcutaneously into the
flank of adult SCID mice. The cell line used was U-87 MG which had been previously
transduced to express green fluorescent protein to aid in imaging of the tumor. After
seeding, the tumors were allowed to develop for 5 days and the mice were then treated
with KM-233 at a dose of 2mg/kg either intratumorally or intraperitoneally every 12
hours for 15 days. Control groups were treated with vehicle at the same frequencies and
routes of administration. The animals were sacrificed after 15 days of treatment and the
tumors removed with the aid of epifluorescence microscopy.
Once the tumors were removed, they were weighed and the weights compared
between the vehicle treated and the KM-233 treated groups. The groups treated with
KM-233, both intratumorally and intraperitoneally, showed a reduction in tumor size
when compared to the vehicle treated control groups (Figure 2.5). The group treated by
the intraperitoneal route exhibited a greater reduction in tumor size from control when
compared to the intratumorally treated group. Clinical monitoring and daily weights
were similar between groups indicating no gross deleterious effects of KM-233 when
administered locally or systemically. These results, while very promising, did not answer
the question of whether or not KM-233 could cross the BBB and be a viable candidate for
GBM therapy.
To further assess the ability of KM-233 to cross the BBB, intracranial model
studies were carried out, also by the Duntsch group. The development of a
chemotherapeutic agent against GBM that crosses the BBB provides distinct advantages
to existing agents; 1) most existing agents used against GBM do not cross the BBB, and
to achieve therapeutic levels they are generally administered directly into the tumor; and
2) direct administration may not target distant GBM foci whereas a systematically active
agent should “bathe” the brain in drug thus targeting distant foci. Therefore, the ability
of KM-233 to cross the blood brain barrier and affect a reduction in tumor load was
studied in the orthotopic U87 model of GBM.
Tumors were induced in SCID mice by direct intracranial inoculation of human
GFP-expressing U87 glioma cells. Five days following tumor cell inoculation, animals
were assigned randomly to treatment groups and injected intraperitoneally twice a day for
20 subsequent days with vehicle, 2, 4, 8, or 12 mg/kg of KM-233 formulated in 100 µl of
saline containing 3% of Cremophor and 3% of ethanol. The animals were then sacrificed
on the 25th day (20th day of treatment) and the brains prepared for confocal laser scanning
microscopy to measure tumor surface area using imaging software. As shown in Figures
2.6 and 2.7, treatment of KM-233 significantly reduced the average tumor load of each
treatment group in a dose-dependent manner as compared to untreated and vehicle treated
controls. Clinical monitoring and daily weights were similar between all controls and
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Figure 2.5: In vivo efficacy of KM-233 against human U87 glioma in the murine sidepocket model

Human glioma cells were inoculated into the flanks of nude mice (n = 4 per group). After
5 days of tumor cell incubation, groups were treated either by i.p. injection (a) or direct
injection into the tumor (b) every 12 h for 15 subsequent days with vehicle or 2 mg/kg of
KM-233. Panel c depicts an epifluorescence photomicrograph of the average size of
tumors dissected from control animals vs. animals treated with i.p. injection KM-233 and
panel d represents vehicle control vs. treated with intertumoral injection of KM-233.
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Figure 2.6: Tumor load in the U87 glioma model
Adult SCID mice bearing intracranial human U87 glioma were treated with KM-233 for
20 days. A one-way ANOVA of the untreated control vs. all treatments (symbols without
parenthesis) and vehicle control vs. drug treatment (symbols with parenthesis) was
conducted. * = p < 0.05 and # = p < 0.001.
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Figure 2.7: Dose-dependent reduction of U87 glioma after KM-233 treatment

Adult SCID mice bearing orthotopic human U87 glioma were treated with KM-233 for
20 days. Representative fluorescence micrographs showing tumor sizes in mouse brains
where: (A) untreated control (B) vehicle control; (C) 2 mg/kg KM-233; (D) 4 mg/kg KM233; (E) 8 mg/kg KM-233; and (F) 12 mg/kg KM-233. Brains were serial sectioned
(asterisks indicate areas where tumor separated from normal brain tissue) and the region
of the needle track identified. Pictures represent the largest fluorescent section within an
animal brain where measurements were taken.
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treated groups. These studies in conjunction with the flank model described above
suggest that KM-233 is safe and effective in reducing tumor load, even in the context of
the BBB, and even when given systemically. Pathology on the organs of the study
animals showed that there was no evidence of toxicity-related tissue damage due to KM233 administration. The results of this study demonstrated that KM-233 is a viable
candidate for further development as an anti-glioma agent.
2.3 Efficacy of KM-233 and Analogs against Multiple Glioma Lines

To further evaluate the potential of KM-233 as a chemotherapeutic for the
treatment of GBM, the drug was screened against four other human glioblastoma cell
lines: LN-229, T98G, DBTRG-05MG, and MT-310 (a primary GBM cell line provided
by the Department of Neurosurgery at the University of Tennessee Health Science
Center). We hypothesized that KM-233 initiated GBM cell death by ligation to one or
more of the CB receptors CB1, CB2, and/or GPR55. The first step in this study was to
determine the relative expression levels of these receptors in these cell lines along with
U-87 MG. Western blot analysis of the particulate fraction, membrane bound proteins,
and cytosolic fraction of cell lysates is shown in Figure 2.8. Consistent with earlier
reports,110 both CB1 and CB2 receptors are present in all the human GBM cell lines with
CB1 showing a lower immunohistochemical staining relative to CB2. Interestingly, the
GPR55 receptor exhibited a relative increased blotting in both the particulate and
cytosolic fractions. The presence of GPR55 in the cytosolic fraction may indicate active
synthesis of the protein or compartmental localization in the cytosol. The qualitative
analysis of the Western data was not interpreted in terms of absolute expression levels but
was used to verify the presence or absence of each receptor type.
The similarities in receptor expression patterns found in each GBM cell line may
account for the comparable efficacies of KM-233 in cytotoxicity assays against the
human GBM cell lines U-87 MG, T98G, LN-229, DBTRG-O5MG, and MT310 (Table
2.1). The EC50 values were determined using escalating doses of KM-233 and cell
viability assayed 18 hours post treatment using the CCK-8 assay which utilizes the
tetrazolium salt, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium, monosodium salt), which produces a water-soluble
formazan dye upon bioreduction in the presence of an electron carrier, 1-Methoxy PMS.
WST-8 is bioreduced by cellular dehydrogenases to an orange formazan product that is
soluble in tissue culture medium. The amount of formazan produced is directly
proportional to the number of living cells. The EC50 for KM-233 was comparable
between the cell lines with a mean EC50 of 3.44 μM. In comparison, the clinically
relevant anti-GBM agents BCNU and temozolomide were either ineffective or
manifested high micromolar EC50s (Table 2.1). Specifically, U87 and LN-229 were
sensitive to BCNU after 18 hours of exposure with EC50s of 223 and 178 μM,
respectively. All cell lines responded to BCNU following 48 hours of exposure
manifesting EC50s ranging from 119 to 305 μM. In contrast, the EC50s of KM-233
ranged from 2.3 to 4.9 μM and were effective in the 18 hour assay window.
Temozolomide was inactive against the cell lines following 18 and 48 hours exposure
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Figure 2.8: Western blots for cannabinoid receptors in human glioma cell lines

Western blots of the particulate (P) and cytosolic (C) fractions of whole cell lysates of U87 MG, T98G, LN-229, and DBTRG-O5MG. All blots are indexed to the structural
protein α-tubulin, cell lysates were divided into 3 aliquots and run on separate gels for
each receptor.
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Table 2.1: EC50 values for KM-233 and BCNU against human GBM cell lines
KM-233 18 hrs

BCNU 18 hrs

BCNU 48 hrs

Cell line

EC50 (μM) ±
S.D.

EC50 (μM) ±
S.D.

EC50 (μM) ±
S.D.

U-87 MG

3.08 ± 0.30

233 ± 5.1

156.0 ± 2.4

T98G

4.68 ± 0.45

> 1000

305 ± 1.2

LN-229

2.26 ± 0.32

178 ± 2.3

119 ± 4.2

DBTRGO5MG

2.27 ± 0.19

> 1000

124 ± 3.0

MT310

4.92 ± 1.08

n.d.

n.d.

Note: The EC50 values were obtained from three independent experiments run in
triplicate. Abreviations: n.d. = not determined.
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(data not shown). Temozolomide is pH activated in vivo and the concentration of the
active compound was not assessed and therefore these results are viewed with caution.
To further evaluate the KM-233 scaffold as an anti-GBM agent we screened a
series of substituted aryl analogs (Figure 2.9) that displayed a broad range of binding
affinities for the CB1 and CB2 receptors.111 The CB1 binding affinities ranged from 1.08
nM to 142.2 nM while the CB2 affinities ranged from 0.27 nM to 134.5 nM. The
CB1/CB2 affinity ratios ranged from 0.23 to 13.5 yielding compounds with modest
selectivity for the CB1 or CB2 receptor. To assess if receptor subtype selectively
affected cytotoxicity in the GBM cell lines, the EC50s for the 4-ethylphenyl 2, 4propylphenyl 3, 4-fluorophenyl 4, 4-chlorophenyl 5, 2-thiophenyl 6, and KM-233 were
determined (Figure 2.10). This study indicates that receptor subtype selectivity does not
affect cytotoxicity; however, due to the modest selectivity range it is not possible to
identify a specific target, i.e. CB1, CB2, or GPR55 receptor, for KM-233 or the analogs.
2.4 Receptors Involved in the Anti-Glioma Activity of KM-233

To study the contribution(s) of the CB1, CB2, and/or GPR55 receptors to the
cytotoxic effect of KM-233 we utilized pharmacological probes. The CB1 and CB2
receptors couple through Gαi whereas GPR55 couples via Gα12/13. To assess the possible
contribution of CB1 and/or CB2 to the mechanism of action of KM-233, cytotoxicity
assays were carried out using U87 cells pre-treated 18 hours before the assay with 100,
200, and 300 ng/ml of pertussis toxin (Ptx). The Ptx inactivates Gαi via catalytic ADPribosylation thus blocking G-protein-receptor interactions, whereas the Gα12/13 proteins
are Ptx-resistant. Increasing concentrations of Ptx caused a 0.75 fold average decrease in
the EC50 of KM-233 against human U87 cells (Figure 2.11). We have determined that
KM-233 is an agonist of the CB1 and an antagonist of the CB2 receptor (Figure 2.12),
both of which signal through Gαi. If KM-233 acted only through CB1 or CB2 it would,
therefore, be predicted that Ptx would block the affects of KM-233 thus the results
indicate that CB1 and CB2 do not initiate KM-233 anti-cancer activity.
The compound SR141716A is reported to be an antagonist of GPR55 that has
antagonist/inverse agonist activity (depending on the type of assay) at the CB1
receptor.11,112 The dose response curve of KM-233 in the presence of 10 μM SR141716A
(Figure 2.11) shifted the curve to the right increasing the EC50 7 fold. The shift in the
dose response curve suggests that GPR55 is a target of KM-233; however, additional
pharmacological probes need to be employeed such as cholera toxin (Ctx, constitutively
activates Gs), inhibition of the Gα12/13-RhoA-ROCK pathway (possible GPR55 mediated
pathway) with Y-27632, or decoupling Gαi with Ptx and screening GPR55 selective
ligands such as O-1602 or lysophosphatidylinsoitol (LPI). These studies are ongoing but
may not conclusively identify the mechanism(s) of KM-233 action. We have also begun
to utilize shRNA to knock-down each of these receptors to compliment the
pharmacological studies. Additionally, we are in the process of developing functional
assays for the GPR55 receptor to aid in studying the pharmacology of KM-233 and
related analogs.
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Figure 2.9: C1'-dimethyl-aryl Δ8-tetrahydrocannabinol analogs screened against human
glioblastoma cell lines
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Figure 2.10: EC50 values of KM-233 and analogs

Comparison of the EC50 values of KM-233 and analogs as a function of the CB1/CB2 Ki
ratio in five human glioma cell lines.
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Figure 2.11: Effects of KM-233 on U-87 MG in the presence or absence of Ptx and
SR141716A

Dose response curves for U-87 MG cells treated with KM-233 in the presence or absence
of 100, 200, or 300 ng/ml Ptx or 10 μM SR141716A. Data is derived from 3 independent
experiments conducted in triplicate.
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Figure 2.12: Functional activity of KM-233 at the CB1 and CB2 receptors

KM-233 does not reverse cAMP production in the CB2 assay and abolishes the activity
of CP-55,940 identifying KM-233 as an antagonist at CB2.
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2.5 Mechanistic Studies to Determine the Anti-Glioma Activity of KM-233

The second component of the mechanism(s) of human GBM cytotoxicity of KM233 is the downstream pathway(s) resulting in cell death. This is where I took over the
study of the anti-glioma activity of KM-233. In order to elucidate the mechanism(s) by
which KM-233 elicits anti-glioblastoma activity, we employed a number of techniques
including epifluorescence microscopy and protein quantification using Meso Scale
Discovery (MSD) MULTI-ARRAY® microplate technology. The MSD technology
platform consists of 96- and 384-well microplates in which there are 1, 4, 7, or 10
electrodes coated with capture antibodies. Cell lysates are added to the wells of the plate
and analytes are captured on the appropriate electrodes. The plates are then incubated
with a secondary antibody that is conjugated to ruthenium (II) tris-bipyridine-(4methylsulfonate) NHS ester that luminesces when an electrical current is applied to each
electrode within the well. The plates are imaged optically and the relative luminescent
intensity of each sample is compared. We first conducted a preliminary screen of the
effect(s) of KM-233 on pathways known to be over active in many cancers. Initially we
examined total and phosphorylated ERK1/2, JNK, p38, and, Akt using MSD plates. The
screen utilized U-87 MG cells treated with KM-233 at the EC50 (8.7 μM) to evaluate
signal cascade modulation over a 24 hour time course. It should be noted that the change
in the EC50 from the previous experiments is due to modifications made in our
cytotoxicity protocol which will be discussed in chapter 3. The preliminary screen
showed that ERK1/2 and Akt, but not JNK or p38, are downstream signals in U-87 MG
cells following KM-233 exposure (data not shown). Based on these results we analyzed
the kinetic profile of phosphorylation of MEK-ERK-STAT pathway using the MSD
triplex plate for pMEK1/2, pERK1/2, and pSTAT3. A significant increase in pSTAT3
occurred 1 hour post drug treatment (Figure 2.13) which continued thru 18 hours
followed by a rapid decline at 24 hours post drug treatment. The level of pERK1/2
(Figure 2.13) significantly decreased in 1 hour and increased from 12 to 18 hours then
declined 24 hours post treatment. The decline in pSTAT3 is of particular interest due to
its role in tumorigenesis, i.e. proliferation, angiogenesis, and inhibition of apoptosis,113
and its proposed role in immune tolerance in GBM patients,114 thus it provides a novel
target in cancer therapy.113,115 This suggest that CBs may be a novel target for the
regulation of STAT3 function via CB1 or CB2 regulation of Gαo- c-Src116 or via a GPR55
regulated Gα12/13-RhoA-ERK-STAT3 pathway.117 The level of pMEK (Ser 217, 221)
showed a significant decline at 6 hours (Figure 2.14), rebounded at 18 hours (though still
lower than control), and then significantly decreased at 24 hours. The increases in
pMEK, pERK (Thr 202, Tyr 204, Thr 185, Tyr 187), and pSTAT3 (Tyr705) in the 6 to 18
hours time interval may represent a pro-survival response to changes in pAkt and pBAD
levels. The temporal increases in pMEK and pERK from 1 to 18 hours are generally
consistent with the reported effects of HU-210 against U373MG and Neuro2a cell lines118
while the overall decrease is consistent with studies in C6 glioma cell lines.119 The
activation is reported to originate from CB1 activation based on the inhibition of
cytotoxicity by SR141716A; however, decoupling of the signal cascade by Ptx was not
studied with HU-210 thus leaving open the question of GPR55 participation. Regardless
of the molecular mechanism, the Ras-Raf-MEK-ERK pathway is a potential target for the
development of anti-cancer agents.120
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Figure 2.13: pERK and pSTAT3 profiles of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals.
Cells were scraped from the culture dishes, collected by centrifugation, lysed, and the
protein concentration per lysate was determined. Total protein added to each well of the
MSD plate was 20μg. Aliquots from this experiment were used in all the following
assays. All data points represent 3 independent determinations analyzed in duplicate. * =
p < 0.02, ** = p < 0.01, and *** = p < 0.001.
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Figure 2.14: pMEK profile of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals
and treated as defined in Figure 2.13. All data points represent 3 independent
determinations analyzed in duplicate. * = p < 0.02, ** = p < 0.01, and *** = p < 0.001.
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Interplay between the ERK1/2 and Akt pathways in C6 glioma cells was
previously reported by Ellert-Miklaszewska et al.119 To assess the contribution of Akt to
the signal cascade associated with KM-233 we utilized the pAkt-pGSK-3β-pP70S6K
MSD assay plate. Treatment of U87 cells with KM-233 triggers a significant and rapid
decrease in pAkt beginning at 6 hours and continuing through 24 hours (Figure 2.15).
Within this time interval a significant increase in glycogen synthase kinase 3 β (pGSK3β, Ser9) and a decrease in 70-kDa ribosomal protein S6 kinase (pP70S6K, Ser 217/221)
were manifested (Figure 2.16). The reduction in pAkt and pP70S6K are consistent with
the recent report by Salazar et al. wherein U-87 MG cells were treated with THC.121 The
inhibition of Akt in cancer therapy is well established; however, it has recently been
shown that knock-down of p70S6K with siRNA inhibited U-251MG glioma cells by
greater than 50 percent. The observed increase in pGSK-3β is consistent with the
reported increase in apoptosis observed with GSK-3β activation122 although Kotliarova et
al. reports that inhibition of GSK-3β induces cell death.123 In GBM cell lines it is
generally reported that regulation of Akt pathways, as well as ERK signaling, is mediated
through a Gαi/o and/or Gβ/γ pathways; however, it is possible that a Gα12/13-RhoA pathway,
and by extension GPR55, may regulate the downstream activation/inactivation of the Akt
and/or the ERK pathways. For example, Gα12/13 activation of the PI3K-Akt axis has been
proposed in neuroblastoma cells124 and a pathway involving Rho-ROCK signaling and
ERK activation has been proposed in the human GBM line LN-19.125
The down-regulation of the pro-survival kinase cascades ERK1/2 and Akt raised
the possibility that one downstream mediator may be the Bcl-2 family protein BAD.
Specifically, phosphorylation of BAD by Akt and ERK has been previously reported;126
therefore, KM-233 may suppress phosphorylation of BAD resulting in heterodimerization
with Bcl-2 death suppressors. To evaluate the effect of KM-233 on BAD
phosphorylation status we utilized the MSD pBAD (Ser 112) plate. Treatment of U-87
MG cells with KM-233 caused a significant decrease in total pBAD (Figure 2.17),
therefore it was expected that the decrease in pBAD would correlate with mitochondrial
dysfunction. One manifestation would be cytochrome C release and activation of caspase
3. To evaluate this component we employed the MSD apoptosis plate to screen cleaved
caspase 3, cleaved PARP, and total- and phospho-p53. A significant increase in cleaved
caspase 3 began at 12 hours with a rapid elevation at 18 hours post drug treatment
(Figure 2.18). There were no changes in the levels of cleaved PARP or total/phosphop53 (data not shown).
The possible contribution of mitochondrial dysfunction to the mechanism of
action of KM-233 was further evaluated using DePsipher® (Trevigen; Gaithersburg,
MD) to evaluate the collapse of the mitochondrial membrane potential (Figure 2.19).
Treatment of U87 cells with 3μM KM-233 resulted in a significant increase in
mitochondrial membrane depolarization, as indicated by the inability of the fluorescent
stain, DePsipher to form red fluorescent eximers inside mitochondria with an almost
complete depolarization a 6 hours. Mitochondrial involvement was further verified by
the observation of cytochrome C release in U-87 MG after 18 hours of exposure to KM233 at the EC50 (Figure 2.20).
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Figure 2.15: pAKT profile of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals
and treated as defined in Figure 2.13. All data points represent 3 independent
determinations analyzed in duplicate. *** = p < 0.001.
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Figure 2.16: pGSK-3β and pP70S6K profiles of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals
and treated as defined in Figure 2.13. All data points represent 3 independent
determinations analyzed in duplicate. * = p < 0.01, ** = p < 0.005, *** = p < 0.001, ****
= p < 0.0005, and ***** = p < 0.00001.
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Figure 2.17: pBAD profile of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals
and treated as defined in Figure 2.13. All data points represent 3 independent
determinations analyzed in duplicate. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001.
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Figure 2.18: Cleaved caspase 3 profile of U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals
and treated as defined in Figure 2.13. All data points represent 3 independent
determinations analyzed in duplicate. * = p < 0.05, ** = p < 0.005, and *** = p < 0.001.
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Figure 2.19: Effects on membrane polarization in U-87 MG cells treated with KM-233

Change in mitochondrial membrane polarization (Δψm) with DePsipher® - U-87 MG
cells were treated with KM-233 at the EC50 for 6 hours then stained with dual fluorescent
stain; Green fluorescence shifts to red emission following the formation of eximers
within mitochondria as stain crosses polarized outer mitochondrial membrane.
Mitochondrial depolarization by KM-233 inhibits DePsipher® permeability and
subsequent red fluorescence. Images of U-87 MG cells were collected using 568 nm
(Red) and 458 (Green) lines of a CLSM. Control (vehicle treated) cells are shown in the
A panels and 6 hours post drug treatment is shown in the B panels.
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Figure 2.20: Effects on cytochrome C release in U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 for 18 hours and evaluated for
changes in localization of cytochrome C (red); nuclei are shown in blue. Control (vehicle
treated) cells are shown in panel A and 18 hour drug treated cells are shown in panel B.
Control cells exhibit localization of cytochrome C in the mitochondria (arrows) along the
cytoskeletal network. KM-233 treated cells show a diffuse pattern of labeling (arrows)
indicating that cytochrome C has been released from the mitochondria into the cytosol.
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We also conducted a microscopic study to assess the effects of KM-233 on
cytoskeleton structure based on the known activity of RhoA and the possibility of a
GPR55 initiated mechanism. At 18 hours post KM-233 treatment the cytoskeleton
manifests profound contraction of F-actin and α-tubulin (Figure 2.21). Though it is not
possible to conclude a specific mechanism, the results provide a basis for further
evaluating RhoA-ROCK contributions to cell death.
While many of the downstream signaling pathways have been identified, the
receptor or receptors responsible for initiating the cascades are yet to be elucidated. We
have utilized pharmacological knockouts in an effort to identify the target of KM-233
action. Pharmacological intervention has distinct limitations due to overlap in activity of
known agonists and antagonists of the CB1, CB2, and GPR55 receptors. Our preliminary
data suggest that GPR55 is the target of KM-233 however this cannot be confirmed
without the selective knock-down of each CB receptor subtype. Knowledge of the target
is critical for the development of a complete mechanism of action for the antiglioblastoma activity of KM-233. The contributions of each cannabinoid receptor are
currently under investigation using shRNA stably transfected cell lines.
2.6 Experimental Methods
2.6.1 Cytotoxicity Assays

Human glioblastoma cells U-87MG, T98G, LN-229, DBTRG-O5MG (American
Type Culture Collection), and MT310 (primary GBM cell line, grade IV, a gift from Dr.
Valery Kukekov, University of Tennessee Health Science Center, Department of
Neurosurgery) were cultured in supplemented media according to the recommendations
of the supplier at 37°C in an atmosphere of 5% CO2 and 95% air. Cell lines were plated
in 96-well polystyrene flat-bottom plates (7,500 cells/well) at 70% confluency in a 100 µl
total volume of supplemented media as indicated, and incubated overnight at 37°C to
allow for adherence. The media was then replaced with media containing 1% FBS and
the cultures were inoculated with escalating amounts of drug; cell death was analyzed at
18h using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek Instruments,
Inc.). The percentage of viable cells present in the culture at each time point was
calculated by comparing the absorbance value at 450nm from the CCK-8 assay (Dojindo
Molecular Technologies) for each condition with untreated control cells. All assays were
conducted per manufacturer’s protocol. All described values represent the average of
three data points per determination and three independent determinations.
2.6.2 Cytotoxicity Assays with Pertussis Toxin

U-87 MG cells were seeded in 96-well polystyrene flat-bottom plates (7,500
cells/well) at 70% confluency in a 100 µl total volume of complete growth media and
incubated overnight at 37°C in an atmosphere of 5% CO2 and 95% air to allow for
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Figure 2.21: Effects on cytoskeleton structure in U-87 MG cells treated with KM-233

U-87 MG cells were treated with KM-233 at the EC50 and evaluated for changes in Factin (green) and α-tubulin (red), nuclei are shown in blue. Control (vehicle treated) cells
are shown in panel A and 18 hour drug treated cells are shown in panel B. KM-233
causes significant contraction of the cytoskeleton network as evidenced by the compact
F-actin around the nucleus.
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adherence. The media was then replaced with complete growth media containing 0, 100,
200, or 300 ng/ml pertussis toxin and the plates returned to the incubator for 18 hours.
Drug solutions were prepared in DMSO at 100X concentration, and mixed 1:100 in
media containing 1% FBS to yield the desired concentration. After 18 hour incubation
with or without Ptx, full serum media was removed and replaced with drug-media
mixtures and incubated for an additional 18 hours. 10μl of CCK-8 reagent was added to
each well to colorimetrically assess viability. After 2-4 hours of incubation with the
CCK-8 dye, absorbance was read at 450nm using a BioTek Synergy 2 plate reader.
2.6.3 CB1/CB2 Functional Assays

HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and
either human CB1 or CB2 receptors (BD Biosciences, San Jose, CA USA) were seeded
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well. Plates were
incubated at 37°C in 5% CO2 overnight prior to assay. Plates were then removed from
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and
1µg/ml puromycin) was replaced with 100µl DMEM containing 0.25% BSA. Next,
100µl membrane potential dye loading buffer (Molecular Devices) was added to each
well. The plates were placed back into the incubator for 30 minutes and then the baseline
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm
excitation and 590nm emission filters prior to drug addition. Drugs were added in 50µl
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM
Ro 20-1724. Plates were then incubated at room temperature for 25 minutes and
fluorescence measured again at 540nm excitation and 590nm emission.
2.6.4 MSD Protein Quantification

U-87 MG cells were plated in poly-D-lysine coated 10cm Petri dishes at a density
of 4 x 105 cells/ml with 12ml of cell suspension added to each plate. The cells were
grown overnight in EMEM media containing 10% FBS. The following day the media
was changed to EMEM media containing 1% FBS and allowed to equilibrate for 24
hours. This step is essential to allow basal levels of signaling protein to re-equilibrate
due to changes in the serum concentration. The media was then replaced at the
appropriate time points with media containing 1% serum and KM-233 at the EC50 or
media containing 1% serum and vehicle (DMSO). After the incubation period with KM233 or vehicle, the media was removed from the dishes and transferred to a 15ml
centrifuge tube to collect any cells that were in suspension. Cells were then scraped from
the surface of the dish and transferred into the same 15ml centrifuge tubes and pelleted at
1000rpm, 4oC for 5min. Supernatant was removed and 0.5ml lysis buffer was added to
each pellet. The cells were suspended in the buffer and transferred to 1.5ml
microcentrifuge tubes. These were incubated on ice for 30 minutes, being vortexed every
5 minutes. The lysates were then centrifuged at 10,000 x g, 4oC for 10 minutes to clear
cellular debris from the lysate. The supernatant was removed and assayed for protein
concentration using a Pierce BCA Protein Assay Kit (Thermo Scientific). The lysates
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were then diluted with complete lysis buffer to a concentration of 20μg of protein in 25μl
volume. Signaling proteins were then analyzed using MSD phosphoprotein and
intracellular marker multiplex kits which were imaged on a SECTOR Imager 2400 (Meso
Scale Discovery) according to the manufacturer’s instructions.
2.6.5 Mitochondrial Membrane Potential Assay

U-87 MG cells were grown in 75cm2 flasks in complete growth medium until
80% confluent. At the appropriate time points, the media was removed and replaced with
media containing 1% FBS and either KM-233 at the EC50 or vehicle (DMSO). After
incubation with drug or vehicle, cells were harvested by trypsonization and pelleted by
centrifugation. The cells were then dyed in suspension using DePsipher membrane
potential dye according to the manufacturer’s instructions. The cells were then placed on
glass slides and covered with glass cover slips. The cells were then imaged using an
Olympus BX50 microscope (Olympus America) fitted with a Bio-Rad MRC1024
confocal laser scanning system (Bio-Rad Laboratories).
2.6.6 Microscopic Analysis of Cytoskeleton and Cytochrome C Release

U-87 MG cells were plated in complete growth medium at a density of 15,000
cells/well in poly-D-lysine coated 96-well polystyrene tissue culture plates and allowed
to attach over night at 37°C in an atmosphere of 5% CO2 / 95% air. The media was then
replaced with media containing 1% FBS and either KM-233 at the EC50 or vehicle
(DMSO). The cells were returned to the incubator and after 18 hours exposure to the
drug or vehicle, media was aspirated and the cells fixed using 4% paraformaldehyde.
Cells were then stained by immunohistochemical methods using either a Cellomics
Multiparameter Cell Death Detection Kit or a Cellomics Cytoskeletal Rearrangement Kit
(Thermo Scientific) according to the manufacturer’s instructions. Plates were then
imaged using an Olympus IX71 inverted fluorescence microscope (Olympus America)
fitted with a Retiga-SRV camera (QImaging).
2.6.7 Synthesis of Compounds 1 – 6

All chemicals and reagents were purchased from Sigma–Aldrich or Thermo
Fisher Scientific Inc. Anhydrous solvents were prepared by distillation over sodium
metal or calcium hydride prior to use. Reactions were carried out under dry conditions
under an argon atmosphere. A Biotage SP1 system was used for flash chromatography
purification. Routine NMR spectra were obtained on a Varian Inova 500 MHz NMR and
were consistent with the assigned structures. Routine mass spectra were determined on a
Bruker ESQUIRE Ion Trap LC/MS system. Compounds 1 through 6 were prepared
according to the methods reported by Krishnamurthy et al.108,111 and all spectral analyses
of said compounds were in agreement with published data.
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Chapter 3: Anti-Glioma Activity of HB-I-172 and Analogs
3.1 Introduction

We have previously reported the synthesis of a small series of CB2 selective
triaryl cannabinoids.127 These compounds were designed with the goal of producing
cannabinoid ligands that would still elicit the desired physiological effects seen with
other cannabinoids (antineoplastic activity, anti-inflammatory activity, etc.) but which
would be void of the unwanted CNS side effects mediated by the CB1 receptor. These
triaryl compounds were developed by merging structural aspects of two previously
reported classes of cannabinoids. The design utilizes the C1’ aryl substitution of the
classical cannabinoid core previously reported by our laboratory with compounds such as
KM-233 and the introduction of an aryl ring in place of the terpene C ring in a series of
biaryl compounds reported by Makriyannis and co-workers as represented by the gemdimethyheptyl side chain analog compound 7128 (Figure 3.1). The design was developed
with the hypothesis that the A ring of compounds 1 and 7 occupy the same region in the
CB1 and CB2 ligand binding pockets.
In an effort to improve CB2 receptor affinity, the C ring of our triaryl cannabinoid
core possesses a 3,5-dichloro substitution. This modification was based on the
observation of Makriyannis that the 3,5-dichlo substitution pattern improves CB2
receptor affinity in the biaryl cannabinoids.128 In addition to the abovementioned
structural modifications, three types of side chain linkers: hydroxyl, carbonyl, and gem
dimethyl were utilized in the design and four compounds were synthesized and assayed
for CB1 and CB2 receptor binding affinity (Figure 3.2).
The compounds designed were hypothesized to be selective at the CB2 receptor
sub-type. This was based not only on the contribution of the 3,5-dichlorophenyl C ring
but also on the fact that the compounds comprising the phenyl series, represented by KM233, were predominantly CB2 selective. We believed that the combined increase in
electronic interactions of the substituents at both the C3 position of the phenolic A ring
and the aryl C ring in the novel core would enhance the affinity and selectivity of these
compounds to the cannabinoid receptor sub-type 2.
The four compounds initially synthesized with the novel triaryl core show
significant binding affinity to the CB2 cannabinoid receptor subtype (Table 3.1). The
receptor subtype affinity Ki values ranged from 1.07 to 4.77 nM at the CB2 receptor with
9–600 fold selectivity towards the CB2 receptor subtype. Although omission of the B
ring from the C10 phenyl substituted classical core does not seem to affect the binding
affinity to the CB2 cannabinoid receptor, there is a pronounced effect on the affinity for
the CB1 receptor as evidenced by the new analogs 8-11. The extent to which the
compounds show selectivity towards the CB2 receptor appears to depend on the
substitution pattern on ring A and the type of side chain linker at the C10 position. Our
binding affinity data show that compounds with a hydroxyl 8 and carbonyl linker
(compounds 9 and 10) retain affinity for the CB2 receptor when compared to the gem
dimethyl analog 11. The presence of the gem dimethyl group as a linker in compound 11
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Figure 3.1: Design of the novel triaryl cannabinoid core

The design utilized elements from our C1’ aryl Δ8 classical cannabinoid analogs 1 and
the biaryl cannabinoids 7 reported by Makriyannis.
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Figure 3.2: Initial triaryl cannabinoids

Initial novel triaryl cannabinoids synthesized and screened for receptor binding affinity.
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Table 3.1: Binding affinity (Ki) of compounds 8-11 for the CB1 and CB2 receptors
compared to KM-233 1 and Δ8-THC
Compound

CB1 Ki (nM)

CB2 Ki (nM)

CB1/CB2 Ratio

Δ8-THC

28.5 (± 3.3)

25.0 (± 4.8)

1.1

KM-233 1

12.3 (± 0.61)

0.91 (± 0.08)

13.5

8

> 1000

1.66 (± 0.38)

> 602.4

9

> 1000

4.77 (± 0.57)

> 209.6

10

27.0 (± 2.30)

2.94 (± 1.69)

9.2

11

93.66 (± 2.33)

1.07 (± 0.05)

87.5

Notes: Values are the mean of three experiments run in triplicate; standard deviation is
given in parentheses. CB1/CB2 ratio is expressed as Ki for CB1 / Ki for CB2.
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results in a CB2 selective compound with a Ki value of 1.07 nM at the CB2 receptor
compared to 93.66 nM at the CB1 receptor subtype (CB1/CB2 = 87.5). Compound 8,
which was initially viewed as a synthetic intermediate, gave perhaps the most significant
finding. This compound showed high binding affinity for the CB2 receptor with a Ki of
1.66 nM and exhibited a high 600-fold selectivity for the CB2 receptor. The introduction
of a C10 hydroxyl or carbonyl group in classical cannabinoids has not been extensively
investigated; however, previous findings by our group108,129 and by Papahatjis and
coworkers130 indicate that these C10 substituents reduce cannabinoid receptor affinity.
Interestingly, binding affinity data for these first four compounds show that the carbonyl
and hydroxyl substituents at the C10 position selectively decrease CB1 receptor affinity
without altering CB2 receptor binding. The beneficial effect of the C10 equivalent
hydroxyl, as well as the carbonyl, in CB2 receptor affinity may reflect that the removal of
the pyran ring provides greater conformational flexibility thus allowing for more
favorable receptor interactions at CB2, or that the triaryl compounds possess a different
binding orientation relative to classical cannabinoids.
3.2 SAR of Triaryl Cannabinoids

To begin to develop an SAR (structure activity relationship) of this new triaryl
class of cannabinoids, five more compounds were synthesized. Compounds 12-16
(Figure 3.3) completed the possible permutations of the three types of side chain linkers:
hydroxyl, carbonyl, and gem-dimethyl, combined with the three substitution patterns on
the A ring: dimethoxy, methoxy-hydroxy, and dihydroxy. These compounds were then
screened for receptor binding affinity and functional activity at the CB1 and CB2
receptors.
After the remaining compounds were synthesized and evaluation of their affinity
to the CB1 and CB2 receptors had begun, compound 10 was screened again. The results
were contradictory to the previously published values. The Ki values for both CB1 and
CB2 increased significantly from 27.0 (± 2.30)nM to 6040 (± 1477)nM and from 2.94 (±
1.69)nM to 487 (± 101)nM, respectively. At first, it was suspected that there was some
error in the more current assay technique or analysis. However, after performing several
Scatchard analyses on the membrane preparations and screening several well
characterized cannabinoids such as Δ8-THC and CP-55,940, the current analytical
techniques were validated. The remaining three original compounds (8, 9, and 11) were
reevaluated for their receptor binding affinities and these values (along with compounds
12-16) are summarized in Table 3.2. There has been, as yet, no sufficient explanation as
to the differences between the current Ki values and those previously reported.
A general SAR concerning the side chain linker and the substitutions on the A
ring for this class of compounds can be easily developed from the binding data. First, the
A ring must possess at least one hydroxyl group with two being ideal for maximum
affinity at both the CB1 and CB2 receptors. The three dimethoxy analogs 8, 14, and 15
showed very little binding at either receptor with Ki values above 10,000nM while the
methoxy-hydroxy analogs 9 and 16 possessed detectable binding at the CB1 receptor
with Ki values of 7235 (± 3056)nM and 206 (± 130)nM and at CB2 with values of 2439
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Figure 3.3: Nine triaryls used to develop SAR of this new class of cannabinoids
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Table 3.2: Binding affinity (Ki) of compounds 8-16 for the CB1 and CB2 receptors
compared to KM-233 1 and Δ8-THC
Compound

CB1 Ki (nM)

CB2 Ki (nM)

CB1/CB2 Ratio

Δ8-THC

28.5 (± 3.3)

25.0 (± 4.8)

1.1

KM-233 1

12.3 (± 0.61)

0.91 (± 0.08)

13.5

8

> 10,000

> 10,000

n.d.

9

7235 (± 3056)

2439 (± 639)

3.0

10

6040 (± 1477)

487 (± 101)

12.4

11

250 (± 49)

7.67 (± 3.14)

32.6

12

> 10,000

> 10,000

n.d.

13

> 10,000

3382 (± 1389)

> 3.0

14

> 10,000

> 10,000

n.d.

15

> 10,000

> 10,000

n.d.

16

206 (± 130)

66.0 (± 17.2)

3.1

Notes: Values are the mean of three experiments run in triplicate; standard deviation is
given in parentheses. CB1/CB2 ratio is expressed as Ki for CB1 / Ki for CB2. n.d. = not
determined when there is no specific Ki that can be determined for either CB1 or CB2.
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(± 639)nM and 66.0 (± 17.2)nM, respectively. The methoxy-hydroxy compound 12
which has a hydroxyl side chain linker, on the other hand, still possesses very low affinity
for each receptor with Ki values above 10,000nM. The three compounds possessing the
dihydroxy substituted A ring were the best binders at each receptor subtype. Compound
11 which has the gem-dimethyl linker displayed the highest affinity for CB1 (Ki = 250 (±
49)nM) and for CB2 (Ki = 7.67 (± 3.14)nM) while the hydroxyl side chain compound 13
possessed very low affinity for CB1 (Ki > 10,000nM) and only very modest affinity for
CB2 (Ki = 3382 (± 1389)nM). Examining within each set of three compounds that have
the same substitution pattern on the A ring: the dimethoxy (8, 14, and 15), the methoxyhydroxy (12, 9, 16), and the dihydroxy (13, 10, and 11), it becomes clear that the side
chain linker has a very profound effect on the binding affinity of the triaryl cannabinoids.
The rank order for the highest affinity to both CB1 and CB2 is gem-dimethyl > ketone >
hydroxyl. The negative effects on binding contributed by the hydroxyl linker is perhaps
the most significant deviation from the originally reported data which showed that
compound 8 retained high affinity for CB2 (Ki = 1.66 (± 0.38)nM). It is also worth
noting that while all of the compounds with detectable affinity were CB2 selective, none
were as selective as the previously reported values for compounds 8 and 9 (> 602.4 and >
209.6, respectively). Compound 11 which showed the highest affinity for each receptor
also has the highest level of CB2 selectivity with a Ki (CB1) / Ki (CB2) ratio of 32.6. The
next most CB2 selective compound was 10 with a ratio of 12.4.
3.3 Antineoplastic Activity of Triaryl Cannabinoids and Selection of HB-I-172

Due to reported efficacy of cannabinoids against a wide range of cancers,72a,131 it
was decided to screen the nine triaryl analogs against a panel of varied human neoplastic
cell lines. The compounds were tested against human lung (H69AR), prostate (DU-145
and PC-3), colorectal (HCT-15), glioma (U-87 MG, LN-229, T98G, and DBTRG-05MG)
and pancreatic (BxPC-3) cancer cell lines (Tables 3.3 and 3.4). The dimethoxy-ketone
14 and dimethoxy-dimethyl 15 analogs were quickly eliminated due to a lack of
solubility in the cytotoxicity assay conditions. All but one of the remaining seven triaryls
exhibited broad spectrum antineoplastic activity against all cell lines tested. Compound
13, the dihydroxy-hydroxy analog, was efficacious only against the PC-3 prostate
carcinoma line and two glioblastoma lines: U-87 MG and LN-229. Even though
compound 13 lacked broad spectrum activity, it proved to be potent against the
susceptible cancers with EC50s ranging from 4.63 to 5.10µM. Compounds 8, 9, 10, 11,
12, and 16 were active against all cancers screened with EC50s ranging from 0.30 to
6.34µM. These results were unexpected considering the vast range in binding affinity of
these compounds for the CB1 and CB2 receptors. This finding is evidence for the
possibility that the antineoplastic activity of the triaryls is mediated through a receptor
other than the cannabinoid receptor subtypes 1 and 2.
To begin to elucidate the antineoplastic mechanism of action of this new class of
cannabinoids we needed to pick one lead compound for the studies. We decided to
evaluate their metabolic stability in order to select a compound that could potentially be
evaluated in vivo. Phase I metabolism studies were performed in the lab of Dr. Bernd
Meibohm at the University of Tennessee Health Science Center with an in vitro method
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Table 3.3: Efficacy of three triaryl cannabinoids against a variety of human cancer cell
lines
Compound
8
EC50 (µM) ±
S.D.

Compound
12
EC50 (µM) ±
S.D.

Compound
13
EC50 (µM) ±
S.D.

DU-145
prostate

5.07 (± 0.30)

3.72 (± 0.83)

n.a.

PC-3
prostate

3.47 (± 1.36)

4.08 (± 0.82)

4.63 (± 0.63)

H69AR
lung

6.30 (± 0.19)

5.16 (± 0.53)

n.a.

HCT-15
colorectal

5.43 (± 0.73)

3.74 (± 0.57)

n.a.

BxPC-3
pancreatic

3.28 (± 1.21)

2.49 (± 0.28)

n.a.

U-87 MG
glioma

4.67 (± 0.23)

3.13 (± 0.31)

4.94 (± 0.11)

LN-229
glioma

2.57 (± 0.19)

1.93 (± 0.09)

5.10 (± 0.18)

T98G
glioma

5.20 (± 0.69)

5.29 (± 2.39)

n.a.

n.a.

5.03 (± 1.10)

n.a.

Cell Line

DBTRG-05MG
glioma

Note: The EC50 values were obtained from three independent experiments run in
triplicate; standard deviation is given in parentheses. Compounds 14 and 15 were not
screened due to insolubility in assay conditions. Abreviations: n.a. = not active.
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Table 3.4: Efficacy of four triaryl cannabinoids against a variety of human cancer cell
lines
Compound
9
EC50 (µM) ±
S.D.

Compound
10
EC50 (µM) ±
S.D.

Compound
16
EC50 (µM) ±
S.D.

Compound
11
EC50 (µM) ±
S.D.

DU-145
prostate

4.45 (± 0.35)

2.38 (± 0.75)

2.56 (± 0.63)

2.46 (± 0.46)

PC-3
prostate

1.96 (± 0.32)

3.83 (± 0.62)

2.90 (± 0.55)

1.83 (± 0.24)

H69AR
lung

3.49 (± 0.66)

5.22 (± 1.12)

3.34 (± 0.39)

1.73 (± 0.13)

HCT-15
colorectal

2.23 (± 0.07)

4.40 (± 1.03)

2.42 (± 0.37)

2.09 (± 0.46)

BxPC-3
pancreatic

2.47 (± 0.20)

4.60 (± 0.11)

4.32 (± 0.74)

2.18 (± 0.39)

U-87 MG
glioma

2.01 (± 0.27)

2.90 (± 0.27)

2.68 (± 0.74)

1.20 (± 0.58)

LN-229
glioma

1.29 (± 0.40)

4.63 (± 1.10)

1.14 (± 0.08)

0.30 (± 0.06)

T98G
glioma

3.15 (± 0.75)

4.25 (± 0.26)

2.34 (± 0.49)

3.69 (± 0.74)

6.20 (± 3.33)

6.34 (± 4.10)

4.73 (± 1.94)

2.18 (± 1.92)

Cell Line

DBTRG-05MG
glioma

Note: The EC50 values were obtained from three independent experiments run in
triplicate; standard deviation is given in parentheses. Compounds 14 and 15 were not
screened due to insolubility in assay conditions.
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utilizing rat liver microsomal preparations. The criteria used for selecting acceptable
compounds would be that at least 30% of the parent drug must remain after a 90 minute
incubation with the microsomes. The results of that study narrowed the compounds to
three potential candidates: 10, 12, and 13 with 45.3, 38.7, and 42.1% remaining,
respectively. Compound 13 was eliminated due to the previously mentioned lack of
broad spectrum activity and compound 12 was dropped from consideration because of the
presence of a chiral center in this molecule. The development of an asymmetric ligand
with therapeutic potential requires efficacy and toxicology studies on each isomer along
with the racemic mixture. The synthesis of each chirally pure isomer can be expensive or
the attempted separation of the isomers from the mixture can be very difficult and time
consuming. Therefore, compound 10 (henceforth named HB-I-172) was selected to
proceed into studies to determine the mechanism of action of these compounds and to
determine the receptor responsible for the antineoplastic efficacy.
3.4 Receptors Involved in the Anti-Glioma Activity of HB-I-172

Based on our previous experience with both in vitro and in vivo models of
glioblastoma multiforme,109,111 it was decided to focus on this particular type of neoplasm
for our further studies. We hypothesized that HB-I-172 initiated GBM cell death by
ligation to one or more of the CB receptors CB1, CB2, and/or GPR55. The first step in
our target receptor studies was to determine the relative expression levels of the receptors
in the human GBM lines U-87 MG, T98G, LN-229, and DBTRG-O5MG. Western blot
analysis of the particulate fraction (membrane bound proteins) and cytosolic fraction of
cell lysates is shown in Figure 3.4. Consistent with earlier reports,110b,132 both CB1 and
CB2 receptors are present in all the human GBM cell lines with the CB1 showing a lower
immunohistochemical staining relative to CB2. Interestingly, the GPR55 receptor
exhibited a relative increased blotting in both the particulate and cytosolic fractions. The
presence of GPR55 in the cytosolic fraction may indicate active synthesis of the protein
or compartmental localization in the cytosol. The qualitative analysis of the Western data
is not interpreted in terms of absolute expression levels but is used to verify the presence
or absence of each receptor type. The similarities in receptor expression patterns found
in each GBM cell line may account for the comparable efficacies of HB-I-172 against the
four human GBM cell lines screened.
To study the contribution(s) of the CB1, CB2, and/or GPR55 receptors to the
cytotoxic effect of HB-I-172 we utilized pharmacological probes. The CB1 and CB2
receptors couple through Gαi whereas GPR55 couples via Gα12/13. To assess the possible
contribution of CB1 and/or CB2 to the mechanism of action of HB-I-172, cytotoxicity
assays were carried out using U87 cells pre-treated 8 hours before the assay with
100ng/ml of pertussis toxin (Ptx). The Ptx inactivates Gαi via catalytic ADP-ribosylation
thus blocking G-protein-receptor interactions, the Gα12/13 proteins are Ptx-resistant. The
decoupling of CB1 and CB2 from Gαi using Ptx caused an insignificant increase in EC50
of HB-I-172 against human U87 cells (Figure 3.5). We have determined that HB-I-172
is an antagonist of the CB1 receptor (binding affinity Ki = 6040 (± 1477)nM) and an
inverse agonist (EC50 = 361nM) of the CB2 receptor (binding affinity Ki = 487
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Figure 3.4: Western blots for cannabinoid receptors in human glioma cell lines

Western blots of the particulate (P) and cytosolic (C) fractions of whole cell lysates of U87 MG, T98G, LN-229, and DBTRG-O5MG. All blots are indexed to the structural
protein α-tubulin; cell lysates were divided into 3 aliquots and run on separate gels for
each receptor.
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Figure 3.5: Effects of HB-I-172 on U-87 MG in the presence or absence of Ptx

Dose response curves for U-87 MG cells treated with HB-I-172 in the presence or
absence of 100 ng/ml Ptx. The EC50 manifested a slight shift from 13.4 to 17.6µM in the
presence of Ptx. Data is derived from 3 independent experiments conducted in triplicate.
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(± 101)nM) coupling through Gαi (Figure 3.6). If the antineoplastic activity is initiated
by CB1 or CB2 it would be predicted that Ptx would block the effects of HB-I-172 thus
the results indicate that CB1 and CB2 do not play a role in HB-I-172 anti-cancer activity.
Selective pharmacological inhibition of the three receptors is not a viable
approach to identifying the target receptors. Specifically, the CB1 antagonist AM-251 is
an agonist of GPR55, and SR141716A is reported to be either an agonist or antagonist of
GPR55, depending on assay conditions.85 The selective CB2 antagonist/inverse agonist
SR144528 to our knowledge has not been tested against GPR55; however, the inverse
agonist activity at CB2 is the same as HB-I-172 and as such would not unambiguously
help in identifying the target receptor. We are currently developing lines of U-87 MG
that are stably expressing shRNA to knock-down each of the three receptors in an effort
to overcome the limitations of pharmacological knock-downs.
3.5 Comparison of HB-I-172 to Standard GBM Treatments

During the course of a study utilizing immunohistochemical staining techniques
to microscopically analyze the cytotoxic activities of other compounds prepared in our
laboratory, it was discovered that the previously utilized method for determining
cytotoxicity possessed an inherent error. In this method, cells were plated in 96-well
polystyrene plates and allowed to attach overnight in an incubator. The complete growth
media was then replaced with serum-free media (100µl) before drug addition. Small
volumes of drug solutions (1µl) prepared in DMSO were then pipetted into the
appropriate wells. The small ratio of drug solution to media did not allow for proper
mixing and dilution of the drug and allowed for a much higher localized concentration of
the test compounds in certain areas of the well. Figure 3.7 illustrates this finding. This
micrograph is of LN-229 that has been treated with KM-233 at the EC50. It is evident
that there is a disparity in the effects that the drug has on cells within this one field of
view. In another set of experiments designed to evaluate the activity of caspase 3 in
glioma cells treated with KM-233, we found that exposure to serum-free media during
the drug incubation period increases the activity of caspase 3 separate and apart from any
effect of the drug.
With the knowledge obtained from these two experiments, we developed a
revised method for determining cytotoxicity of our compounds. The drug solutions are
premixed in media containing 1% serum and added after the removal of the complete
growth media. This allows for thorough mixing of the test compounds with the media
and the small amount of serum reduces the interference with the basal metabolic activity
observed in serum-free conditions.
We then screened HB-I-172 against U-87 MG and LN-229 utilizing the new
method. We also tested two clinically relevant compounds, BCNU and temozolomide,
under these conditions for comparison. We observed a 4.6 and 2.1 fold increase in the
EC50 of HB-I-172 against U-87 MG and LN-229, respectively. In comparison, BCNU
and temozolomide were either ineffective or manifested high micromolar EC50s (Table
3.5). Specifically, U87 and LN-229 were sensitive to BCNU after 18 hours of exposure
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Figure 3.6: Functional activity of HB-I-172 at the CB1 and CB2 receptors

HB-I-172 does not reverse cAMP production in the CB1 ActOne© assay and shifts the
response curve of CP-55,940 to the right identifying HB-I-172 as an antagonist at CB1.
The increase in response in the CB2 assays is indicative of inverse agonist activity.
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Figure 3.7: Inefficient mixing of drug solutions with media in cytotoxicity assays

Representative immunofluorescence micrograph of LN-229 GBM cells treated with KM233 at the EC50 imaged using a 10X objective. The labels are: cytochrome C (red), DAPI
nuclear stain (blue), and whole cell stain (green). Cells with dysfunctional cell
membranes show increased permeability so that the double stained nucleus appears cyan
color (white arrows). The effects due to localized concentration of KM-233 can be easily
observed in the upper right hand corner of the micrograph while the cells in the
remainder of the image are relatively unaffected.
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Table 3.5: Efficacy of HB-I-172 against U-87 MG and LN-229
HB-I-172 18 hrs

BCNU 18 hrs

BCNU 48 hrs

Cell Line

EC50 (μM) ±
S.D.

EC50 (μM) ±
S.D.

EC50 (μM) ±
S.D.

U-87 MG

13.4 (± 0.98)

233 (± 5.1)

156.0 (± 2.4)

LN-229

9.74 (± 0.56)

178 (± 2.3)

119 (± 4.2)

Note: The EC50 values were obtained from three independent experiments run in
triplicate; standard deviation is given in parentheses.
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with EC50s of 223 and 178 μM, respectively. Following 48 hours of exposure to BCNU
the EC50s decreased to 156 and 119µM. In contrast, the EC50s of HB-I-172 were found
to be 13.4 and 9.74µM for U-87 MG and LN-229, respectively, and were effective in the
18 hour assay window. Temozolomide was inactive against the cell lines following 18
and 48 hours exposure (data not shown). Although temozolomide is pH activated, the
concentration of the active compound was not assessed and therefore these results are
viewed with caution.
3.6 Mechanistic Studies to Determine the Anti-Glioma Activity of HB-I-172
3.6.1 Methods and Results

The second component of the mechanism(s) of human GBM cytotoxicity of HBI-172 is the downstream pathway resulting in cell death. To evaluate the downstream
signal cascade(s) we utilized a combination of fluorescence microscopy and protein
quantification using Meso Scale Discovery (MSD) MULTI-ARRAY® microplate
technology. We first conducted a preliminary screen of the effect(s) of HB-I-172 on total
and phosphorylated ERK1/2, JNK, p38, and, Akt using MSD plates. The screen utilized
U-87 MG cells treated with HB-I-172 at the EC50 (13.4μM) to evaluate signal cascade
modulation over a 24 hour time course. The preliminary screen showed that ERK1/2 and
Akt, but not JNK or p38, are downstream signals in U-87 MG cells following HB-I-172
exposure (data not shown). Based on these results we analyzed the kinetic profile of
phosphorylation of the MEK-ERK-STAT pathway using the MSD triplex plate for
pMEK1/2 (Ser217/221), pERK1/2 (Thr202/Tyr204 and Thr185/Tyr187), and pSTAT3
(Tyr705). Cells were cultured in 10cm Petri dishes using media containing 1% serum for
24 hours to equilibrate intracellular signaling cascades. The media was replaced after
equilibration with either media containing 1% serum and vehicle alone (DMSO) or media
containing 1% serum and HB-I-172. The level of pMEK1/2 showed a significant decline
in relative intensity 1 hour after the change in media in both control and drug treated cells
(Figure 3.8). The control cells manifested a return to basal levels at 6 hours; however,
HB-I-172 significantly reduced pMEK1/2 levels throughout the remainder of the
experiment.
The levels of pERK1/2 exhibited a similar decline 1 hour post media change in
both groups (Figure 3.9). Unlike pMEK1/2, the control group exhibited a significant
increase in pERK1/2 at 6 hours that continued the remainder of the experiment. The
effect of HB-I-172 on pERK1/2 however caused a significant and lasting decrease in
relative levels. The Ras-Raf-MEK-ERK pathway is a potential target for the
development of anti-cancer agents.120 The precise mechanism whereby HB-I-172
inhibits ERK phosphorylation remains to be determined. Due to the observed decrease in
activated MEK, it must be further upstream in the signaling cascade. We do not believe
that the response is due to Ras-Raf since we would predict an increase in pERK1/2 with
decreased pAkt (see below), i.e. pAkt negatively regulates Raf thus an increase in
pERK1/2 is predicted.133
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Figure 3.8: pMEK1/2 profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
Cell cultures were plated for 24 hours; the media changed to 1% serum for 24 hours to
equilibrate intracellular pathways, then media was changed to either media containing 1%
serum or media containing 1% serum plus HB-I-172. At the designated time intervals
cells were scraped from the dishes, collected by centrifugation, the pellet lysed, and the
protein concentration per lysate was determined. Total protein added to each well of the
MSD plate was 20μg. Aliquots from this experiment were used in all the following
pathway assays. All data points represent 3 independent determinations analyzed in
duplicate. Dashed lines indicate comparisons between control samples and solid lines
between control and drug treated samples. * = p < 0.001.
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Figure 3.9: pERK1/2 profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Dashed lines indicate comparisons
between control samples and solid lines between control and drug treated samples. * = p
< 0.001.
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Interplay between the ERK1/2 and Akt pathways in C6 glioma cells was
previously reported by Ellert-Miklaszewska et al.119 To assess the contribution of Akt to
the signal cascade associated with HB-I-172 we utilized the MSD Akt Signaling Panel
which measures pAkt, pGSK-3β, and p-p70S6K. Treatment of U-87 MG cells with HBI-172 triggers a significant and rapid decrease in pAkt (Ser 473) beginning at 1 hour and
continuing through 24 hours (Figure 3.10). Within this time interval a decrease in
phosphorylated 70-kDa ribosomal protein S6 kinase (p-p70S6K, Ser 217/221) (Figure
3.11) was observed along with a significant decrease in the Akt target glycogen synthase
kinase 3 beta (pGSK-3β, Ser 9) (Figure 3.12) at 1 and 6 hours followed by a highly
significant increase in GSK-3β phosphorylation beginning at 18 hours post treatment.
The reductions in pAkt and p-p70S6K are consistent with the recent report by
Salazar et al. wherein U-87 MG cells were treated with THC.134 The inhibition of Akt in
cancer therapy is well established; however, it has recently been shown that knock-down
of p70S6K with siRNA inhibited U-251 MG glioma cells by greater than 50 percent. The
observed increase in pGSK-3β is consistent with the reported increase in apoptosis
observed with GSK-3β activation122 although Kotliarova et al. report that inhibition of
GSK-3β induces cell death.123 In GBM cell lines it is generally reported that regulation
of Akt pathways, as well as ERK signaling, is mediated through a Gαi/o and/or Gβ/γ
pathway; however, it is possible that a Gα12/13-RhoA pathway, and by extension GPR55,
may regulate the downstream activation/inactivation of the Akt and/or the ERK
pathways. For example, Gα12/13 activation of the PI3K-Akt axis has been proposed in
neuroblastoma cells124 and a pathway involving Rho-ROCK signaling and ERK
activation in the human GBM line LN-19.125
The reduction in pERK1/2 could significantly impact the activity of cancer
survival and gene expression pathways, for example p90RSK-BAD, p53, NF-κB,
STAT1/3, Elk-1, and/or c-fos. Three of these pathways, p53, BAD, and STAT1/3 were
evaluated using MSD technology. A significant decrease in pSTAT3 occurred at 1 hour
in both treatment groups (Figure 3.13). The levels of pSTAT3 recovered by 12 hours;
however, thereafter HB-I-172 caused a significant decrease in pSTAT3 levels relative to
controls. The decline in pSTAT3 is of particular interest due its role in tumorigenesis,
i.e. proliferation, angiogenesis, and inhibition of apoptosis,113 the proposed role in
immune tolerance in glioblastoma patients,114 and provides a novel target in cancer
therapy.113,115 This suggests that cannabinoid receptors may be a novel target for the
regulation of STAT3 function via CB1 or CB2 regulation of Gαo- c-Src116 or via a GPR55
regulated Gα12/13-RhoA-ERK-STAT3 pathway.117
The effect of HB-I-172 on the tumor suppressor protein p53 was determined using
the MSD Multiplex Apoptosis Panel which measures levels of p53, p-p53 (Ser 15),
cleaved PARP and cleaved caspase-3. Treatment of U-87 MG cells with HB-I-172
caused a significant increase in levels of both total p53 (Figure 3.14) and phospho-p53
(Figure 3.15) beginning 1 hour post treatment and continuing for the duration of the 24
hour experiment. This increase is probably a result of the decrease in ERK1/2 which
suggests a negative regulation of p53 by ERK. This agrees with previous reports that
also observed increases in p53 following suppression of ERK.135 This increase in p53 is
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Figure 3.10: pAkt profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Dashed lines indicate comparisons
between control samples and solid lines between control and drug treated samples. * = p
< 0.005, ** = p < 0.0005, *** = p < 0.00001.
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Figure 3.11: Phospho-p70S6K profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Dashed lines indicate comparisons
between control samples and solid lines between control and drug treated samples. * = p
< 0.05, ** = p < 0.005, *** = p < 0.001, **** = p < 0.00001.
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Figure 3.12: pGSK-3β profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Solid lines indicate comparisons
between control and drug treated samples. * = p < 0.01, ** = p < 0.001, *** = p <
0.0005.
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Figure 3.13: pSTAT3 profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Dashed lines indicate comparisons
between control samples and solid lines between control and drug treated samples. * = p
< 0.0005, ** = p < 0.000005, *** = p < 0.00000005.

69

Figure 3.14: p53 profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Solid lines indicate comparisons
between control and drug treated samples. * = p < 0.005, ** = p < 0.0001, *** = p <
0.000001.
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Figure 3.15: Phospho-p53 profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Solid lines indicate comparisons
between control and drug treated samples. * = p < 0.005, ** = p < 0.001, *** = p <
0.0001.
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of interest due to its role in suppression of tumor proliferation by initiating cellular
senescence136 and its ability to initiate apoptosis.137
The down-regulation of the pro-survival kinase cascades ERK1/2 and Akt raised
the possibility that one downstream mediator of glioblastoma cytotoxicity due to HB-I172 may be the Bcl-2 family protein BAD. Specifically, phosphorylation of BAD by Akt
and ERK has been previously reported;126 therefore, HB-I-172 may suppress
phosphorylation of BAD resulting in heterodimerization with Bcl-2 death suppressors.
To evaluate the effect of HB-I-172 on BAD phosphorylation status we utilized the MSD
Phospho (Ser 112)/Total BAD assay. Treatment of U-87 MG cells with HB-I-172 caused
a significant decrease in BAD phosphorylation at 6 hours post-exposure (Figure 3.16).
It was expected that the decrease in pBAD would correlate with mitochondrial
dysfunction. One manifestation would be cytochrome C (cytC) release and activation of
caspase 3. To evaluate this component we employed the previously mentioned MSD
Apoptosis Panel. A rapid and significant increase in cleaved caspase 3 began at 6 hours
post-drug treatment and persisted until the end of the experiment (Figure 3.17). The
increase in caspase 3 activity is followed downstream by activation of caspase 9 twelve
hours later at the 18 hour time point as determined by the Caspase-Glo® 9 Assay System
from Promega (Figure 3.18). This probably accounts for the further increase in cleaved
caspase 3 at the 24 hour time point as caspase 9 cleaves procaspase 3 into the active
enzyme.
Coinciding with the increase in caspase 3 activity, the same rapid increase at 6
hours was observed in the level of cleaved PARP (Figure 3.19). The increase in cleaved
PARP is of interest due to its ability to potentiate apoptosis by depleting the intracellular
supply of ATP and also to independently initiate apoptosis by production of poly(ADPribose) which stimulates mitochondria to release apoptosis inducing factor.138
The possible contribution of mitochondrial dysfunction to the mechanism of
action of HB-I-172 was further evaluated using DePsipher® (Trevigen; Gaithersburg,
MD) to evaluate the collapse of the mitochondrial membrane potential (Figure 3.20).
Treatment of LN-229 glioblastoma cells with HB-I-172 at the EC50 resulted in a
significant increase in mitochondrial membrane depolarization, as indicated by the
inability of the fluorescent stain DePsipher to form red fluorescent eximers inside
mitochondria with a marked effect at 6 hours and an almost complete depolarization at 18
hours post-drug treatment. Mitochondrial involvement was further verified by the
observation of cytochrome C release in U-87 MG after 6 hours of exposure to HB-I-172
at the EC50 as determined by immunohistochemical staining techniques (Figure 3.21).
This same fluorescence photomicrograph also depicts cells with nuclei in which DNA has
become fragmented and has begun to condense which is further evidence for an apoptotic
mechanism of cell death.
The increased activity of PARP which was observed in the MSD assay was also
confirmed by immunohistochemistry. In U-87 MG cells treated with HB-I-172 at the
EC50, the presence of PARP can be seen in the nuclei 6 hours after drug exposure (Figure
3.22). The presence of PARP in the nuclei further confirms that there has been DNA
fragmentation as one of its major roles is to repair DNA breaks.
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Figure 3.16: BAD phosphorylation of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for 6 hours. See legend of Figure
3.8 for experimental details. Solid line indicates comparison between control and drug
treated samples. * = p < 0.00005.
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Figure 3.17: Caspase 3 activity profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Solid lines indicate comparisons
between control and drug treated samples. * = p < 0.000005, ** = p < 0.000000005.
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Figure 3.18: Caspase 9 activity of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for 18 and 24 hours. Cells were
seeded in white, opaque 96-well culture plates at a density of 10,000 cells/well in a
volume of 100µl media. The cells were allowed to attach overnight and the complete
growth media was changed to media containing 1% serum for 24 hours to equilibrate
intracellular signaling pathways, then media was changed to either media containing 1%
serum or media containing 1% serum plus HB-I-172. At the designated time intervals
100µl of Caspase-Glo® 9 Assay Reagent (Promega) was added to each well and the plate
mixed on a rotary shaker for 30 seconds. After incubation at room temperature for 90
minutes the luminescence was read on a Biotek Synergy 2 plate reader. The luminescent
signal is proportional to the amount of caspase 9 activity present. All data points
represent 6 independent determinations. Solid lines indicate comparisons between
control and drug treated samples. * = p < 0.01, ** = p < 0.005.
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Figure 3.19: Cleaved PARP profile of U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.
See legend of Figure 3.8 for experimental details. Solid lines indicate comparisons
between control and drug treated samples. * = p < 0.000001, ** = p < 0.0000005, *** =
p < 0.00000005.
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Figure 3.20: Effects on membrane polarization in U-87 MG cells treated with HB-I-172

Change in mitochondrial membrane polarization (Δψm) with DePsipher® - U-87 MG
cells were treated with HB-I-172 at the EC50 for 6 and 18 hours, and then stained with
dual fluorescent stain; green fluorescence shifts to red emission following the formation
of eximers within mitochondria as stain crosses polarized outer mitochondrial membrane.
Mitochondrial depolarization by HB-I-172 inhibits DePsipher permeability and
subsequent red fluorescence. U-87 MG cells were imaged using an Olympus IX71
inverted fluorescence microscope fitted with a Retiga-SRV camera. Control (vehicle
treated) cells are shown in panel A, 6 hours post drug treatment in panel B, and 18 hours
post drug treatment in panel C.
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Figure 3.21: Effects on cytochrome C release in U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 for 18 hours and evaluated for
changes in localization of cytochrome C (red); nuclei are shown in blue. Control (vehicle
treated) cells are shown in panel A and 18 hour drug treated cells are shown in panel B.
Control cells exhibit localization of cytochrome C in the mitochondria (white arrow)
along the cytoskeletal network. HB-I-172 treated cells show a diffuse pattern of labeling
(green arrow) indicating that cytochrome C has been released from the mitochondria into
the cytosol. Some of the drug treated cells show a much fainter red labeling (yellow
arrow, approximate cell outline represented by dashed white line) indicating depletion of
cytochrome C. Some drug treated cells also show DNA fragmentation and condensation
(red arrow). U-87 MG cells were imaged using an Olympus IX71 inverted fluorescence
microscope fitted with a Retiga-SRV camera.
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Figure 3.22: Activity of PARP in U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 at the EC50 and evaluated for activity of
PARP (red) in the nuclei (blue). Control (vehicle treated) cells are shown in panel A and
6 hour drug treated cells are shown in panel B. HB-I-172 causes activation of PARP as
seen by the red staining in the nuclei (white arrows). U-87 MG cells were imaged using
an Olympus IX71 inverted fluorescence microscope fitted with a Retiga-SRV camera.
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We also conducted a microscopic study to assess the effects of HB-I-172 on
cytoskeleton structure based on the known activity of RhoA and the possibility of a
GPR55 initiated mechanism. At 18 hours post HB-I-172 treatment the cytoskeleton
manifests profound contraction of F-actin and α-tubulin (Figure 3.23). Though it is not
possible to conclude a specific mechanism, this result provides a basis for further
evaluating the possibility of RhoA-ROCK contributions to cell death.
3.6.2 Proposed Mechanism of the Anti-Glioma Activity of HB-I-172

The ability of HB-I-172 (and possibly the other triaryl cannabinoids) to block two
major pro-survival signaling pathways, namely Raf1/MEK/ERK and PI3K/Akt, may
account for its broad spectrum antineoplastic activity. Activation of these pathways is
essential for cell survival and over-activation of each has been shown to be common in
many forms of cancer.119 Constitutive Akt over-activation can many times be attributed
to amplification of the Akt gene or mutations in components of the upstream signaling
pathway.139 Akt plays a critical role in the regulation of cell survival and apoptosis by
phosphorylation and inhibition of a number of proteins including GSK-3β140 and caspase9.141 The Raf1/MEK/ERK pathway has been shown to be over-active in nearly one-third
of all human cancers. This pathway appears to play a large role in cell survival and
transduction of differentiation and mitogenic signals.142 Both of these pro-survival
pathways converge on the pro-apoptotic Bcl-2 protein BAD. Each pathway (Akt directly
and ERK1/2 through p90 ribosomal S6 kinase (p90RSK)) phosphorylates and inhibits
BAD which allows the pro-survival members of the Bcl-2 family to remain active and
prevent apoptosis. Since each pathway is capable of inhibiting BAD, it would be
predicted that inhibition of a single pathway would not be sufficient to bring about
apoptosis. This has, in fact, been demonstrated in a recent report by EllertMiklaszewska, Kaminska, and Konarska in which specific inhibition of each pathway in
the C6 glioma cell line did not bring about any significant cell death.119 These two
pathways share another common signaling protein, namely GSK-3β. Akt and p90RSK
both inhibit GSK-3β by phosphorylation. Inhibition of the two pathways leads to
increases in the activity of GSK-3β which, in turn, activates the pro-apoptotic Bcl-2–
associated X protein (BAX) which leads to loss of mitochondrial membrane potential.143
GSK-3β also up-regulates the transcription factor protein 53 (p53) which leads to further
up-regulation of BAX and also the pro-apoptotic Bcl-2 homologous antagonist/killer
(BAK).144 By down-regulation of both the PI3K/Akt and Raf1/MEK/ERK pathways,
HB-I-172 decreases the downstream phosphorylation of BAD and allows it to dimerize
with Bcl-2 in the mitochondrial membrane leading to loss of membrane potential, release
of cytochrome C and activation of the caspase cascade beginning with caspase 9 (Figure
3.24).
The down regulation of the two pro-survival pathways in glioblastoma by HB-I172 does not give clear evidence for the molecular target of the drug. We know that HBI-172 is an inverse agonist at the CB2 receptor. Since CB2 signals through Gαi, the
effects of an agonist would lead to decreases in cAMP which would decrease the activity
of protein kinase A (PKA) and up-regulate the Raf1/MEK/ERK pathway. An inverse
agonist, on the other hand, would cause increases in cAMP which would increase the
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Figure 3.23: Effects on cytoskeleton structure in U-87 MG cells treated with HB-I-172

U-87 MG cells were treated with HB-I-172 and evaluated for changes in F-actin (yellow)
and α-tubulin (red), nuclei are shown in blue. Control (vehicle treated) cells are shown in
panel A and 12 hour drug treated cells are shown in panel B. HB-I-172 causes significant
contraction of the cytoskeleton network as evidenced by the compact F-actin (yellow
arrows) and α-tubulin (white arrows) around the nuclei. U-87 MG cells were imaged
using an Olympus IX71 inverted fluorescence microscope fitted with a Retiga-SRV
camera.
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activity of PKA and down-regulate Raf1/MEK/ERK. This correlates with our observed
decreases in phosphorylated MEK1/2 and ERK1/2. The inhibition of the PI3K/Akt
pathway can also be explained by a CB2 mediated mechanism. Ligation of the CB2
receptor can cause an intracelleular buildup of ceramide produced from sphingomyelin
by the action of sphingomyelinase which is activated by factor associated with neutral
sphingomyelinase (FAN) (Figure 3.24). The increase in ceramide inhibits the activation
of both PI3K and Akt145 which, again, agrees with our data.
HB-I-172 acting through CB2 alone would however not account for the observed
effects on the cytoskeleton of U-87 MG cells. The formation of stress fibers following
treatment with HB-I-172 is better explained through a GPR55 mediated mechanism.
GPR55 signals through Gα12/13 which activates the Rho family of GTPases through the
activity of guanine nucleotide exchange factors (GEFs). One of these GTPases, Rho A,
then activates focal adhesion kinase (FAK) and Rho-associated, coiled-coil containing
protein kinase (ROCK) which lead to cytoskeleton rearrangement and formation of stress
fibers.146 GPR55 can also affect both the PI3K/Akt and Raf1/MEK/ERK pathways
through the action of Ras on PI3K and Raf1. For this to be a viable explanation, HB-I172 would have to be an antagonist or an inverse agonist at GPR55 also. This would lead
to decreases in the activities of Ras-related C3 botulinum toxin substrate 1 (Rac1) and
cell division control protein 42 homolog (cdc42) and downstream decreases in p21activated kinase (PAK) and Ras which would lead to decreases in the activity of PI3K
and Raf1 (Figure 3.25).
The effects of either CB2 or GPR55 (or possibly both) on the two pro-survival
pathways would be sufficient to initiate apoptosis in glioma cells via activation of BAD
and GSK-3β by each pathway, the activation of caspase 9 by Akt, and the activation of
p53 by both GSK-3β and ERK1/2. There, however, seems to be more to the puzzle than
the inhibition of these two pathways. Our observation that caspase 3 is active
approximately 12 hours before caspase 9 led us to look for alternative mechanisms for the
activation of caspase 3. One such possibility is through endoplasmic reticulum (ER)
stress caused by the unfolded protein response (UPR). ER stress has been shown to
initiate apoptosis in a mitochondria independent manner by activation of caspase 3 via
caspase 12147 (Figure 3.26). ER stress can also initiate apoptosis via a mitochondria
dependent pathway involving the release of calcium from the ER into the cytosol which
causes the collapse of the mitochondrial membrane potential and leads to the release of
cytochrome C.148 ER stress can play further roles in the initiation of apoptosis also. The
UPR can lead to activation of the transcription factor C/EBP homologous protein
(CHOP) which inhibits the pro-survival Bcl-2 at the transcription level.149 We observed
increased translocation of active CHOP to the nuclei of HB-I-172 treated U-87 MG cells
in as little as 3 hours. At the 3 hour time point, the percent of drug treated cells showing
positive immunohistochemical staining for CHOP in the nucleus was nearly 8-fold higher
than in control cells (data not shown). The number of CHOP positive cells in the drug
treated group continued to grow throughout the length of the experiment and was 40-fold
higher than control at the 18 hour terminal time point. ER stress has also been shown to
inhibit Akt by activation of the tribbles homolog 3 (TRIB3) pseudo-kinase by the
transcriptional co-activator p8.134 Much like ERK1/2, ER stress can increase the activity
of the tumor suppressor p53 which leads to the transcription of p53-up-regulated
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modulator of apoptosis (PUMA) and Noxa which cause cytochrome C release from
mitochondria through activation of BAX and BAK.150
ER stress has been shown to be caused by the accumulation of de novo
synthesized ceramide in the ER.151 Considering the increase in ceramide synthesis
caused by ligation of the CB2 receptor, this seems a reasonable pathway to consider. In
the recent report by Salazar et al., THC was shown to induce ER stress in human glioma
cells which led to autophagy preceding apoptosis.121 They determined that autophagy
was initiated by the inhibition of Akt by TRIB3 which leads to the down-regulation of the
autophagy inhibitor mammalian target of rapamycin complex 1 (mTORC1) (Figure 3.27)
which consists of mTOR, regulatory associated protein of mTOR (Raptor), and
mammalian LST8/G-protein β-subunit like protein (GβL). Though the authors were not
able to determine the exact manner in which autophagy leads to apoptosis, they did
determine that it is a necessary precursor to cannabinoid induced apoptotic cell death in
glioblastoma. This, in fact, does fit with our data. The human glioblastoma cell line LN229 was treated with HB-I-172 at the cytotoxic EC50 and the cells were
immunohistochemically stained for the microtubule associated protein 1 light chain 3
(LC3B) which associates into membranes of autophagosomes during autophagy. The
number of cells positive for LC3B increased 6-fold over control in just 3 hours with a 20fold increase at the 18 hour terminal time point (data not shown). This corroborates the
autophagy component of cannabinoid mediated glioma toxicity as reported by Salazar et
al. The authors of the study however attributed the process to activation of the CB1
receptor. We do not believe that the CB1 receptor plays a role in the activity of HB-I-172
due to the previously mentioned finding that it is an antagonist at CB1. This same
experiment needs to be repeated using U-87 MG to strengthen the evidence for
autophagy in this mechanism of cell death.
I believe that there is clear evidence to support a mechanism of cell death in U-87
MG cells following HB-I-172 exposure that involves multiple targets such as CB2 and
GPR55. The early intracellular events following drug exposure are most likely due to
inverse agonism at the CB2 receptor. The increases in cAMP and ceramide following the
ligation of CB2 by HB-I-172 would clearly lead to the down-regulation of the PI3K/Akt
and Raf1/MEK/ERK pathways which is seen beginning at one hour post exposure. ER
stress, as a result of ceramide production, is responsible for the activation of caspase 3 six
hours before the observed activation of caspase 9. The case for ER stress is further
supported by other events at earlier time points such as the activity of CHOP and the
observance of autophagy as determined by LC3B staining at 3 hours. We believe that the
observed changes in the cytoskeleton are due to GTPase activity resulting from ligation
of the GPR55 receptor. The role that GPR55 plays in the down regulation of the
PI3K/Akt and Raf1/MEK/ERK pathways remains to be determined. As previously
stated, HB-I-172 could perhaps be an antagonist/inverse agonist at GPR55 which would
lead to the down-regulation of Ras and the inhibition of the two pro-survival pathways.
If HB-I-172 were a GPR55 agonist, an increase in the signaling of these two pathways
would be expected. Cross talk and inhibition of signaling between the two receptors has
been demonstrated following anandamide ligation.152 The complete proposed signaling
pathway is shown in Figure 3.28.
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Much remains unanswered about the signaling cascade initiated by HB-I-172 in
glioblastoma. We are currently in the process of preparing for a series of assays that will
evaluate the activation of the GTPases RhoA and Rac1. This will give a clearer picture
of the activity, or lack thereof, of GPR55 following exposure to HB-I-172. Selective
inhibition of any of a number of signaling proteins in the proposed pathways either
pharmacologically or by shRNA knock-down would give further insight into the
importance of each segment of the cascade initiated by HB-I-172.
While many of the downstream signaling pathways have been identified, the
receptor or receptors responsible for initiating the cascades are yet to be elucidated. We
have utilized pharmacological knockouts in an effort to identify the target of HB-I-172
action. Pharmacological intervention has distinct limitations due to overlap in activity of
known agonists and antagonists of the CB1, CB2, and GPR55 receptors. Our preliminary
data suggests that both CB2 and GPR55 are both targets of HB-I-172 however this cannot
be confirmed without the selective knock-down of each CB receptor subtype.
Knowledge of the target is critical for the development of a complete mechanism of
action for the anti-glioblastoma activity of HB-I-172. The contributions of each
cannabinoid receptor are currently under investigation using shRNA stably transfected
cell lines.
3.7 Chemical Synthesis
3.7.1 General

In order to synthesize the core of the triaryl compounds 8-16, and provide a route
for future functionalization of this series, an efficient synthetic route was designed.
Commercially available syringaldehyde 17 was selected to form the A ring in the triaryl
series. The phenolic hydroxyl was activated for a Suzuki coupling by reaction with
trifluoromethanesulfonic anhydride to yield intermediate 18 (Scheme 3.1). Formation of
the biaryl ring system was carried out via a Suzuki coupling reaction with 3,5dichlorophenyl boronic acid 19 in the presence of tetrakis(triphenylphosphine) palladium,
and potassium carbonate in toluene and water to yield the aldehyde intermediate 20
(Scheme 3.1). The resulting aldehyde was reacted with phenyl magnesium bromide 21
to obtain the racemic alcohol 8, which was oxidized using PCC, to yield the ketone 14.
The ketone 14 was dimethylated using dimethylzinc and titanium (IV) chloride to yield
compound 15 (Scheme 3.2). The mono- and di-deprotected analogs of 14 and 15 were
prepared by reaction with BBr3 (Scheme 3.3). To prepare the equivalent analogs
possessing the hydroxyl linker compounds 9 and 10 were reduced with sodium
borohydride to give analogs 12 and 13 (Scheme 3.4).
All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc.
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic
sodium and benzophenone. Final compounds and intermediates were purified using
column chromatography on the Biotage SP1 system employing Flash column cartridges
or by crystallization. NMR spectra were obtained on a Bruker 300MHz or Varian
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OH

500MHz Inova NMR. HPLC analysis of final products was carried out by gradient
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min),
and 10% (15min). A reverse-phase ODS Hypersil column, manufactured by Thermo
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC
analyses.
3.7.2 Synthesis of 4-formyl-2,6-dimethoxyphenyl trifluoromethanesulfonate
(18)

Syringaldehyde 17 (10g, 55mmol) and 2,3,5 collidine (26.7g, 28.7ml, 220mmol)
were dissolved in anhydrous DCM (250ml) under an atmosphere of argon,stirred, and
cooled to -20°C followed by the dropwise addition of triflic anhydride (23.4g, 14ml,
83mmol). The reaction was maintained at this temperature, with stirring, for 2 hours. The
reaction was stopped by the addition of saturated aqueous NaHCO3. The layers were
separated and the aqueous layer was extracted with DCM. The organic fractions were
combined and washed with saturated aqueous CuSO4, water, and brine and dried over
Na2SO4. The organic phase was concentrated and the product purified by column
chromatography using 100% DCM as the mobile phase to yield a white to off-white
solid. Yield: 14.14g (82%) (Rf = 0.648; 100% DCM). MS: m/z (ESI, pos.) = 315.1 [M +
H]+. 1H NMR (300 MHz, CDCl3): δ 9.93 (s, 1H), 7.18 (s, 2H), 3.99 (s, 6H), 13C NMR
(300MHz, CDCl3): δ 190.52, 153.48, 136.15, 121.00, 116.52, 106.18, 56.88.
3.7.3 Synthesis of 3',5'-dichloro-2,6-dimethoxybiphenyl-4-carbaldehyde (20)

Triflate 18 (8g, 25.5mmol) along with 3,5 dichloro phenyl boronic acid (7.25g,
38mmol), Tetrakis(triphenylphosphine)palladium (1.18g, 1.02mmol), and K2CO3 (7.05g,
51mmol) were added to toluene (100ml) and water (33ml) in a round bottom flask fitted
with a condenser. The reaction was heated to reflux for 18 hours. The reaction was then
allowed to cool to room temperature and diluted with diethyl ether. The organic layer
was separated and washed with saturated aqueous NaHCO3, water, and brine and then
dried over Na2SO4. The organic phase was concentrated and the product was purified by
column chromatography using an EtOAc / hexanes gradient to yield a white solid. Yield:
4.97g (63%) (Rf = 0.402; 15% EtOAc / hexanes). MS: m/z (ESI, pos.) = 333.1 [M +
Na]+. 1H NMR (500 MHz, CDCl3): δ (ppm) 9.98 (s, 1H), 7.34 (t, 1H), 7.21 (d, 2H), 7.15
(s, 2H), 3.83 (s, 6H). 13C NMR (500MHz, CDCl3): δ (ppm) 191.70, 158.17, 137.66,
136.21, 134.44, 129.27, 127.73, 122.95, 105.34, 56.37.
3.7.4 Synthesis of (3',5'-dichloro-2,6-dimethoxybiphenyl-4yl)(phenyl)methanol (8)

Aldehyde 20 (4.94g, 15.9mmol) was dissolved in anhydrous THF (100ml), stirred
under argon, and cooled to 0°C. Phenyl MgBr (21) (3M solution, 1.67ml, 5mmol) was
then added by syringe and the reaction maintained with stirring at 0°C for 4 hours and
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then allowed to warm to room temperature overnight. The reaction mixture was then
diluted with diethyl ether, washed with water and brine, and dried over Na2SO4. The
organic phase was concentrated and the product was crystallized from EtOAc / hexanes
to yield a white solid. Yield: 2.1g (79%) (Rf = 0.341; 20% EtOAc / hexanes). MS: m/z
(ESI, pos.) = 411.1 [M + Na]+. 1H NMR (500 MHz, CDCl3): δ (ppm) 7.43 (d, 2H, J =
7Hz), 7.38 (t, 2H, J = 7.5Hz), 7.31 (t, 1H, J = 7Hz), 7.28 (t, 1H, J = 2Hz), 7.20 (d, 2H, J =
1.5Hz), 6.67 (s, 2H), 5.85 (d, 1H, J = 3Hz), 3.72 (s, 6H), 2.26 (d, 1H, J = 3Hz), 13C NMR
(500MHz, CDCl3): δ (ppm) 157.63, 145.94, 143.60, 137.24, 134.15, 129.73, 128.88,
128.15, 127.02, 126.82, 102.44, 76.65, 56.12. HPLC retention time: 10.612min; purity
98.92%.
3.7.5 Synthesis of (3',5'-dichloro-2,6-dimethoxybiphenyl-4yl)(phenyl)methanone (14)

Alcohol 8 (2.1g, 5.4mmol), pyridinium chlorochromate (2.33g, 10.8mmol) and
Celite® (2.33g) were added to anhydrous CH2Cl2 and stirred under argon at room
temperature for 18 hours. The reaction mixture was then filtered over a plug of silica gel
and the filtrate was washed with saturated aqueous NaHCO3, water, and brine and then
dried over Na2SO4. The organic phase was concentrated and the product was purified by
column chromatography using an EtOAc / hexanes gradient to yield an off-white solid.
Yield: 1.77g (85%) (Rf = 0.448; 15% EtOAc / hexanes). MS: m/z (ESI, pos.) = 409.1 [M
+ Na]+. 1H NMR (300 MHz, CDCl3): δ (ppm) 7.86 (m, 2H), 7.56 (m, 4H), 7.34 (t, 1H, J
= 1.8Hz), 7.25 (t, 1H, J = 2.4Hz), 7.05 (s, 2H), 3.75 (s, 6H). 13C NMR (300MHz,
CDCl3): δ 196.18, 157.64, 139.26, 137.44, 135.62, 135.30, 132.93, 130.28, 129.26,
128.63, 128.59, 118.91, 111.49, 104.61, 56.34. HPLC retention time: 12.051min; purity
98.37%.
3.7.6 Synthesis of 3',5'-dichloro-2,6-dimethoxy-4-(2-phenylpropan-2yl)biphenyl (15)

Anhydrous CH2Cl2 was added to a round bottom flask, stirred under argon and
cooled to -40°C using a dry ice / acetonitrile bath. Titanium chloride (1M, 30ml,
30mmol) was added by syringe followed by dimethyl zinc (2M, 15ml, 30mmol). This
mixture was allowed to stir at -40°C for 15 minutes. Ketone (14) (1.95g, 5mmol)
dissolved in anhydrous CH2Cl2 (100ml) was then added by syringe and the reaction
stirred at -40°C for 2 hours and was then allowed to warm to room temperature
overnight. The reaction was then quenched by the addition of ice. The organic layer was
separated and washed with saturated aqueous NaHCO3, water, and brine and then dried
over Na2SO4. The organic phase was concentrated and the product was purified by
column chromatography using an EtOAc / hexanes gradient to yield a white solid. Yield:
1.9g (95%) (Rf = 0.750; 15% EtOAc / hexanes). MS: m/z (ESI, pos.) = 423.1 [M + Na]+.
1
H NMR (500 MHz, CDCl3): δ 7.43 (m, 1H), 7.30 (m, 3H), 7.27 (t, 1H, J = 1.5Hz), 7.24
(d, 1H, J = 2Hz), 7.20 (m, 2H), 6.48 (s, 2H), 3.65 (s, 6H), 1.72 (s, 6H). 13C NMR
(500MHz, CDCl3): δ 157.04, 153.70, 150.12, 136.27, 135.36, 129.69, 129.54, 128.02,
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126.84, 125.99, 112.49, 107.64, 102.75, 55.91, 43.50, 30.85, 30.73. HPLC retention
time: 13.909min; purity 96.42%.
3.7.7 Synthesis of (3',5'-dichloro-2-hydroxy-6-methoxybiphenyl-4yl)(phenyl)methanone (9) and (3',5'-dichloro-2,6-dihydroxybiphenyl-4yl)(phenyl)methanone (10)

Ketone 14 was dissolved in anhydrous CH2Cl2 (120ml), stirred under argon, and
cooled to -78°C in a dry ice / acetone bath. Boron tribromide (1M, 9ml, 9mmol) was
slowly added by syringe and the reaction was allowed to stir at -78°C for 3 hours and
then allowed to warm to room temperature and stirred an additional 16 hours. The
reaction was then quenched by the addition of methanol and washed with saturated
aqueous NaHCO3, water, and brine and then dried over Na2SO4. The organic phase was
concentrated and the products were purified by column chromatography using an EtOAc
/ hexanes gradient to yield an off-white solid 9 and a reddish solid 10.
9 Yield: 314mg (21%) (Rf = 0.390; 20% EtOAc / hexanes). MS: m/z (ESI, neg.) =
370.9 [M - H]-. 1H NMR (500 MHz, CDCl3): δ 7.84 (d, 2H, J = 8Hz), 7.61 (t, 1H, J =
8Hz), 7.51 (t, 2H, J = 7.5Hz), 7.42 (d, 1H, J = 1.5Hz), 7.30 (d, 2H, J = 1.5Hz), 7.04 (s,
1H), 7.00 (d, 1H, J = 1.5Hz), 5.19 (d, 1H, J = 16Hz), 3.79 (s, 3H), 13C NMR (500MHz,
CDCl3): δ 196.18, 157.64, 153.36, 139.26, 137.44, 135.62, 135.30, 132.93, 130.28,
129.26, 128.63, 128.59, 118.91, 111.49, 104.61, 56.34. HPLC retention time: 10.780min;
purity 99.03%.
10 Yield: 106mg (7%) (Rf = 0.235; 20% EtOAc / hexanes). MS: m/z (ESI, neg.) =
356.9 [M - H]-. 1H NMR (500 MHz, CDCl3): δ 7.84 (d, 2H, J = 7.5Hz), 7.61 (t, 1H, J =
7.5Hz), 7.48 (m, 3H), 7.37 (d, 2H, J = 1.5Hz), 7.02 (s, 2H), 5.42 (s, 2H), 13C NMR
(500MHz, CDCl3): δ 196.24, 153.77, 139.32, 137.18, 136.29, 134.46, 133.08, 130.34,
129.25, 129.18, 128.61, 117.63, 110.18. HPLC retention time: 9.618min; purity 100%.
3.7.8 Synthesis of 3',5'-dichloro-6-methoxy-4-(2-phenylpropan-2-yl)biphenyl2-ol (16) and 3',5'-dichloro-4-(2-phenylpropan-2-yl)biphenyl-2,6-diol (11)

Dimethyl compound 15 was reacted with boron tribromide (1M, 9ml, 9mmol) in
anhydrous CH2Cl2 (120ml) in a manner similar to the synthesis of compounds 9 and 10.
The products were purified by column chromatography using an EtOAc / hexanes
gradient to yield a yellow resin 16 and a golden foam 11.
16 Yield: 290mg (17%) (Rf = 0.317; 10% EtOAc / hexanes). MS: m/z (ESI, pos.)
= 409.2 [M + Na]+. 1H NMR (500 MHz, CDCl3): δ 7.35 (t, 1H, J = 1.5Hz), 7.29 (m, 6H),
7.20 (m, 1H), 6.51 (d, 1H, J = 1.5Hz), 6.37 (d, 1H, J = 1.5Hz), 4.73 (s, 1H), 3.63 (s, 3H),
1.69 (s, 6H), 13C NMR (500MHz, CDCl3): δ 157.04, 153.70, 153.01, 150.12, 136.27,
135.36, 129.69, 129.54, 128.02, 126.84, 125.99, 112.49, 107.64, 102.75, 55.91, 43.50,
30.85, 30.73. HPLC retention time: 11.716min; purity 99.48%.
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11 Yield: 950mg (57%) (Rf = 0.167; 10% EtOAc / hexanes). MS: m/z (ESI, pos.)
= 395.2 [M + Na]+. 1H NMR (500 MHz, CDCl3): δ 7.40 (t, 1H, J = 2Hz), 7.29 (m,
6H),7.19 (m, 1H), 6.40 (s, 2H), 4.81 (s, 2H), 1.65 (s, 6H), 13C NMR (500MHz, CDCl3): δ
154.07, 153.11, 149.97, 136.07, 135.34, 129.58, 129.43, 128.68, 128.58, 128.23, 111.10,
107.27, 43.16, 30.58. HPLC retention time: 10.271min; purity 96.81%.
3.7.9 Synthesis of 3',5'-dichloro-4-(hydroxy(phenyl)methyl)-6methoxybiphenyl-2-ol (12)

Ketone 9 (75mg, 0.2mmol) was dissolved in MeOH (5ml) and cooled to 0°C.
NaBH4 (9.5mg, 0.25mmol) was slowly added with stirring. The reaction was then
allowed to warm to room temperature and stirred for 2 hours. The solvent was then
removed by rotary evaporation and the product was purified by column chromatography
using an EtOAc / hexanes gradient to yield a white foam. Yield: 63mg (84%) (Rf =
0.361; 30% EtOAc / hexanes). MS: m/z (ESI, neg.) = 372.8 [M - H]-. 1H NMR (300
MHz, MeOD): δ 7.37 (m, 6H), 7.25 (m, 2H), 6.65 (s, 1H), 6.62 (s, 1H), 5.80 (d, 1H, J =
5Hz), 4.83 (s, 1H), 3.73 (s, 3H), 2.25 (d, 1H, J = 5.5Hz). 13C NMR (500MHz, MeOD): δ
152.65, 153.77, 146.12, 143.03, 135.90, 135.23, 129.45, 129.40, 128.87, 128.21, 126.81,
112.96, 106.47, 105.62, 76.09, 56.54. HPLC retention time: 9.989min; purity 94.88%.
3.7.10 Synthesis of 3',5'-dichloro-4-(hydroxy(phenyl)methyl)biphenyl-2,6-diol
(13)

Ketone 10 (33mg, 0.092mmol) was reacted with NaBH4 (4.8mg, 0.129mmol) in
MeOH (4ml) in a manner similar to compound 12. The product was purified by column
chromatography using an EtOAc / hexanes gradient to yield a white solid. Yield: 18mg
(54%) (Rf = 0.441; 40% EtOAc / hexanes). MS: m/z (ESI, neg.) = 358.9 [M - H]-. 1H
NMR (500 MHz, CDCl3): δ 7.37 (t, 1H, J = 1.5Hz), 7.33 (m, 4H), 7.29 (m, 1H), 7.25 (d,
2H, J = 1Hz), 6.52 (s, 2H), 5.67 (s, 1H), 5.38 (s, 2H), 2.71 (s, 1H), 13C NMR (500MHz,
CDCl3): δ 153.77, 146.12, 143.03, 135.90, 135.23, 129.45, 129.40, 128.87, 128.21,
126.81, 112.96, 106.47, 76.09. HPLC retention time: 9.046min; purity 96.05%.
3.8 Experimental Methods
3.8.1 Radioligand Binding Assays

Binding affinity studies were carried out using cell membranes from HEK293
cells transfected with the human CB1 receptor (Kd for tritiated CP-55,940 binding: 1.0
nM) and membranes from HEK293 cells transfected with the human CB2 receptor (Kd
for tritiated CP-55,940 binding: 1.0 nM). Non-specific binding was determined using 10
µM WIN55, 212-2. Increasing concentrations of compounds to be tested were made
ranging from 10-12 M to 10-4 M and were added in triplicate for each experiment and the
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individual molar IC50 values were determined using GraphPad Prism software. The
corresponding Ki values for each drug were determined utilizing the Cheng-Prusoff
equation and final data are presented as Ki ± standard deviation of n = 3 experiments run
in triplicate.
3.8.2 Cytotoxicity Assays

Human glioblastoma cells U-87MG, T98G, LN-229, DBTRG-O5MG (American
Type Culture Collection) were cultured in supplemented media according to the
recommendations of the supplier at 37°C in an atmosphere of 5% CO2 and 95% air. Cell
lines were plated in 96-well polystyrene flat-bottom plates (7,500 cells/well) at 70%
confluency in a 100 µl total volume of supplemented media as indicated, and incubated
overnight at 37°C to allow for adherence. The media was then replaced with serum-free
media and the cultures were treated with escalating amounts of drug and cell death was
analyzed at 18h, using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek
Instruments, Inc.). The percentage of viable cells present in the culture at each time point
was calculated by comparing the absorbance value at 450nm from the CCK-8 assay
(Dojindo Molecular Technologies) for each condition with untreated control cells. All
assays were conducted per manufacturer’s protocol. All described values represent the
average of three data points per determination and three independent determinations.
3.8.3 Cytotoxicity Assays with Pertussis Toxin

U-87 MG cells were seeded in 96-well polystyrene flat-bottom plates (7,500
cells/well) at 70% confluency in a 100 µl total volume of complete growth media and
incubated overnight at 37°C in an atmosphere of 5% CO2 and 95% air to allow for
adherence. The media was then replaced with complete growth media containing 0 or
100ng/ml pertussis toxin and the plates returned to the incubator for 18 hours. Drug
solutions were prepared in DMSO at 100X concentration, and mixed 1:100 in media
containing 1% FBS to yield the desired concentration. After 18 hour incubation with or
without Ptx, full serum media was removed and replaced with drug-media mixtures and
incubated for an additional 18 hours. 10μL of CCK-8 reagent was added to each well to
colorimetrically assess viability. After 2-4 hours of incubation with the CCK-8 dye,
absorbance was read at 450nm using a BioTek Synergy 2 plate reader.
3.8.4 CB1/CB2 Functional Assays

HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and
either human CB1 or CB2 receptors (BD Biosciences, San Jose, CA USA) were seeded
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well. Plates were
incubated at 37°C in 5% CO2 overnight prior to assay. Plates were then removed from
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and
1µg/ml puromycin) was replaced with 100µL DMEM containing 0.25% BSA. Next,
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100µL membrane potential dye loading buffer (Molecular Devices) was added to each
well. The plates were placed back into the incubator for 30 minutes and then the baseline
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm
excitation and 590nm emission filters prior to drug addition. Drugs were added in 50µL
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM
Ro 20-1724. Plates were then incubated at room temperature for 25 minutes and
fluorescence measured again at 540nm excitation and 590nm emission.
3.8.5 MSD Protein Quantification

U-87 MG cells were plated in poly-D-lysine coated 10 cm Petri dishes at a density
of 4 x 105 cells/ml with 12ml of cell suspension added to each plate. The cells were
grown overnight in EMEM media containing 10% FBS. The following day the media
was changed to EMEM media containing 1% FBS and allowed to equilibrate for 24
hours. This step is essential to allow basal levels of signaling protein to re-equilibrate
due to changes in the serum concentration. The media was then replaced at the
appropriate time points with media containing 1% serum and KM-233 at the EC50 or
media containing 1% serum and vehicle (DMSO). After the incubation period with KM233 or vehicle, the media was removed from the dishes and transferred to a 15ml
centrifuge tube to collect any cells that were in suspension. Cells were then scraped from
the surface of the dish and transferred into the same 15ml centrifuge tubes and pelleted at
1000rpm, 4oC for 5min. Supernatant was removed and 0.5ml lysis buffer was added to
each pellet. The cells were suspended in the buffer and transferred to 1.5ml
microcentrifuge tubes. These were incubated on ice for 30 minutes, being vortexed every
5 minutes. The lysates were then centrifuged at 10,000 x g, 4oC for 10 minutes to clear
cellular debris from the lysate. The supernatant was removed and assayed for protein
concentration using a Pierce BCA Protein Assay Kit (Thermo Scientific). The lysates
were then diluted with complete lysis buffer to a concentration of 20μg of protein in 25μl
volume. Signaling proteins were then analyzed using MSD phosphoprotein and
intracellular marker multiplex kits which were imaged on a SECTOR Imager 2400 (Meso
Scale Discovery) according to the manufacturer’s instructions.
3.8.6 Caspase 9 Assay

U-87 MG cells were seeded in white, opaque 96-well culture plates at a density of
10,000 cells/well in a volume of 100µl complete growth media. The cells were allowed
to attach overnight and the complete growth media was changed to media containing 1%
serum for 24 hours to equilibrate intracellular signaling pathways, then media was
changed to either media containing 1% serum or media containing 1% serum plus HB-I172. At the appropriate time intervals 100µl of Caspase-Glo® 9 Assay Reagent
(Promega, prepared according to manufacturer’s instructions) was added to each well and
the plate mixed on a rotary shaker for 30 seconds. After incubation at room temperature
for 90 minutes the luminescence was read on a Biotek Synergy 2 plate reader. The
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luminescent signal is proportional to the amount of caspase 9 activity present. All data
points represent 6 independent determinations.
3.8.7 Mitochondrial Membrane Potential Assay

U-87 MG cells were seeded in poly-D-lysine coated 96-well plates at a density of
10,000 cells per well. At the appropriate time points, the media was removed and
replaced with media containing 1% FBS and either HB-I-172 at the EC50 or vehicle
(DMSO). After incubation with drug or vehicle, cells were dyed using DePsipher
membrane potential dye according to the manufacturer’s instructions. Plates were then
imaged using an Olympus IX71 inverted fluorescence microscope (Olympus America)
fitted with a Retiga-SRV camera (QImaging).
3.8.8 Microscopic Analysis Using Immunohistochemical Techniques

U-87 MG cells were plated in complete growth medium at a density of 15,000
cells/well in poly-D-lysine coated 96-well polystyrene tissue culture plates and allowed
to attach over night at 37°C in an atmosphere of 5% CO2 / 95% air. The media was then
replaced with media containing 1% FBS and either HB-I-172 at the EC50 or vehicle
(DMSO). The cells were returned to the incubator and after the appropriate periods of
exposure to the drug or vehicle, media was aspirated and the cells fixed using 4%
paraformaldehyde. Cells were then stained by immunohistochemical methods using
either a Cellomics Multiparameter Cell Death Detection Kit, Cellomics Cytoskeletal
Rearrangement Kit, or Cellomics Cleaved PARP Activation Kit (Thermo Scientific)
according to the manufacturer’s instructions. Plates were then imaged using an Olympus
IX71 inverted fluorescence microscope (Olympus America) fitted with a Retiga-SRV
camera (QImaging).
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Chapter 4: Design, Synthesis, and Testing of Novel Cannabinoid Ligands
4.1 Introduction

Classical cannabinoids are tricyclic terpenoid compounds consisting of a
benzopyran core structure that are either naturally occurring in the hemp plant
(phytocannabinoids) or are synthetic analogs of naturally occurring compounds. Δ9-THC
and its isomer Δ8-THC (Figure 4.1) are the prototypical members of this class of
cannabinoids. They bind without selectivity to the CB1 and CB2 cannabinoid receptors
and act as agonists or partial agonists.11 The classical cannabinoids are by far the most
well studied of the cannabinoid compounds in terms of pharmacology and structure
activity relationships (SAR) and have gained considerable attention over the years due to
their potential indication in the treatment of several pathological conditions from
inflammation to asthma, inflammatory bowel diseases, multiple sclerosis, Parkinson’s
disease, epilepsy, glaucoma, septic shock, hemorrhagic shock, and cancer.
SAR studies have determined that there are three pharmacophoric elements
(Figure 4.1) in classical cannabinoids that are required for cannabimimetic activity.
These include:
a. C-1 phenolic hydroxyl group
b. lipophilic C-3 alkyl side chain
c. trans ring junction at the B and C rings.
Many studies have been performed in an attempt to elucidate the SAR of the classical
cannabinoids with respect to modifications of the tricyclic ring and side chain
substituents at the C-3 position. Some of the different side chain modifications that have
been reported thus far include the branched chain alkyls,153 unsaturated alkyls,130,154 and
alkyls that contain a 1',1'-cyclic functionality.155 Each of these modifications has been
directed at the goal of producing compounds that have higher binding affinities for the
cannabinoid receptors and also that are selective for one subtype over the other.
The potential for important therapeutic interventions from this class of
compounds has provided the impetus to develop ligands that can elicit the desired
physiological effects of Δ9-THC (mediated through CB2) without producing the
unwanted CNS side effects. In the absence of X-ray crystal structures of cannabinoid
receptors, medicinal chemists have relied on chemical diversifications to develop new
ligands for CB1 and CB2. Structurally diverse compounds that probe the available space
in the ligand binding pocket of the cannabinoid receptors have provided important
insights into the structural requirements for binding as well as for activity.
This need for diversity in the cannabinoid chemical arsenal has led to the
development of compounds belonging to diverse chemical classes, both classical and
non-classical. The term “non-classical” was originally used to describe compounds that
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Figure 4.1: Structure of Δ8-THC with identification of its various structural domains
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lack the B ring of the classical cannabinoids and possess an alkyl side chain such as the
compound CP-55,940 (Figure 4.2). The term is now more widely used to describe any
compound which is a ligand that binds the cannabinoid receptors which lacks the basic
tricyclic benzopyran ring system. An explosion of work into the non-classical arena has
led to several new structural classes of cannabinoids. These new compounds can be
classified broadly into 9 distinct chemical scaffolds (Figures 4.2 and 4.3):
a. Non-classical cannabinoids – exemplified by the CP-55,940 group of
compounds.156
b. Aminoalkyl indoles – exemplified by the WIN 55,212-2 group of
compounds.157
c. Biaryl pyrazoles – exemplified by SR14716A group of compounds.158
d. Biphenyls – exemplified by the biaryl-gem-dimethyl heptyl group of
compounds.128
e. Triaryls – exemplified by HB-I-172.127
f. N-alkyl isatin acylhydrazones exemplified by MDA77.159
g. Benzimidazoles as exemplified by PF-03550096.160
h. N-arylamide oxadiazoles.161
i. Quinolone-3 carboxamides.162
j. Triaryl bis-sulfones.163
These compounds act via the CB1 or CB2 receptors (and possibly GPR55) and are
agonists, antagonists, inverse agonists, or partial agonist/antagonists. They are
collectively known as “cannabimimetic” agents, “cannabinergic” agents, or simply
“cannabinoids.” These structural classes of ligands display varying affinities as well as
selectivity for the cannabinoid receptor subtypes, though most of the recent work has
been in improving CB2 selectivity. Although all of these cannabinoids essentially bind to
the same receptors and activate or deactivate the same downstream signaling cascade, it
is not surprising that there is increasing evidence to suggest that they display different
binding modes. It is believed that each structural class interacts with different critical
amino acids in the binding pocket of each receptor. This may explain why the differing
chemical classes display very different selectivities for CB1/CB2. This growing volume
of knowledge can be exploited for the further tailoring of compounds that have specific
binding affinity profiles.
The reported SAR studies of cannabinoid receptor ligands indicate that there are
important amino acid residues in the transmembrane domains 3, 5, and 6 of the CB1 and
the CB2 receptors that are involved in the discrimination of the cannabinergic ligands.164
Molecular modeling studies have also suggested the importance of specific amino acid
residues in the CB1 receptor binding pocket that play a critical role in binding to classical
cannabinoids (Figure 4.4). These residues are as follows:
103

OH

O
OH

N
O
OH

N

CP 55,940
N

O

O

NH

WIN 55,212-2
N
N

Cl

Cl

SR141716A

Cl

Cl

Cl
OH

OH
Cl

Cl

HO

HO

O

Biphenyl

HB-I-172

Figure 4.2: Representatives of various classes of non-classical cannabinoids

104

O

O
O
NH

NH

N

NH 2

N
O

O

N

N

O

HO

MDA77
PF-03550096
O

O
N

N

N

NH

F

N-arylamide oxadiazoles
Cl
O

N
H

N
H
Cl

O

O

O

N

S
F

Quinolone-3 carboxamides

O

O

O

S

S
O

Triaryl bis-sulfones

Figure 4.3: Further representatives of various classes of non-classical cannabinoids

105

Figure 4.4: Classical cannabinoid binding interactions

Interactions between classical cannabinoids and key amino acid residues in the ligand
binding pocket of the cannabinoid receptors.
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a. Lys 192 is a very important residue required for binding to classical
cannabinoids. Due to the conformational flexibility of this residue, it can
adopt an orientation that interacts with the phenolic hydroxyl in the A ring
of classical cannabinoids.165
b. A predominantly hydrophobic pocket comprised of residues Tyr 275, Trp 279,
Leu 359, Met 363, and Phe 200 is involved in binding to the C-3 side
chain.166
c. Phe 189 lies in close proximity to the A ring of classical cannabinoids and may
be involved in aromatic stacking interactions with the ring.166
While there is a sufficient understanding of binding interactions involved between
ligands and the CB1 receptor, interactions at the CB2 receptor are not as well defined. It
has been demonstrated that compounds lacking the phenolic hydroxyl of the A ring or
having it occupied in an ether linkage, show enhanced affinity for CB2 as well as
selectivity.167 The observations made with these modifications indicate the involvement
of additional specific electronic and steric factors in ligand recognition at the CB2
receptor. It is also important to note that elimination of the B ring of the classical
cannabinoid core with the biphenyl or triaryl core has resulted in compounds that are
more CB2 selective also.127-128 Work in our laboratory has also demonstrated that
classical cannabinoids with phenyl substitutions at the C3 position have affinities shifted
toward CB2 selectivity.108
4.2 Design and Synthesis of Novel Compounds
4.2.1 Rationale

Upon careful review of past and current literature, it became clear that there had
been one major design possibility that had been overlooked. In the efforts to design
compounds that were more CB2 selective, no group had reported heteroaromatic
modifications to the A ring of classical cannabinoids. Replacement of the phenyl ring
with a pyrimidine could take advantage of the additional electronic interactions that are
involved in ligand recognition at the CB2 receptor. A logical extension of this design
was the addition of the heteroaromatic motif to the triaryl scaffold as well (Figure 4.5).
It was also speculated that the addition of the pyrimidine to these cannabinoid structures
could increase water solubility thereby making it easier to formulate these compounds
into dosage forms. The decrease in lipophilicity could also limit the blood-brain barrier
penetration of the cannabinoids which would make them ideal candidates as therapies for
systemic inflammatory conditions.
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Figure 4.5: General design of pyrimidyl cannabinoids

Rationale for the pyrimidine heteroaromatic substitution in the classical cannabinoids and
the triaryls.
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4.2.2 Synthesis of Hexahydro Pyrimidine Classical Cannabinoids

The hexadydro pyrimidine classical cannabinoids were prepared by reacting an
intermediate pyrimidine with the appropriate terpene to generate the desired compounds
according to the Scheme 4.1. The hexahydro compounds are synthesized utilizing a
modification of the Diastereoselective Domino Knoevenagel Hetero-Diels-Alder
Reaction described by Tietz.168 The ring formations are accomplished under microwave
conditions with the appropriately substituted pyrimidine and citronellal.
Synthesis of the intermediate substituted pyrimidines proved to be more
challenging. The first strategy was to form the hexahydro core with commercially
available 4,6 dihydroxy pyrimidine which lacked the side chain (Scheme 4.2). The
phenolic -OH would then be protected by a tert-butyldimethylsilyl (TBDMS) group. The
addition of the side chain could then be accomplished by deprotonation of the 2 position
of the pyrimidine and then reacting with an appropriate aldehyde to form the intermediate
alcohol or lithiation of the same position by butyl lithium and N,N-dimethylaminoethanol
and then reacting with the aldehyde to form the alcohol or a nitrile to form the ketone
(Scheme 4.3). Neither of these methods was successful in formation of the side chain.
An attempt to prime the 2 position of the pyrimidine as a Grignard substrate was also
performed by reacting the lithiate with dimethylformamide to form an aldehyde in this
position which could then be reacted with the appropriate magnesium halides (Scheme
4.3). This method was also unsuccessful.
The second strategy involved the synthesis of ethyl 4,6-dimethoxypyrimidine-2carboxylate from malononitrile, methanol, and ethyl chloroxoacetate (Scheme 4.4).169
This intermediate would then serve as the scaffold for building the side chain. The ester
was then reduced to the aldehyde using diisobutylaluminum hydride (DIBAL-H) to
prepare the molecule for the Grignard reaction (Scheme 4.5). The aldehyde was then
reacted with an appropriate aldehyde and the resulting alcohol oxidized to the ketone
using pyridinium chlorochromate (PCC) (Scheme 4.5). The ketone could then be
dimethylated using tin chloride and dimethyl zinc according to the method employed by
Krishnamurthy.108 This method, however led to the monomethyl alcohol as did
methylation using trimethyl aluminum (Scheme 4.6). The same product was also formed
when trimethyl aluminum was paired with trimethylsilyl trifluoromethanesulfonate in an
attempt to make the alcohol a better leaving group to allow for the formation of the
dimethyl linker170 (Scheme 4.7). An attempt to activate the alcohol was also made by
converting it to the mesylate;171 this however led to the vinyl elimination product
(Scheme 4.7).
It became clear that forming the dimethyl linker in the side chain would not be
feasible using 4,6-dimethoxypyrimidine-2-carboxylate as the starting material. This
would work, however, for the hydroxyl and ketone linker. Unfortunately, another
problem arose. In order to form the hexahydro classical cannabinoids, citronellal must be
reacted with the deprotected pyrimidine, not the dimethoxy intermediate. The differences
between dimethoxy phenyl rings and pyrimidine rings caused difficulties here also.
Previous methods employed by our laboratory to cleave the methyl ethers such as boron
tribromide108,129 were unsuccessful in the deprotection of the dimethoxy pyrimidines.
109

O
OH

+

OH
H

a

N

N
H

R
HO

N

R

X

O

X=
OH

R=

or

O

N

X

or

Alkyl or Aryl

Scheme 4.1: Synthesis of hexahydro pyrimidine classical cannabinoids

Hexahydro pyrimidine classical cannabinoids are synthesized from R-citronellal and a
substituted dihydroxy pyrimidine. (a) piperidine, pyrimidine, EtOH, µwave, 200 watts,
130°C, 1hr.
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Scheme 4.2: Synthesis of TBDMS protected hexahydro pyrimidine classical
cannabinoids

TBDMS protected hexahydro pyrimidine classical cannabinoids were synthesized from
R-citronellal and substituted dihydroxy pyrimidine. (a) piperidine, pyrimidine, EtOH ,
µwave, 200 watts, 130°C, 1hr. (b) TBDMS-Cl, imidazole, CH3CN, µwave, 150 watts,
140°C, 2hr.
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Scheme 4.3: Attempts at introduction of the hexahydro pyrimidine side chain

Failed attempts at introduction of the hexahydro pyrimidine side chain to protected
hexahydro pyrimidine classical cannabinoids. (a) n-butyllithium, THF, -78°C - RT, 18hr.
(b) n-butyllithium, N,N dimethylaminoethanol, hexanes, THF, -78°C - RT, 18hr.
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Scheme 4.4: Synthesis of 4,6-dimethoxypyrimidine-2-carboxylate

(a) methanol, HCl (gas), methyl acetate, -18°C, 3hr, cooled to 5°C. (b) DIEA, CH2Cl2,
40°C - RT, 18hr.
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Scheme 4.5: Introduction of the side chain to 4,6-dimethoxypyrimidine-2-carboxylate

(a) DIBAL-H, toluene, -78°C - 25min, HCl 0°C. (b) Phenyl MgBr, THF, 0°C – 4hr, RT
- 18hr. (c) PCC, Celite, CH2Cl2, RT, 18hr.
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Scheme 4.6: Attempts at dimethylation of the ketone intermediate

(a) TiCl4, Zn(CH3)2, CH2Cl2, -40°C – 2hr, RT – 16hr. (b) Me3Al, CH2Cl2, 0°C – 1hr, RT
- 16hr.
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Scheme 4.7: Further attempts at dimethylation of the ketone intermediate

Me3Al, TMSOSO2CF3, CH2Cl2, 0°C – 1hr, RT – 16hr. (b) NaH, THF, 0°C – RT, 1hr,
40°C – 3hr, methane sulfonyl chloride, RT – 1hr, 40°C - 2hr.
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Other methods were also employed: KOH, HBr, and methylmagnesium iodide. None of
these proved successful (Scheme 4.8).
This combination of difficulties led to the abandonment of methods that had
previously been employed successfully in our laboratory for synthesis of classical
cannabinoid side chains. It was decided to form the side chain first which would contain
a cyano group. This cyano group would be converted to the amidine which would be
reacted with diethyl malonate to form the dihydroxy pyrimidine with the side chain in
place.
The nitriles were formed either by reaction of a commercially available aryl or
alkyl halide with isobutyronitrile in the presence of potassium bis(trimethylsilyl)amide
(KHMDS) (Scheme 4.9)172 or by dimethylation of a commercially available aryl or alkyl
nitrile with methyl iodide in the presence of KHMDS (Scheme 4.10).173 The amidines
are then formed from the nitriles by Garigipati’s reaction utilizing methylchloroaluminum
amide formed in situ from trimethylaluminum and ammonium chloride (Scheme 4.11).174
This method, which only provided moderate yields of around 40%, was chosen due to the
known unreactivity of hindered nitriles in the more common Pinner reaction. The limited
availability of anhydrous ammonia at that time also made the Pinner reaction less
feasible. One major drawback of this method is that it requires an extensive two day
purification procedure to separate the amidines from residual ammonium chloride.
The amidines were to then be cyclized into dihydroxy pyrimidines by reacting
with diethyl malonate. This reaction was first attempted in the presence of N,Ndiisopropylethylamine (DIEA). This method did not lead to formation of the desired
product and it was speculated that perhaps DIEA was not a strong enough base to drive
the reaction forward. Sodium ethoxide was chosen as the base and commercially
available solid sodium ethoxide was purchased and tried in the reaction. This also did not
lead to formation of the product. The reaction was also attempted under solvent-free
conditions and also under microwave irradiation. Each of these efforts remained
unfruitful. Successful formation of the pyrimidines was finally achieved by in situ
formation of fresh sodium ethoxide to deprotonate the amidines (Scheme 4.12).175
Diethyl malonate was then added and the reactions heated to reflux overnight. The solid
sodium chloride was then filtered out and the filtrate was diluted with water and acidified
to pH 2 causing the dihydroxy pyrimidnes to precipitate.
The pyrimidine hexahydro classical cannabinoids were then formed by reaction of
the appropriately substituted dihydroxy pyrimidines with R-citronellal under microwave
conditions (Scheme 4.13). This Domino Knoevenagel Hetero-Diels-Alder method uses
ethanol as the solvent and piperidine and pyridine as co-solvents and as the base to
catalyze the coupling. The final compounds are easily purified using flash
chromatography and are isolated in good yields of ~80%. The side chains selected for
these novel structures were the dimethyl heptyl, dimethyl cyclohexyl, dimethyl phenyl,
and the dimethyl 2-thiophene. These selections were made based on the known binding
affinity afforded to classical cannabinoids by the linear dimethyl heptyl and by our
groups findings that that the cyclohexyl has similar binding affinities to the linear alkyl
and that aryl groups such as the phenyl and thiophenyl shift selectivity toward the CB2
receptor.153a
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Scheme 4.8: Attempts at deprotection of the dimethoxy pyrimidine intermediates

(a) BBr3, CH2Cl2, -78°C – 3hr, RT – 16hr. (b) HBr–AcOH (1:3), 80°C, 1h, then
saturated NaHCO3. (c) MeMgI, 1,4 dioxane, reflux, 16hr. (d) KOH, 1,4 dioxane, reflux,
16hr.
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Scheme 4.9: Formation of nitrile intermediates from halides and isobutyronitrile

(a) KHMDS, toluene, 80°C, 24hr.
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Scheme 4.10: Formation of nitrile intermediates from cyanides

(a) KHMDS, MeI, THF, 0°C, 10min.
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Scheme 4.11: Formation of amidines from nitriles

(a) NH4Cl, Me3Al, toluene, 0°C - RT, 45min, reflux, 18hr, then silica gel, CHCl3, RT,
10min, then methanolic HCl, diethyl ether, RT, overnight, then isopropanol:acetone 4:1,
RT, overnight, then diethyl ether, RT.
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Scheme 4.12: Synthesis of dihydroxy pyrimidine intermediates

(a) Na metal, diethyl malonate, EtOH, reflux, 18hr.
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Scheme 4.13: Coupling of pyrimidine hexahydro classical cannabinoids

(a) piperidine, pyrimidine, EtOH , µwave, 200 watts, 130°C, 1hr.
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All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc.
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic
sodium and benzophenone. Final compounds and intermediates were purified using
column chromatography on the Biotage SP1 system employing Flash column cartridges
or by crystallization. NMR spectra were obtained on a Bruker 300MHz or Varian
500MHz Inova NMR. HPLC analysis of final products was carried out by gradient
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min),
and 10% (15min). A reverse-phase ODS Hypersil column, manufactured by Thermo
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC
analyses.
4.2.2.1 Synthesis of 2-methyl-2-phenylpropanenitrile (22)

To a solution of fluorobenzene (5.85mL, 62.4mmol) in 100 mL of anhydrous
toluene was added isobutyronitrile (22.5mL, 250mmol) followed by 200mL (100mmol)
of a 0.5M solution of KHMDS in toluene. The reaction was stirred at 80°C for 24 hours.
The reaction was then allowed to cool to room temperature, diluted with diethyl ether,
and washed with water and brine. The organic fraction was then dried over sodium
sulfate and concentrated under reduced pressure. The product was purified by flash
chromatography using an ethyl acetate/hexanes gradient to yield 4.57g (50%) of the
objective compound as a brown oil. MS: (ESI, pos.) m/z 168.0 [M + Na]+, I.R. (neat)
nitrile 2230 cm-1, 1H NMR (500 MHz, CDCl3): δ (ppm) 7.48 (d, 2H), 7.39 (t, 2H), 7.31
(t, 1H), 1.73 (s, 6H).
4.2.2.2 Synthesis of 2-cyclohexyl-2-methylpropanenitrile (23)

Prepared in a manner similar to compound 22 from bromo cyclohexane (0.8 ml,
6.4 mmol) and isobutyronitrile (2.34ml, 26mmol) in the presence of KHMDS (20ml,
10mmol). Purified via vacuum distillation (Bp 50-55°C at 1.1 torr). Yield: 84%, MS:
(ESI, pos.) m/z 174.1 [M + Na]+, I.R. (neat) nitrile 2230 cm-1, 1H NMR (500 MHz,
CDCl3): δ (ppm) 1.5 (m, 4H) 1.4-1.3 (m, 12H), 0.9 (s, 3H).
4.2.2.3 Synthesis of 2-methyl-2-(thiophen-2-yl)propanenitrile (24)

To a solution of 2-(thiophen-2-yl) acetonitrile (1g, 8.13mmol) in 4ml anhydrous
THF, KHMDS (24.4mmol, 48.9ml, 0.5M in toluene) was added at 0°C. The mixture was
allowed to stir for 3 minutes, after which a solution of 16.26mmol iodomethane (1.13ml
in 26ml anhydrous THF) was added slowly over a period of 10 minutes. The mixture
was stirred for 5 minutes and monitored by TLC. Upon completion, the reaction was
quenched with aqueous ammonium chloride. The organic phase was separated with ethyl
acetate and dried over sodium sulfate. The product was purified via vacuum distillation.
(bp 42°C at 1 torr) Yield: 89%, MS: (ESI, pos.) m/z 174.1 [M + Na]+, I.R. (neat) nitrile
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2230 cm-1, 1H NMR (500 MHz, CDCl3): δ (ppm) 7.4 ppm (d, 1H), 7.2 ppm (t, 1H),
7.0 ppm (d, 1H), 1.9 ppm (s, 6H).
4.2.2.4 Synthesis of 2,2-dimethyloctanenitrile (25)

Prepared in a manner similar to compound 24 from octanenitrile and iodomethane
in the presence of KHMDS. Purified via vacuum distillation (bp 50-55°C at 1.1 torr).
Yield: 84%, MS: (ESI, pos.) m/z 176.2 [M + Na]+, I.R. (neat) nitrile 2230 cm-1, 1H NMR
(500 MHz, CDCl3): δ (ppm) 1.5 (m, 4H), 1.4-1.3 (m, 12H), 0.9 (s, 3H).
4.2.2.5 Synthesis of 2-methyl-2-phenylpropanimidamide
hydrochloride (26)

Ammonium chloride (1.06 g, 19.8mmol) was suspended in 10 ml of anhydrous
toluene, stirred under argon, and cooled to 0°C. To this suspension was added 9.2ml
(18.4 mmol) of a 2M solution of trimethylaluminum in toluene. The reaction was
allowed to warm to room temperature and stirring was continued until the evolution of
methane ceased (~1 hour). Then, 1.6g (11mmol) of nitrile 22 in 5ml of anhydrous
toluene was added and the reaction was heated to 80°C for 18 hours. The reaction was
then cooled to room temperature and slowly poured into a slurry of 5.5g of silica gel in
18ml of chloroform and stirred for 5 minutes. The silica was filtered and washed with
methanol. The filtrate and washings were combined and reduced to a volume of ~5ml
and refiltered. Then, 4ml (12mmol) of a 3N solution of methanolic HCl was added to the
filtrate followed by 300ml of diethyl ether. After 16 hours of stirring at room
temperature, a white precipitate formed was subsequently filtered. This crude solid was
then added to 150ml of a 4:1 mixture of isopropanol-acetone and stirred for an additional
16 hours at room temperature. Undissolved ammonium chloride was then removed by
filtration and the filtrate reduced to ~5ml. After the addition of 300ml of diethyl ether the
mixture was stirred for ~1 hour. The white precipitate was then filtered and dried to yield
639mg (29%) of the objective compound as the hydrochloride salt. MS: (ESI, pos.) m/z
163.0 [M + H]+, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.27 (br.s, 2H), 8.71 (br.s,
2H), 7.41 (m, 2H), 7.36 (m, 2H), 7.32 (m, 1H), 1.60 (s, 6H) 13C NMR (500 MHz,
DMSO-d6): δ (ppm) 175.91, 143.27, 128.71, 127.42, 125.65, 44.06, 26.31.
4.2.2.6 Synthesis of 2-methyl-2-(thiophen-2-yl)propanimidamide
hydrochloride (27)

Prepared in a manner similar to compound 26 from nitrile 24 (1.5g, 9.9mmol),
ammonium chloride (952mg, 17.8mmol), and trimethylaluminum (8.25ml, 16.5mmol).
Yield: 36% (white solid) MS: (ESI, pos.) m/z 169.0 [M + H]+, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 8.8 (br.d, 3H), 7.53 (dd, 1H), 7.13 (dd, 1H), 7.04 (dd, 1H), 1.70 (s,
1H) 13C NMR (500 MHz, DMSO-d6): δ (ppm) 174.75, 147.04, 127.18, 125.72, 125.48,
41.92, 27.20.
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4.2.2.7 Synthesis of 2-cyclohexyl-2-methylpropanimidamide
hydrochloride (28)

Prepared in a manner similar to compound 26 from nitrile 23 (6g, 40mmol),
ammonium chloride (3.92g, 72mmol), and trimethylaluminum (33.3ml, 66.6mmol). An
exception to the procedure is that after the addition of methanolic HCL and diethyl ether,
the solid that formed was ammonium chloride and the amidine remained in solution. The
solid was removed and the solvent evaporated to yield the product as a highly viscous
yellow resin. Yield: 70%. MS: (ESI, pos.) m/z 169.1 [M + H]+, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 8.84 (b.d., 3H), 1.78 (m, 3H), 1.57 (m, 3H), 1.25 (s, 2H), 1.19 (t,
1H), 1.12 (s, 6H), 0.97 (m, 2H). 13C NMR (500 MHz, DMSO-d6): δ (ppm) 177.11,
44.74, 42.90, 27.47, 26.73, 26.15, 25.80, 25.73, 23.86, 21.29.
4.2.2.8 Synthesis of 2,2-dimethyloctanimidamide hydrochloride (29)

Prepared in a manner similar to compound 28 from nitrile 25 (1.5g, 9.8mmol),
ammonium chloride (957mg, 17.6mmol), and trimethylaluminum (8.15ml, 16.3mmol).
Product is a highly viscous yellow resin. Yield: 60.7%. MS: (ESI, pos.) m/z 171.1 [M +
H]+, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.87 (b.d., 4H), 1.56 (t, 2H), 1.3-1.0 (m,
14H), 0.85 (t, 3H). 13C NMR (500 MHz, DMSO-d6): δ (ppm) 176.63, 39.97, 39.62,
31.02, 28.87, 24.80, 23.72, 22.02, 13.92.
4.2.2.9 Synthesis of 2-(2-phenylpropan-2-yl)pyrimidine-4,6-diol (30)

Sodium metal (145mg, 6.29mmol) was reacted with 8ml of anhydrous ethanol.
To this was added 500mg (2.52mmol) of amidines hydrochloride 26 and the reaction was
allowed to stir at room temperature for 5 minutes. Diethyl malonate (400mg, 2.5mmol)
was then added and the reaction was heated to reflux overnight. The reaction was then
cooled to room temperature and filtered. The solid was washed several times with
absolute ethanol. The filtrate and washings were combined and diluted with 2 volumes
of water and acidified with 5N HCl to a pH of ~2 and the product precipitated. The
mixture was chilled and then filtered. The solid was washed several times with diethyl
ether and then dried to yield 218mg (38%) of an off-white solid. MS: (ESI, neg.) m/z
228.9 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.35 (br.s, 2H), 7.33 (t, 2H),
7.23 (m, 3H), 5.19 (s, 1H), 1.62 (s, 6H)
4.2.2.10 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)pyrimidine-4,6diol (31)

Prepared in a manner similar to compound 30 from sodium metal (140mg,
6.11mmol), amidine hydrochloride 27 (500mg, 2.44mmol), and diethyl malonate
(388mg, 2.42mmol). Product is an off-white solid. Yield: 185mg (32%). MS: (ESI,
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neg.) m/z 235.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.39 (br.s, 2H), 7.41
(d, 1H), 6.99 (d, 1H), 6.97 (t, 1H), 5.2 (s, 1H),1.72 (s, 6H).
4.2.2.11 Synthesis of 2-(2-cyclohexylpropan-2-yl)pyrimidine-4,6-diol
(32)

Prepared in a manner similar to compound 30 from sodium metal (140mg,
6.11mmol), amidine hydrochloride 28 (500mg, 2.44mmol), and diethyl malonate
(509mg, 3.18mmol). Product is an off-white solid. Yield: 185mg (32%). MS: (ESI,
neg.) m/z 235.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.41 (br.s, 2H), 5.12
(s, 1H), 1.80 (t, 1H), 1.69 (d, 2H), 1.38 (s, 1H),1.72 (d, 2H), 1.19 – 1.02 (m, 4H), 1.15 (s,
6H), 0.94 (dd, 2H).
4.2.2.12 Synthesis of 2-(2-methyloctan-2-yl)pyrimidine-4,6-diol (33)

Prepared in a manner similar to compound 30 from sodium metal (111mg,
4.84mmol), amidine hydrochloride 29 (400mg, 1.93mmol), and diethyl malonate
(309mg, 1.93mmol). Product is a light peach colored solid. Yield: 39% MS: (ESI, neg.)
m/z 236.8 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.33 (br.s, 2H), 5.13 (s,
1H), 1.62 (m, 2H), 1.22 (s, 6H), 1.20 (m, 6H), 1.04 (m, 2H), 0.83 (t, 3H).
4.2.2.13 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4d]pyrimidin-1-ol (34)

Dihydroxy pyrimidine 30 (100 mg, 0.434 mmol) was added to 3ml of absolute
ethanol in a 10ml microwave reaction vessel. To this was also added 66µl of pyridine
and 3µl of piperidine followed by (R)-(+)-citronellal (201mg, 235µl, 1.3mmol). The
reaction vessel was then sealed and irradiated at 200 watts to 130°C for 1 hour. The
reaction mixture was then concentrated and the product purified by flash chromatography
using a methanol/methylene chloride gradient to yield 180 mg (69%) of the objective
product as an off-white solid. MS: (ESI, neg.) m/z 365.0 [M – H]-, 1H NMR (500 MHz,
DMSO-d6): δ 11.43 (s, 1H), 7.32 (q, 2H, J = 7.5Hz), 7.21 (m, 3H), 3.06 (d, 1H, J =
12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.76 (m, 2H), 1.56 (m, 11H), 1.37 (s, 3H),
1.01 (m, 2H), 0.87 (d, 3H, J = 6.5Hz), 0.48 (q, 1H, J = 12Hz). 13C NMR (500 MHz,
DMSO-d6): δ (ppm) 163.44, 163.23, 145.75, 128.27, 128.23, 126.46, 126.06, 125.86,
99.47, 79.98, 47.47, 44.48, 36.86, 34.83, 33.44, 31.81, 27.19, 27.05, 26.90, 22.40, 19.46.
HPLC retention time: 10.631min; purity 100%.

127

4.2.2.14 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-(thiophen-2yl)propan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4d]pyrimidin-1-ol (35)

Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 31
(23mg, 0.097mmol) and (R)-(+)-citronellal (45mg, 53µl, 0.292mmol). Yield: 46% MS:
(ESI, neg.) m/z 371.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.52 (s, 1H), 7.40 (d,
1H, J = 4.5Hz), 6.97 (m, 2H), 3.06 (d, 1H, J = 12Hz), 2.16 (td, 1H, J = 11.5Hz and 2Hz),
1.70 (m, 8H), 1.50 (m, 2H), 1.36 (s, 3H), 1.06 (m, 5H), 0.87 (d, 3H, J = 6.5Hz), 0.47 (q,
1H, J = 12Hz). 13C NMR (500MHz, DMSO-d6): δ (ppm) 163.46, 163.07, 150.12,
126.70, 126.64, 124.86, 124.39, 99.63, 80.07, 47.42, 42.72, 36.79, 34.80, 33.42, 31.80,
28.08, 28.00, 27.02, 26.87, 22.40, 19.43. HPLC retention time: 10.580min; purity
98.04%.
4.2.2.15 Synthesis of (6aS,9R,10aR)-3-(2-cyclohexylpropan-2-yl)-6,6,9trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4d]pyrimidin-1-ol (36)

Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 32
(100mg, 0.42mmol) and (R)-(+)-citronellal (194mg, 228µl, 1.26mmol). Yield: 36% MS:
(ESI, neg.) m/z 371.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.52 (s, 1H), 3.10 (d,
1H, J = 12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.73 (m, 5H), 1.52 (m, 2H), 1.34 (s,
3H), 1.26 (m, 4), 1.10 (m, 10H), 1.05 (s, 3H), 0.96 (m, 2H), 0.88 (d, 3H, J = 6.5Hz), 0.48
(q, 1H, J = 12Hz). 13C NMR (500MHz, DMSO-d6): δ (ppm) 165.54, 163.41, 163.34,
98.96, 79.78, 47.47, 44.61, 43.13, 36.97, 34.83, 33.45, 31.83, 27.17, 27.03, 26.90, 26.39,
26.06, 22.41, 22.05, 21.99, 19.41. HPLC retention time: 11.732min; purity 97.65%.
4.2.2.16 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-methyloctan2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol
(37)

Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 33
(100mg, 0.42mmol) and (R)-(+)-citronellal (194mg, 228µl, 1.26mmol). Yield: 31% MS:
(ESI, neg.) m/z 373.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.57 (s, 1H), 3.10 (d,
1H, J = 12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.75 (m, 2H), 1.56 (m, 6H), 1.34 (s,
3H), 1.18 (m, 12H), 1.02 (m, 5H), 0.89 (d, 3H, J = 6.5Hz), 0.82 (t, 3H, J = 7Hz), 0.48 (q,
1H, J = 12Hz). 13C NMR (500MHz, DMSO-d6): δ (ppm) 163.79, 163.47, 163.14, 99.01,
79.78, 47.52, 44.58, 40.14, 36.95, 34.85, 33.44, 31.82, 30.98, 29.00, 27.03, 26.89, 25.71,
25.59, 23.87, 22.42, 22.02, 19.37, 13.91. HPLC retention time: 12.503min; purity
95.12%.
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4.2.3 Synthesis of Pyrimidine Non-Classical Cannabinoids

The first attempts at synthesis of the heteroaromatic triaryl compounds utilized
reactions that were successfully employed in the creation of the carbocyclic triaryl
compounds.127 The rationale was that the previously created dihydroxy pyrimidines
(Compounds 30, 31, 32, and 33) could be activated for Suzuki coupling to introduce the
aromatic C ring. This was accomplished by bromination of the dihydroxy pyrimidines in
the 5 position by N-bromosuccinimide (Scheme 4.14).176 This brominated compound
would then be a substrate for the palladium catalyzed Suzuki reaction. This reaction,
however, was not successful in formation of the triaryl coupled products (Scheme 4.15).
With the experience gained from the successful formation of the dihydroxy
pyrimidines, it was decided to form the final compounds by cyclization of the pyrimidine
ring with the side chain and the aromatic C ring already in place. This could be
accomplished in a reaction similar to the formation of the dihydroxy pyrimidines by
reaction of an amidine with a substituted diethyl malonate (Scheme 4.16). The 2position substituted diethyl malonates can be formed by copper catalyzed coupling of an
alkyl or aryl halide and diethyl malonate (Scheme 4.17).177 Six substituted malonates
were reacted with four amidine hydrochlorides to successfully yield fifteen pyrimidine
nonclassical cannabinoids (Figure 4.6). Some of the combinations of synthons would
not react to yield a substituted pyrimidine product in every permutation . The
purification of theses compounds was more involved than the dihydroxy pyrimidines
which were precipitated by acidification. The pyrimidine nonclassical cannabinoids
formed a gummy resin in the aqueous solution upon acidification. This was extracted
with ethyl acetate, dried over sodium sulfate, concentrated by rotary evaporation, and
purified using flash chromatography.
All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc.
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic
sodium and benzophenone. Final compounds and intermediates were purified using
column chromatography on the Biotage SP1 system employing Flash column cartridges
or by crystallization. NMR spectra were obtained on a Bruker 300MHz or Varian
500MHz Inova NMR. HPLC analysis of final products was carried out by gradient
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min),
and 10% (15min). A reverse-phase ODS Hypersil column, manufactured by Thermo
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC
analyses.
4.2.3.1 Synthesis of diethyl 2-m-tolylmalonate (38)

A two-necked round-bottomed flask was charged sequentially with CuI (0.114 g,
0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), and CsCO3 (5.89 g, 18 mmol). The
flask was evacuated and back filled with nitrogen 3 times. Anhydrous 1,4-dioxane
(10 ml) was added volumetrically followed by distilled diethyl malonate (1.9 ml,
12 mmol) and 3-iodotoluene (0.8ml, 6 mmol). The reaction was heated to 70°C for 30
hours. After monitoring the progress by TLC, the reaction was cooled to room
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temperature, diluted with ethyl acetate and washed with ammonium chloride. The
organic phase was dried over sodium sulfate, concentrated, and the product purified by
column chromatography using a 1:9 ethyl acetate/hexane mixture to yield the product as
a colorless oil. Yield: 92%, Rf = 0.48 (ethyl acetate/hexane = 1:9). MS: (ESI, pos.) m/z
273.0 [M + Na]+, 1H NMR (500 MHz, CDCl3): δ (ppm) 7.12-7.3 (m, 4H), 4.62 (s, 1H),
4.20-4.28 (m, 4H),2.27 (s, 3H), 1.22-1.25 (m, 6H).
4.2.3.2 Synthesis of diethyl 2-(3,5-dichlorophenyl)malonate (39)

Compound 39 was prepared in a manner similar to compound 38 from CuI
(0.17 g, 0.89 mmol), 2-picolinic acid (0.22 g, 1.78 mmol), CsCO3 (8.7 g, 26.7 mmol),
diethyl malonate (2.9ml, 17.8mmol), and 1,3-dichloro-5-iodobenzene (2.4g, 8.9mmol).
Rf = 0.41 (ethyl acetate/hexane = 1:9). MS: (ESI, pos.) m/z 328 [M + Na]+, 1H NMR
(500 MHz, CDCl3): δ (ppm) 7.34 (m, 3H), 4.54 (s, 1H), 4.25 (m, 4H), 1.28 (t, 6H).
4.2.3.3 Synthesis of diethyl 2-cyclohexylmalonate (40)

Compound 40 was prepared in a manner similar to compound 38 from CuI
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol),
diethyl malonate (1.9ml, 12mmol), and iodocyclohexane (0.8ml, 6mmol). Yield: 94%,
Rf = 0.59 (ethyl acetate/hexane = 1:9). MS: (ESI, pos.) m/z 265 [M + Na]+, 1H NMR
(500 MHz, CDCl3): δ (ppm) 4.22-4.14 (m, 4H), 3.12 (d, 1H), 2.14-2.05 (m, 1H), 1.751.63 (m, 5H), 1.34-1.24 (m, 8H), 1.20-1.20 (m, 3H).
4.2.3.4 Synthesis of diethyl 2-(pyridin-2-yl)malonate (41)

Compound 41 was prepared in a manner similar to compound 38 from CuI
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol),
diethyl malonate (1.9ml, 12mmol), and 2-bromopyridine (0.59ml, 6mmol). Yield: 88%,
Rf = 0.32 (ethyl acetate/hexane = 3:7). MS: (ESI, pos.) m/z 260 [M + Na]+, 1H NMR
(500 MHz, CDCl3): δ (ppm) 8.5 (d, 1H), 7.7 (d, 1H), 7.62-7.58 (m, 1H), 7.18-7.12 (m,
1H), 4.80 (s, 1H), 4.21-4.15 (m, 4H), 1.21 (t, 6H).
4.2.3.5 Synthesis of diethyl 2-benzylmalonate (42)

Compound 42 was prepared in a manner similar to compound 38 from CuI
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol),
diethyl malonate (1.9ml, 12mmol), and benzyl bromide (1.44ml, 6mmol). Yield: 78%.
Rf = 0.52 (ethyl acetate/hexane = 1:9). MS: (ESI, pos.) m/z 273 [M + Na]+, 1H NMR
(300 MHz, CDCl3): δ (ppm) 7.24 (m, 5H), 4.15 (q, 4H), 3.66 (t, 1H), 3.22 (d, 2H), 1.18
(t, 6H).
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4.2.3.6 Synthesis of diethyl 2-hexylmalonate (43)

Compound 43 was prepared in a manner similar to compound 38 from CuI
(0.019 g, 0.1mmol), 2-picolinic acid (0.025 g, 0.2 mmol), CsCO3 (0.977g, 3mmol),
diethyl malonate (0.3ml, 2mmol), and 1-iodohexane (0.15ml, 1mmol). Yield: 91%, Rf =
0.44 (ethyl acetate/hexane = 1:9). MS: (ESI, pos.) m/z 267 [M + Na]+, 1H NMR (300
MHz, CDCl3): δ (ppm) 4.11-4.40 (m, 4H), 331 (t, 1H), 1.80 (m, 2H), 1.38 (m, 2H), 1.11.4 (m, 12H), 0.8 (t, 3H).
4.2.3.7 Synthesis of 2-(2-phenylpropan-2-yl)-5-m-tolylpyrimidine-4,6diol (44)

Sodium metal (115mg, 5mmol) was reacted with 4ml of anhydrous ethanol. To
this was added 400 mg (2 mmol) of 2-methyl-2-phenylpropanimidamide hydrochloride
26 and the reaction was allowed to stir at room temperature for 5 minutes. Diethyl 2-mtolylmalonate 38 (500mg, 2mmol) was then added in 2ml of anhydrous ethanol and the
reaction was heated to reflux overnight. The reaction was then cooled to room
temperature and filtered. The solid was washed several times with absolute ethanol. The
filtrate and washings were combined and diluted with 2 volumes of water and acidified
with 5N HCl to a pH of ~2 and the product precipitated as a sticky resin. The product
was extracted with ethyl acetate and dried over sodium sulfate. The organic phase was
concentrated and the product purified on a Biotage SP-1 flash chromatography using a
MeOH/CH2Cl2 gradient. Yield: 39% MS: (ESI, neg.) m/z 319.0 [M – H]-, 1H NMR (500
MHz, DMSO-d6): δ (ppm) 11.50 (br.s, 2H), 7.36 (t, 2H, J = 7Hz), 7.30 (d, 2H, J =
7.5Hz), 7.25 (m, 3H), 7.19 (t, 1H, J = 7.5Hz), 7.01 (d, 1H, J = 7.5Hz), 2.29 (s, 3H), 1.68
(s, 6H). 13C NMR (500MHz, DMSO-d6): δ (ppm) 145.79, 135.93, 132.54, 130.96,
128.31, 127.56, 127.07, 126.75, 126.51, 126.03, 100.61, 44.64, 27.26, 21.08. HPLC

retention time: 9.724min; purity 99.65%.
4.2.3.8 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)-5-mtolylpyrimidine-4,6-diol (45)

Compound 45 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.11mmol), EtOH (8ml), 2-methyl-2-(thiophen-2-yl)propanimidamide
hydrochloride 27 (500mg, 2.44mmol), and diethyl 2-m-tolylmalonate 38 (611mg,
2.44mmol). Yield 4.3%, MS: (ESI, neg.) m/z 324.9 [M – H]-, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 11.51 (br.s, 2H), 7.44 (dd, 1H, J = 5Hz and 1Hz), 7.23 (s, 1H), 7.20
(q, 2H, J = 8Hz), 7.06 (dd, 1H, J = 3.5Hz and 1.5Hz), 7.00 (m, 2H), 2.28 (s, 3H), 1.70 (s,
6H). 13C NMR (500MHz, DMSO-d6): δ (ppm) 150.33, 136.00, 132.46, 130.96, 127.57,
127.14, 126.85, 126.77, 126.46, 124.91, 124.40, 123.41, 100.76, 42.88, 28.14, 21.11.

HPLC retention time: 8.060min; purity 95.35%.
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4.2.3.9 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-m-tolylpyrimidine4,6-diol (46)

Compound 46 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.11mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide
hydrochloride 28 (500mg, 2.44mmol), and diethyl 2-m-tolylmalonate 38 (796mg,
3.18mmol). Yield 21%, MS: (ESI, neg.) m/z 325 [M – H]-, 1H NMR (500 MHz, DMSOd6): δ (ppm) 11.55(br.s), 7.26 (s, 1H) 7.23 (d, 1H, J = 8Hz), 7.17 (t, 1H, J = 7.5Hz), 6.99
(d, 1H, J = 7.5Hz), 2.28 (s, 3H), 1.87 (t, 1H, J = 12Hz), 1.72 (d, 2H, J = 12.5Hz), 1.44 (d,
2H, J = 12Hz), 1.20 (s, 6H), 1.18 to 1.06 (m, 4H), 0.99 (m, 2H). 13C NMR (500MHz,
DMSO-d6): δ (ppm) 170.36, 165.93, 135.90, 132.80, 131.01, 127.60, 127.07, 126.63,
100.04, 59.77, 44.84, 43.29, 27.22, 26.41, 26.06, 22.11, 21.13, 20.78, 14.10. HPLC

retention time: 10.095min; purity 99.23%.
4.2.3.10 Synthesis of 2-(2-methyloctan-2-yl)-5-m-tolylpyrimidine-4,6diol (47)

Compound 47 was prepared in a similar manner to compound 44 from sodium
metal (111mg, 4.83mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29
(400mg, 1.93mmol), and diethyl 2-m-tolylmalonate 38 (483mg, 1.93mmol). Yield
11.2%, MS: (ESI, pos.) m/z 351.3 [M + Na]+, 1H NMR (500 MHz, DMSO-d6): δ (ppm)
11.58 (br.s, 2H), 7.26 (s, 1H) 7.22 (d, 1H, J = 7.5Hz), 7.19 (t, 1H, J = 7.5Hz), 7.01 (d, 1H,
J = 7.5Hz), 2.91 (s, 3H), 1.68 (m, 2H), 1.28 (s, 6H), 1.24 to 1.07 (m, 16H), 0.853 (m,
3H). 13C NMR (500MHz, DMSO-d6): δ (ppm) 179.57, 165.84, 136.39, 133.20, 131.47,
128.08, 127.55, 127.16, 100.64, 48.48, 40.61, 31.53, 29.57, 26.21, 25.90, 24.48, 22.53,
21.61, 14.39. HPLC retention time: 9.685min; purity 91.54%.
4.2.3.11 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-phenylpropan-2yl)pyrimidine-4,6-diol (48)

Compound 48 was prepared in a similar manner to compound 44 from sodium
metal (115mg, 5mmol), EtOH (6ml), 2-methyl-2-phenylpropanimidamide hydrochloride
26 (400mg, 2mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 (610mg, 2mmol).
Yield: 27%; MS: (ESI, neg.) m/z 372.9 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ
(ppm) 12.48 (br.s, 2H), 7.61 (d, 2H, J = 2Hz), 7.49 (s, 1H), 7.31 (m, 2H), 7.27 (m, 3H),
1.68 (s, 6H). 13C NMR (500MHz, DMSO-d6): δ (ppm) 172.33, 171.56, 141.09, 139.75,
134.08, 133.23, 129.02, 128.97, 126.78, 126.73, 110.00, 45.28, 32.74. HPLC retention
time: 9.335min; purity 92.38%.
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4.2.3.12 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-(thiophen-2yl)propan-2-yl)pyrimidine-4,6-diol (49)

Compound 49 was prepared in a similar manner to compound 44 from sodium
metal (113mg, 4.9mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide
hydrochloride 27 (400mg, 1.95mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39
(595mg, 1.95mmol). Yield: 32%; MS: (ESI, neg.) m/z 378.8 [M – H]-, 1H NMR (500
MHz, DMSO-d6): δ (ppm) 7.62 (s, 2H), 7.48 (s, 1H), 7.43 (d, 1H, J = 5.5Hz), 7.06 (d,
1H, J = 3.5Hz), 6.99 (t, 1H, J = 5Hz), 1.77 (s, 6H). 13C NMR (500MHz, DMSO-d6): δ
(ppm) 172.39, 171.61, 141.14, 139.83, 134.12, 133.24, 129.13, 128.96, 126.87, 126.71,
99.19, 39.41, 28.08. HPLC retention time: 9.335min; purity 90.19%.
4.2.3.13 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(3,5dichlorophenyl)pyrimidine-4,6-diol (50)

Compound 50 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.1mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide
hydrochloride 28 (500mg, 2.44mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39
(970mg, 3.18mmol). Yield: 7%; MS: (ESI, neg.) m/z 379.0 [M – H]-, 1H NMR (500
MHz, DMSO-d6): δ (ppm) 7.69 (s, 2H), 7.38 (s, 1H), 1.87 (m, 1H), 1.68 (m, 3H), 1.44 (d,
2H, J = 11Hz), 1.21 (s, 6H), 1.12 (m, 3H), 0.98 (m, 2H). 13C NMR (500MHz, DMSOd6): δ (ppm) 172.38, 171.61, 140.65, 135.68, 133.24, 128.46, 100.25, 59.77, 44.10, 42.98,
27.22, 26.49, 26.02, 21.67, 20.34, 14.10. HPLC retention time: 8.932min; purity 94.24%.
4.2.3.14 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-methyloctan-2yl)pyrimidine-4,6-diol (51)

Compound 51 was prepared in a similar manner to compound 44 from sodium
metal (111mg, 4.83mmol), EtOH (8ml), 2,2-dimethyloctanimidamide hydrochloride 29
(400mg, 1.93mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 (589mg, 1.93mmol).
Yield: 14%; MS: (ESI, neg.) 380.9 m/z [M – H]-, 1H NMR (500 MHz, methanol-d4): δ
(ppm) 7.57 (s, 2H), 7.24 (s, 1H), 1.71 (m, 2H), 1.34 (m, 5H), 1.28 (s, 6H), 1.20 (m, 3H),
0.88 (t, 3H, J = 6Hz). 13C NMR (500MHz, DMSO-d6): δ (ppm) 170.98, 169.54, 139.32,
135.79, 131.05, 129.09, 100.15, 48.48, 40.61, 30.48, 29.79, 26.92, 25.43, 23.76, 22.53,
14.41. HPLC retention time: 9.132min; purity 96.84%.
4.2.3.15 Synthesis of 5-cyclohexyl-2-(2-phenylpropan-2-yl)pyrimidine4,6-diol (52)

Compound 52 was prepared in a similar manner to compound 44 from sodium
metal (145mg, 6.3mmol), EtOH (6ml), 2-methyl-2-phenylpropanimidamide
hydrochloride 26 (500mg, 2.5mmol), and diethyl 2-cyclohexylmalonate 40 (606mg,
2.5mmol). Yield: 39% (yellow waxy solid) MS: (ESI, neg.) m/z 311.0 [M – H]-, 1H
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NMR (500 MHz, DMSO-d6): δ (ppm) 11.30 (br.s, 1H), 10.93 (br.s., 1H), 7.33 (m, 2H),
7.23 (m, 3H), 2.72 (tt, 1H, J = 12.5Hz and 3Hz), 1.92 (q, 2H, J = 13Hz), 1.70 (d, 2H, J =
12.5Hz), 1.62 (s, 7H), 1.38 (d, 2H, J = 12Hz), 1.18 (m, 3H). 13C NMR (500MHz,
DMSO-d6): δ (ppm) 164.35, 145.90, 128.28, 126.46, 126.02, 104.19, 44.34, 33.28, 28.87,
27.25, 26.67, 25.75. HPLC retention time: 8.983min; purity 99.46%.
4.2.3.16 Synthesis of 5-cyclohexyl-2-(2-(thiophen-2-yl)propan-2yl)pyrimidine-4,6-diol (53)

Compound 53 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.1mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide
hydrochloride 27 (500mg, 2.44mmol), and diethyl 2-cyclohexylmalonate 40 (591mg,
2.44mmol). Yield 8%, MS: (ESI, neg.) m/z 316.9 [M – H]-, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 11.36 (br.s, 1H), 10.88 (br.s, 1H) 7.39 (d, 1H, J = 5Hz), 7.01 (s,
1H), 6.96 (t, 1H, J = 3.5Hz), 2.72 (t, 1H, J = 12Hz), 1.91 (q, 2H, J = 12.5Hz), 1.72 (s,
6H), 1.61 (d, 1H, J = 10.5Hz), 1.36 (d, 2H, J = 12Hz), 1.18 (m, 3H). 13C NMR (500MHz,
DMSO-d6): δ (ppm) 164.41, 126.72, 124.80, 124.29, 109.53, 104.31, 48.61, 42.60, 33.27,
28.80, 28.11, 26.63, 25.72. HPLC retention time: 8.934min; purity 100%.
4.2.3.17 Synthesis of 5-cyclohexyl-2-(2-cyclohexylpropan-2yl)pyrimidine-4,6-diol (54)

Compound 54 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.1mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide
hydrochloride 28 (500mg, 2.44mmol), and diethyl 2-cyclohexylmalonate 40 (770mg,
3.18mmol). Yield 1.3%, MS: (ESI, neg.) m/z 316.9 [M – H]-, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 11.43 (br.s, 1H), 10.64 (br.s, 1H) 2.72 (tt, 1H, J = 12.5Hz and
3.5Hz), 1.91 (m, 2H), 1.81 (t, 1H, J = 12Hz), 1.71 (d, 4H, J = 12Hz), 1.61 (m, 2H), 1.37
(d, 2H, J = 12.5Hz), 1.23 to 0.90 (m, 16H). 13C NMR (500MHz, DMSO-d6): δ (ppm)
164.44, 164.29, 103.69, 44.73, 42.98, 33.25, 28.94, 27.18, 26.68, 26.38, 26.06, 25.75,
22.11. HPLC retention time: 10.273min; purity 98.33%.
4.2.3.18 Synthesis of 5-cyclohexyl-2-(2-methyloctan-2-yl)pyrimidine4,6-diol (55)

Compound 55 was prepared in a similar manner to compound 44 from sodium
metal (111mg, 4.84mmol), EtOH (8ml), 2,2-dimethyloctanimidamide hydrochloride 29
(400mg, 1.93mmol), and diethyl 2-cyclohexylmalonate 40 (468mg, 1.93mmol). Yield
4.5%, MS: (ESI, neg.) m/z 319.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): 2.72 (tt, 1H,
J = 12Hz and 3Hz), 1.92 (m, 2H), 1.70 (d, 2H, J = 12.5Hz), 1.61 (t, 4H, J = 8.5Hz), 1.37
(d, 2H, J = 12Hz), 1.23 to 1.16 (m, 16H), 1.04 (m, 2H), 0.83 (m, 4H). 13C NMR
(500MHz, DMSO-d6): δ (ppm) 164.35, 163.82, 103.74, 40.26, 33.23, 31.03, 29.04, 28.90,
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26.67, 25.75, 25.71, 23.95, 22.04, 13.91. HPLC retention time: 10.304min; purity

99.06%.
4.2.3.19 Synthesis of 5-(pyridin-2-yl)-2-(2-(thiophen-2-yl)propan-2yl)pyrimidine-4,6-diol (56)

Compound 56 was prepared in a similar manner to compound 44 from sodium
metal (112mg, 4.88mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide
hydrochloride 27 (400mg, 1.95mmol), and diethyl 2-(pyridin-2-yl)malonate 41 (463mg,
1.95mmol). Yield 1%, MS: (ESI, pos.) m/z 336.1 [M + Na]+, 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 9.13 (d, 1H, J = 8.5Hz) 8.57 (s, 1H), 8.12 (td, 1H, J = 7.5Hz and
1.5Hz), 7.41 (q, 2H, J = 7.5Hz), 7.59 (d, 1H, J = 4), 6.98 (t, 1H, J = 4Hz), 1.73 (s, 6H).

HPLC retention time: 8.367min; purity 97.78%.
4.2.3.20 Synthesis of 5-benzyl-2-(2-methyloctan-2-yl)pyrimidine-4,6diol (57)

Compound 57 was prepared in a similar manner to compound 44 from sodium
metal (111mg, 4.84mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29
(400mg, 1.93mmol), and diethyl 2-benzylmalonate 42 (483mg, 1.93mmol). Yield 21%
MS: (ESI, neg.) m/z 327.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.34
(br.s), 7.21 (m, 4H) 7.11 (m, 1H), 3.57 (s, 2H), 1.63 (m, 2H), 1.22 (s, 6H), 1.21 to 1.19
(m, 6H), 1.04 (m, 2H), 0.82 (t, 3H, J = 6.5Hz). 13C NMR (500MHz, DMSO-d6): δ (ppm)
164.70, 141.19, 128.23, 127.97, 125.49, 99.07, 54.92, 40.37, 39.77, 31.02, 29.03, 27.81,
25.77, 23.97, 22.02, 13.91. HPLC retention time: 9.716min; purity 100%.
4.2.3.21 Synthesis of 5-hexyl-2-(2-methyloctan-2-yl)pyrimidine-4,6diol (58)

Compound 58 was prepared in a similar manner to compound 44 from sodium
metal (140mg, 6.05mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29
(500mg, 2.42mmol), and diethyl 2-hexylmalonate 43 (591mg, 2.42mmol). Yield 9%,
MS: (ESI, neg.) m/z 321.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.47
(br.s, 2H), 4.10 (q, 1H, J = 7.5Hz) 3.29 (t, 1H, J = 7.5Hz), 2.23 (t, 2H, J = 7.5Hz), 1.71
(q, 1H, J = 7Hz), 1.62 (m, 2H), 1.36 (t, 2H, J = 6.5Hz), 1.24 (s, 6H), 1.21 to 1.16 (m, 9H),
1.02 (m, 2H), 0.83 (m, 6H). 13C NMR (500MHz, DMSO-d6): δ (ppm) 170.52, 169.50,
164.69, 163.88, 99.72, 60.59, 51.39, 40.40, 31.27, 31.06, 29.06, 28.73, 28.34, 27.58,
26.62, 25.81, 23.99, 22.03, 13.97. HPLC retention time: 10.616min; purity 97.38%.
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4.2.4 Synthesis of Furanopyrimidine Cannabinoids

With the successful synthesis of both the pyrimidine hexahydro classical
cannabinoids and the pyrimidine non-classical cannabinoids, sights were set on
expansion of the pyrimidine containing series of compounds. Upon review of the current
medicinal chemistry literature, a series of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines that
had been developed by Amgen Inc. as inhibitors of lymphocyte-specific kinase (Lck)178
caught our attention. The general structure of this series of compounds (Figure 4.7) has
aspects of both a conformationally restricted pyrimidine non-classical cannabinoid and a
ring-contracted pyrimidine classical cannabinoid in which the six-membered pyran ring
has been replaced by a five-membered furan. These compounds lacked the side chain at
the 2-position of the pyrimidine ring found in the previously described pyrimidine
cannabinoids. This series of compounds contained two substituents on the furan ring:
one being an unsubstituted phenyl and the other a substituted phenyl.
It was decided to design the furanopyrimidine with just one aryl substitution on
the furan ring in order to form compounds that would occupy similar space to the
previously described pyrimidine cannabinoids. These new compounds were also to be
synthesized with a side chain present similar to the classical and non-classical pyrimidine
cannabinoids (Figure 4.8). By adapting the chemistry of DiMauro et al.178a the
furanopyrimidine cannabinoids were formed by the base catalysed cyclization of a
substituted dihydroxy pyrimidine with a 2-chloro-2-nitrovinyl substituted aromatic ring
(Scheme 4.18).
The substituted dihydroxy pyrimidines used were the same ones formed for the
pyrimidine hexahydro classical cannabinoids (Scheme 4.12) from substituted amidines
and diethyl malonate. The 2-chloro-2nitrovinyl styrenes were formed from substituted
benzaldehydes, bromonitromethane, dimethylamine hydrochloride, and potassium
fluoride in xylenes (Scheme 4.19). The reaction is fitted with a Dean-Stark trap to allow
for azeotropic removal of water and heated to 125°C for 8 hours. The styrenes were then
readily purified by flash column chromatography.
Four styrenes (phenyl, m-tolyl, 3,5-dichloro phenyl, and 2-thiophenyl) were
cyclized with four substituted dihydroxy pyrimidines (dimethyl phenyl, dimethyl
thiophenyl, dimethyl cyclohexyl, and dimethyl heptyl) to form sixteen new
furanopyrimidine cannabinoids (Figure 4.9).
All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc.
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic
sodium and benzophenone. Final compounds and intermediates were purified using
column chromatography on the Biotage SP1 system employing Flash column cartridges
or by crystallization. NMR spectra were obtained on a Bruker 300MHz or Varian
500MHz Inova NMR. HPLC analysis of final products was carried out by gradient
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min),
and 10% (15min). A reverse-phase ODS Hypersil column, manufactured by Thermo
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC
analyses.
141

NH
N
HN

N
R
O

N

HN
O
N
R
O

N

R = Various amino substituted phenyl rings

Figure 4.7: General structure of Lck inhibitors

142

R1

OH

N

O

R2
N

R1 = Substituted aryl groups
R2 = Alkyl or aryl groups

Figure 4.8: General structure of furanopyrimidine cannabinoids

143

OH

Cl

NO2

a

N

+
HO

N

OH

R1

R1
R2

N
O

N

S

R1 =

R2 =

Cl

Cl
S

Scheme 4.18: General synthesis of furanopyrimidine cannabinoids

(a) DBU, acetonitrile, µwave, 100watts, 120°C, 15min.

144

R2

R

R

a

H
O

Cl

59
R=

H
NO 2

60

Cl

Cl

S
62

61

Scheme 4.19: Synthesis of 2-chloro-2-nitrovinyl styrenes

(a) bromonitromethane, dimethylamine hydrochloride, potassium fluoride, xylenes,
125°C, 8hr.

145

OH
N
O N

OH
N
O N

63

64

OH
N
O N

OH
N
O N

67

Cl

OH
N
O N

OH
N
O N

S

75

OH
N
O N

69

Cl

70

OH
N
O N

Cl

OH
N
O N

S

72
S

66

Cl

OH
N
O N

71

OH
N
O N

65

Cl

OH
N
O N

S

S

68

Cl
Cl

OH
N
O N

Cl

OH
N
O N

73
S
S

76

OH
N
O N
77

Figure 4.9: Furanopyrimidine cannabinoids

146

74
S

OH
N
O N
78

4.2.4.1 Synthesis of (2-chloro-2-nitrovinyl)benzene (59)

Benzaldehyde (3.59g, 33.8 mmol), bromonitromethane (9.0g, 64.3 mmol),
dimethylamine hydrochloride (24.8g, 304.2mmol), potassium fluoride (0.3g, 5.08mmol)
and m- xylenes (50mL) were combined in a 250mL round bottomed flask fitted with a
Dean-Stark trap. The mixture was heated at 125°C with azeotropic removal of water for
8h. The reaction mixture was concentrated and the residue was extracted with a mixture
of 1:1 dicloromethane and water. After separation of the organic layer, the aqueous layer
was extracted three times with dicloromethane. The combined organics were dried over
anhydrous Na2SO4 and concentrated to a brown oil. The oily residue thus obtained was
purified on a silica column (Biotage SP1 system) using a 1:9 ethyl acetate /hexane
mixture to obtain the product as pale yellow needles (4.8g, 77%). Rf = 0.66 (1:9 ethyl
acetate/hexane). 1H NMR (300 MHz, CDCl3): δ (ppm) 8.40 (s,1H), 7.86-7.90 (m,2H),
7.51-7.5 (m,3H).
4.2.4.2 Synthesis of 1-(2-chloro-2-nitrovinyl)-3-methylbenzene (60)

Compound 60 was prepared in a manner similar to compound 59. 1H NMR (300
MHz, CDCl3): δ (ppm) 8.38 (s,1H), 7.67 (t,2H), 7.36-7.41 (m,2H), 2.45 (s,3H).
4.2.4.3 Synthesis of 1,3-dichloro-5-(2-chloro-2-nitrovinyl)benzene (61)

Compound 61 was prepared in a manner similar to compound 59. 1H NMR (300
MHz, CDCl3): δ (ppm) 8.23 (s,1H), 7.74 (d,2H), 7.52 (s,1H).
4.2.4.4 Synthesis of 2-(2-chloro-2-nitrovinyl)thiophene (62)

Compound 62 was prepared in a manner similar to compound 59. 1H NMR (300
MHz, CDCl3): δ (ppm) 8.65 (s,1H), 7.81 (d, 1H), 7.69 (d,1H), 7.27-7.28(t,1H).
4.2.4.5 Synthesis of 5-phenyl-2-(2-phenylpropan-2-yl)furo[2,3d]pyrimidin-4-ol (63)

100mg (0.434mmol) of 2-(2-phenylpropan-2-yl)pyrimidine-4,6-diol 30 and 73mg
(0.4mmol) of (2-chloro-2-nitrovinyl)benzene 59 were dissolved in 2ml acetonitrile in a
10ml microwave reaction vessel. 122 mg (0.8mmol) of 1,8-diazabicyclo[5.4.0]undec-7ene (DBU) was then added and the vessel sealed. The vessel was irradiated in a CEM
LabMate microwave reactor (CEM, Matthews, NC USA) at 100watts to 120°C for 15
minutes. The reaction mixture was then concentrated and the target compound purified
by flash chromatography on a Biotage SP1 (Biotage, Charlottesville, VA USA) using a
methylene chloride / methanol gradient. Yield: 42.3%. MS: (ESI, neg) m/z 329.0 [M –
H]-, 1H NMR (500 MHz, DMSO): δ (ppm) 12.03 (s, 1H), 8.24 (s, 1H), 7.96 (d, 2H, J =
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7.5Hz), 7.41 (t, 2H, J = 7.5Hz), 7.33 (q, 3H, J = 7.5Hz), 7.26 (t, 3H, J = 8Hz), 1.71 (s,
6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.49, 164.18, 159.79, 145.77, 138.41,
130.22, 128.37, 128.32, 127.94, 126.57, 129.17, 123.49, 120.92, 44.98, 27.53. HPLC
retention time: 10.185min; purity 100%.
4.2.4.6 Synthesis of 5-phenyl-2-(2-(thiophen-2-yl)propan-2-yl)furo[2,3d]pyrimidin-4-ol (64)

Compound 64 was prepared in a manner similar to compound 63 from 2-(2(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31(100mg, 0.423mmol), (2-chloro-2nitrovinyl)benzene 59 (73mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 26.8%. MS: (ESI, neg.) m/z 335.0 [M – H]-, 1H NMR (500 MHz, DMSO):
δ (ppm) 12.01 (s, 1H), 8.24 (s, 1H), 7.96 (d, 2H, J = 7.5Hz), 7.42 (q, 3H, J = 8Hz), 7.32
(t, 1H, J = 7Hz), 7.04 (d, 1H, J = 3Hz), 6.99 (t, 1H, J = 4.5Hz), 1.86 (s, 6H); 13C NMR
(500 MHz, CDCl3): δ (ppm) 165.38, 162.99, 159.67, 150.22, 138.60, 130.15, 128.38,
127.94, 127.62, 126.74, 124.98, 124.56, 123.50, 103.02, 43.16, 28.42. HPLC retention
time: 10.136min; purity 100%.
4.2.4.7 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-phenylfuro[2,3d]pyrimidin-4-ol (65)

Compound 65 was prepared in a manner similar to compound 63 from 2-(2cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), (2-chloro-2nitrovinyl)benzene 59 (73mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 43.7%. MS: (ESI, neg.) m/z 335.0 [M – H]-, 1H NMR (500 MHz, DMSO):
δ (ppm) 12.02 (s, 1H), 8.19 (s, 1H), 7.98 (d, 2H, J = 8Hz), 7.42 (t, 2H, J = 7.5Hz), 7.32 (t,
1H, J = 7Hz), 1.94 (t, 1H, J = 11.5Hz), 1.69 (d, 2H, J = 12Hz), 1.60 (d, 2H, J = 12Hz),
1.39 (d, 2H, J = 12Hz ), 1.25 (s, 6H), 1.07 (m, 5H); 13C NMR (500 MHz, CDCl3): δ
(ppm) 165.58, 165.54, 159.89, 138.12, 130.29, 128.36, 127.91, 127.55, 123.41, 102.42,
44.92, 43.61, 27.19, 26.39, 26.01, 22.21. HPLC retention time: 11.245min; purity
99.45%.
4.2.4.8 Synthesis of 2-(2-methyloctan-2-yl)-5-phenylfuro[2,3d]pyrimidin-4-ol (66)

Compound 66 was prepared in a manner similar to compound 63 from 2-(2methyloctan-2-yl)pyrimidine-4,6-diol 33 (40mg, 0.168mmol), (2-chloro-2nitrovinyl)benzene 59 (28mg, 0.153mmol), DBU (47mg, 46.2µl, 0.308mmol), and
CH3CN (1ml). Yield: 32.6%. MS: (ESI, neg.) m/z 337 [M – H]-, 1H NMR (500 MHz,
DMSO): δ (ppm) 12.12 (s, 1H), 8.19 (s, 1H), 7.98 (d, 2H, J = 7.5Hz), 7.42 (t, 2H, J =
8Hz), 7.32 (t, 1H, J = 7.5Hz), 1.73 (m, 2H), 1.31 (s, 6H), 1.19 (m, 6H), 1.06 (m. 2H), 0.8
(t, 3H, J = 7Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.65, 164.91, 159.91, 138.14,
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130.28, 128.36, 127.90, 127.55, 112.34, 102.44, 40.44, 40.33, 30.98, 29.06, 25.90, 23.94,
22.01, 13.88. HPLC retention time: 11.846min; purity 100%.
4.2.4.9 Synthesis of 2-(2-phenylpropan-2-yl)-5-m-tolylfuro[2,3d]pyrimidin-4-ol (67)

Compound 67 was prepared in a manner similar to compound 63 from 2-(2phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.434mmol), 1-(2-chloro-2nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and
CH3CN (2ml). Yield: 29.2%. MS: (ESI, neg.) m/z 343.0 [M – H]-, 1H NMR (500 MHz,
DMSO): δ (ppm) 11.99 (s, 1H), 8.20 (s, 1H), 7.79 (d, 1H, J = 8Hz), 7.74 (s, 1H), 7.29 (m,
6H), 7.13 (d, 1H, J = 7.5Hz), 2.33 (s, 3H), 1.71 (s, 6H); 13C NMR (500 MHz, CDCl3): δ
(ppm) 165.44, 164.12, 159.71, 145.78, 138.31, 137.32, 130.10, 128.37, 128.32, 128.26,
128.23, 126.57, 126.16, 125.30, 123.58, 102.95, 44.96, 27.53, 21.11. HPLC retention
time: 10.569min; purity 100%.
4.2.4.10 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)-5-mtolylfuro[2,3-d]pyrimidin-4-ol (68)

Compound 68 was prepared in a manner similar to compound 63 from 2-(2(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.434mmol), 1-(2-chloro-2nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and
CH3CN (2ml). Yield: 21.5%. MS: (ESI, neg.) m/z 349.0 [M – H]-, 1H NMR (500 MHz,
DMSO): δ (ppm) 12.07 (s, 1H), 8.20 (s, 1H), 7.78 (d, 1H, J = 7.5Hz), 7.73 (s, 1H), 7.43
(d, 1H, J = 5Hz), 7.30 (t, 1H, J = 7.5Hz), 7.14 (d, 1H, J = 7.5Hz), 7.03 (d, 1H, J = 4Hz),
6.99 (t, 1H, J = 5Hz), 2.33 (s, 3H), 1.81 (s, 6H); 13C NMR (500 MHz, CDCl3): δ (ppm)
165.33, 162.94, 159.61, 150.23, 138.49, 137.33, 130.03, 127.94, 128.39, 128.27, 129.74,
125.30, 124.98, 124.55, 123.55, 103.04, 43.15, 25.42, 21.11. HPLC retention time:
10.514min; purity 100%.
4.2.4.11 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-m-tolylfuro[2,3d]pyrimidin-4-ol (69)

Compound 69 was prepared in a manner similar to compound 63 from 2-(2cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.434mmol), 1-(2-chloro-2nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and
CH3CN (2ml). Yield: 30.8%. MS: (ESI, neg.) m/z 349.0 [M – H]-, 1H NMR (500 MHz,
DMSO): δ (ppm) 11.95 (s, 1H), 8.14 (s, 1H), 7.80 (d, 1H, J = 7.5Hz), 7.54 (s, 1H), 7.30
(t, 1H, J = 7.5Hz), 7.14 (d, 1H, J = 7Hz), 2.34 (s, 3H), 1.93 (t, 1H, J = 12Hz), 1.69 (d, 2H,
J = 12.5Hz), 1.60 (d, 1H, J = 12Hz), 1.40 (d, 2H, J = 12Hz), 1.24 (s, 6H), 1.05 (m, 5H);
13
C NMR (500 MHz, CDCl3): δ (ppm) 165.53, 165.49, 138.02, 137.30, 130.17, 128.35,
128.36, 128.25, 128.19, 128.27, 125.27, 123.49, 102.45, 44.92, 43.60, 27.19, 26.82,
26.02, 22.21, 21.15. HPLC retention time: 11.680min; purity 100%.
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4.2.4.12 Synthesis of 2-(2-methyloctan-2-yl)-5-m-tolylfuro[2,3d]pyrimidin-4-ol (70)

Compound 70 was prepared in a manner similar to compound 63 from 2-(2methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 1-(2-chloro-2-nitrovinyl)3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 36.4%. MS: (ESI, neg.) m/z 351 [M – H]-, 1H NMR (500 MHz, DMSO): δ
(ppm) 12.08 (s, 1H), 8.15 (s, 1H), 7.81 (d, 1H, J = 7.5Hz), 7.75 (s, 1H), 7.30 (t, 1H, J =
7.5Hz), 7.14 (d, 1H, J = 7.5Hz), 2.34 (s, 3H), 1.72 (t, 2H, J = 6.5Hz), 1.31 (s, 6H), 1.19
(m. 6H), 1.06 (m. 2H), 0.81 (t, 3H, J = 6.5Hz); 13C NMR (500 MHz, CDCl3): δ (ppm)
165.60, 164.86, 159.85, 138.04, 137.31, 130.16, 128.34, 128.26, 128.20, 125.28, 123.48,
102.46, 40.43, 40.35, 30.99, 29.07, 25.91, 23.95, 22.02, 21.12, 13.88. HPLC retention
time: 12.294min; purity 99.14%.
4.2.4.13 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-phenylpropan-2yl)furo[2,3-d]pyrimidin-4-ol (71)

Compound 71 was prepared in a manner similar to compound 63 from 2-(2phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.42mmol), 1,3-dichloro-5-(2-chloro2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 20.4%. MS: (ESI, neg.) m/z 397.0 [M – H]-, 1H NMR (500 MHz, DMSO):
δ (ppm) 12.16 (s, 1H), 8.51 (s, 1H), 8.20 (s, 2H), 7.56 (s, 1H), 7.35 (t, 2H, J = 8Hz), 7.27
(m, 3H), 1.72 (s, 6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.62, 164.63, 159.83,
145.68, 140.20, 134.13, 133.81, 128.34, 126.90, 126.61, 126.25, 126.17, 121.12, 102.55,
45.06, 27.54. HPLC retention time: 11.468min; purity 97.36%.
4.2.4.14 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-(thiophen-2yl)propan-2-yl)furo[2,3-d]pyrimidin-4-ol (72)

Compound 72 was prepared in a manner similar to compound 63 from 2-(2(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.423mmol), 1,3-dichloro-5(2-chloro-2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol),
and CH3CN (2ml). Yield: 32.9%. MS: (ESI, neg.) m/z 404.9 [M – H]-, 1H NMR (500
MHz, DMSO): δ (ppm) 12.22 (s, 1H), 8.49 (s, 1H), 8.18 (s, 2H), 7.54 (s, 1H), 7.44 (d,
1H, J = 5Hz), 7.03 (d, 1H, J = 3Hz), 6.99 (t, H, J = 4.5Hz), 1.81 (s, 6H); 13C NMR (500
MHz, CDCl3): δ (ppm) 165.50, 163.42, 159.71, 150.08, 140.35, 134.13, 133.72, 126.92,
126.75, 126.26, 125.01, 124.06, 121.12, 102.64, 43.21, 28.42. HPLC retention time:
11.414min; purity 100%.
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4.2.4.15 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(3,5dichlorophenyl)furo[2,3-d]pyrimidin-4-ol (73)

Compound 73 was prepared in a manner similar to compound 63 from 2-(2cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), 1,3-dichloro-5-(2chloro-2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and
CH3CN (2ml). Yield: 24.7%. MS: (ESI, neg.) m/z 403.0 [M – H]-, 1H NMR (500 MHz,
CDCl3): δ (ppm) 10.91 (s, 1H), 7.82 (s, 2H), 7.66 (s, 1H), 7.35 (s, 1H), 1.71 (m, 1H,),
1.64 (m, 2H), 1.55 (d, 1H, J = 10.5Hz), 1.42 (d, 2H, J = 6Hz), 1.36 (s, 6H), 1.00 (m, 5H);
13
C NMR (500 MHz, CDCl3): δ (ppm) 165.55, 160.62, 138.24, 135.21, 133.45, 128.00,
126.78, 122.63, 110.19, 102.97, 47.23, 44.38, 27.89, 26.83, 26.51, 22.97. HPLC
retention time: 13.021min; purity 98.71%.
4.2.4.16 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-methyloctan-2yl)furo[2,3-d]pyrimidin-4-ol (74)

Compound 74 was prepared in a manner similar to compound 63 from 2-(2methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 1,3-dichloro-5-(2-chloro2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 19.7%. MS: (ESI, neg.) m/z 405.1 [M – H]-, 1H NMR (500 MHz, CDCl3):
δ (ppm) 11.41 (s, 1H), 7.82 (s, 2H), 7.66 (s, 1H), 7.35 (s, 1H), 1.72 (m, 2H), 1.43 (s, 6H),
1.14 (m, 8H), 0.78 (t, 3H, J = 7Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 166.90,
166.04, 161.08, 138.29, 135.17, 133.80, 128.02, 126.76, 122.63, 102.98, 41.90, 41.24,
31.77, 29.78, 26.55, 24.74, 22.77, 14.20. HPLC retention time: 13.910min; purity
97.51%.
4.2.4.17 Synthesis of 2-(2-phenylpropan-2-yl)-5-(thiophen-2yl)furo[2,3-d]pyrimidin-4-ol (75)

Compound 75 was prepared in a manner similar to compound 63 from 2-(2phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.434mmol), 2-(2-chloro-2nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 36.1%. MS: (ESI, neg.) m/z 335 [M – H]-, 1H NMR (500 MHz, DMSO): δ
(ppm) 12.07 (s, 1H), 8.22 (s, 1H), 7.97 (d, 1H, J = 3.5Hz), 7.50 (d, 1H, J = 5Hz), 7.34 (t,
2H, J = 7.5Hz), 7.25 (d, 3H, J = 6.5Hz), 7.10 (t, 1H, J = 5.5Hz), 1.71 (s, 6H); 13C NMR
(500 MHz, CDCl3): δ (ppm) 165.23, 164.49, 159.60, 145.72, 137.31, 131.43, 128.32,
128.28, 127.72, 126.58, 126.17, 125.65, 117.49, 102.49, 45.03, 27.51. HPLC retention
time: 10.219min; purity 99.69%.
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4.2.4.18 Synthesis of 5-(thiophen-2-yl)-2-(2-(thiophen-2-yl)propan-2yl)furo[2,3-d]pyrimidin-4-ol (76)

Compound 76 was prepared in a manner similar to compound 63 from 2-(2(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.423mmol), 2-(2-chloro-2nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 19.2%. MS: (ESI, neg.) m/z 341 [M – H]-, 1H NMR (500 MHz, DMSO): δ
(ppm) 12.15 (s, 1H), 8.22 (s, 1H), 7.96 (d, 1H, J = 3Hz), 7.51 (d, 1H, J = 5Hz), 7.44 (d,
1H, J = 5Hz), 7.11 (t, 1H, J = 5Hz), 7.03 (d, 1H, J = 2.5Hz), 6.99 (t, 1H, J = 4Hz), 1.81 (s,
6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.12, 163.29, 159.49, 150.14, 137.49,
131.35, 128.30, 127.73, 126.75, 125.70, 124.99, 124.59, 117.49, 102.58, 43.21, 28.39.
HPLC retention time: 10.151min; purity 98.38%.
4.2.4.19 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(thiophen-2yl)furo[2,3-d]pyrimidin-4-ol (77)

Compound 77 was prepared in a manner similar to compound 63 from 2-(2cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), 2-(2-chloro-2nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 40.2%. MS: (ESI, neg.) m/z 341.0 [M – H]-, 1H NMR (500 MHz, DMSO):
δ (ppm) 12.08 (s, 1H), 8.18 (s, 1H), 8.07 (d, 1H, J = 3.5Hz), 7.51 (d, 1H, J = 4.5Hz), 7.13
(t, 1H, J = 5Hz), 1.94 (t, 1H, J = 12Hz), 1.70 (d, 2H, J = 12.5Hz), 1.62 (d, 1H, J = 12Hz),
1.40 (d, 2H, J = 12.5Hz), 1.25 (s, 6H), 1.02 (m, 5H); 13C NMR (500 MHz, CDCl3): δ
(ppm) 165.91, 165.26, 159.71, 137.01, 131.53, 128.24, 127.71, 125.59, 117.40, 101.99,
44.95, 43.68, 27.19, 26.38, 26.01, 22.19. HPLC retention time: 11.285min; purity 100%.
4.2.4.20 Synthesis of 2-(2-methyloctan-2-yl)-5-(thiophen-2-yl)furo[2,3d]pyrimidin-4-ol (78)

Compound 78 was prepared in a manner similar to compound 63 from 2-(2methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 2-(2-chloro-2nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN
(2ml). Yield: 12.3%. MS: (ESI, neg.) m/z 343.0 [M – H]-, 1H NMR (500 MHz, DMSO):
δ (ppm) 12.16 (s, 1H), 8.71 (s, 1H), 8.00 (d, 1H, J = 3Hz), 7.51 (d, 1H, J = 5Hz), 7.12 (t,
1H, J = 4Hz), 1.72 (m, 2H), 1.30 (s, 6H), 1.19 (m, 6H), 1.05 (m, 2H), 0.81 (t, 3H, J =
6.5Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.37, 165.24, 159.73, 137.04, 131.52,
128.26, 127.72, 125.60, 117.41, 102.01, 40.50, 40.35, 30.99, 29.06, 25.08, 23.94, 22.02,
13.89. HPLC retention time: 11.881min; purity 100%.
4.3 Testing of Novel Compounds

Select compounds from each of the three series of novel pyrimidine cannabinoid
ligands were tested for binding affinity to and functional activity at the CB1 and CB2
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receptors. Select compounds were also tested for efficacy as anti-glioblastoma agents.
The complete series are currently undergoing receptor binding assays and functional
activity screens in order to develop SARs for these new structural classes of
cannabinoids.
4.3.1 Pyrimidine Hexahydro Classical Cannabinoids

All four of the pyrimidine hexahydro classical cannabinoids were screened for
receptor binding affinity to the CB1 and CB2 receptors (Table 4.1). All compounds
exhibited binding affinity to both receptors with the exception of the phenyl substituted
34 which showed very little affinity for the CB1 receptor (Ki > 10,000nM). Compounds
34 and 35 were > 73.0 and 26.9-fold selective for the CB2 receptor, respectively, which
is greater than either KM-233 or HB-I-172. From this small series of compounds it
would seem that aromatic side-chains (compounds 34 and 35) decrease binding affinity
for both receptors yet increase CB2 selectivity. Compounds 36 and 37, which possess
alkyl side-chains, displayed good binding affinity for both receptors yet lower CB2
selectivity (9.7 and 6.5, respectively). All compounds proved to be agonists at both the
CB1 and CB2 receptor subtypes. Compounds 35, 36, and 37 were also tested against the
human glioblastoma cell line LN-229. All three compounds showed efficacy which was
comparable to HB-I-172 and KM-233 (Table 4.2).
4.3.2 Pyrimidine Non-Classical Cannabinoids

Compounds 47, 48, 52, and 55 were assayed for receptor binding affinity at CB1
and CB2. The results of the binding assays are found in Table 4.3. Each of the four
pyrimidine non-classical cannabinoids tested has very little affinity for the CB1 receptor
with all four having a Ki > 10,000. They do, however, retain affinity for the CB2 receptor
in varying degrees. Compound 55 (dimethyl heptyl side-chain with a cyclohexyl
replacement of the A ring) possessed the greatest affinity for the CB2 receptor (Ki = 43.3
(± 19.6)nM) with a high CB2 selectivity ratio of > 230.9-fold. Six of the compounds
from this series were tested for functional activity at the cannabinoid receptors and were
found to be agonists at CB2 with little or no agonist activity at CB1 (probably due to low
affinity). Two exceptions were 47 and 55 which exhibited 59 and 68% agonist activity at
CB1, respectively. Three compounds 47, 48, and 50 were tested against LN-229 and
exhibited EC50s (23.5µM – 55.5µM) slightly higher than HB-I-172 and KM-233, but
much lower than BCNU (Table 4.4).
4.3.3 Furanopyrimidine Cannabinoids

Five furanopyrimidines were screened for receptor binfing affinity at the CB1 and
CB2 receptors. All five compounds exhibited low affinity for both CB1 and CB2 (Ki >
10,000nM). All sixteen compounds were screened for functional activity at the
cannabinoid receptors also. Despite having low affinity, several compounds did exhibit
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Table 4.1: Binding affinity constants (Ki) for compounds 34-37 compared to Δ8-THC,
KM-233, and HB-I-172
Compound

CB1 Ki (nM)

CB2 Ki (nM)

CB1/CB2 Ratio

Δ8-THC

28.5 (± 3.3)

25.0 (± 4.8)

1.1

KM-233

12.3 (± 0.61)

0.91 (± 0.08)

13.5

HB-I-172

6040 (± 1477)

487 (± 101)

12.4

34

> 10,000

137 (± 13)

> 73.0

35

1138 (± 227)

42.3 (± 13.9)

26.9

36

18.8 (± 9.3)

1.94 (± 0.63)

9.7

37

54.6 (± 5.4)

8.36 (± 1.66)

6.5

Notes: Values are the mean of three experiments performed in triplicate; standard
deviation is given in parentheses. CB1/CB2 ratio is expressed as Ki for CB1 / Ki for
CB2.
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Table 4.2: Efficacy of pyrimidine hexahydro classical cannabinoids compared to HB-I172, KM-233, and BCNU against LN-229
Compound

EC50 (µM) ± S.D.

BCNU

233 (± 5.1)

HB-I-172

9.74 (± 0.56)

KM-233

4.74 (± 0.43)

35

30.1(± 2.9)

36

10.6 (± 1.3)

37

27.3 (± 3.4)

Notes: Values are the mean of three experiments performed in triplicate; standard
deviation is given in parentheses.
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Table 4.3: Binding affinity constants (Ki) for select pyrimidine non-classical
cannabinoids compared to Δ8-THC, KM-233, and HB-I-172
Compound

CB1 Ki (nM)

CB2 Ki (nM)

CB1/CB2 Ratio

Δ8-THC

28.5 (± 3.3)

25.0 (± 4.8)

1.1

KM-233

12.3 (± 0.61)

0.91 (± 0.08)

13.5

HB-I-172

6040 (± 1477)

487 (± 101)

12.4

47

> 10,000

9673 (± 566)

> 1.0

48

> 10,000

130 (± 38)

> 76.9

52

> 10,000

621 (± 158)

> 16.1

55

> 10,000

43.3 (± 19.6)

> 230.9

Notes: Values are the mean of three experiments performed in triplicate; standard
deviation is given in parentheses. CB1/CB2 ratio is expressed as Ki for CB1 / Ki for
CB2.
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Table 4.4: Comparison of selected pyrimidine non-classical cannabinoids to HB-I-172,
KM-233, and BCNU against LN-229
Compound

EC50 (µM) ± S.D.

BCNU

233 (± 5.1)

HB-I-172

9.74 (± 0.56)

KM-233

4.74 (± 0.43)

47

55.5 (± 4.3)

48

23.5 (± 2.9)

50

51.8 (± 6.4)

Notes: Values are the mean of three experiments performed in triplicate; standard
deviation is given in parentheses.
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agonist activity. Compounds 66 and 78 proved to be agonists at CB1 and CB2 when
screened at a concentration of 10µM. Compounds 65, 69, 70, 74, 77, and 78 showed
agonist activity at only the CB2 receptor when tested at 10µM. Five of the
furanopyrimidines were tested against the human glioblastoma cell line T98G. When
screened at a concentration of 10µM, five of the compounds displayed cytotoxic activity
against the GBM cell line (Figure 4.10). Interestingly, the cells had to experience a
longer exposure to these compounds (72 hours) in order to manifest the toxic effects
normally seen in 18 hours with other cannabinoid ligands.
4.4 Experimental Procedures
4.4.1 Radioligand Binding Assays

Binding affinity studies were carried out using cell membranes from HEK293
cells transfected with the human CB1 receptor (Kd for tritiated CP-55,940 binding: 4.5
nM) and membranes from HEK293 cells transfected with the human CB2 receptor (Kd
for tritiated CP-55,940 binding: 5.1 nM). Non-specific binding was determined using 10
µM WIN55, 212-2. Increasing concentrations of compounds to be tested were made
ranging from 10-12 M to 10-4 M and were added in triplicate for each experiment and the
individual molar IC50 values were determined using GraphPad Prism software. The
corresponding Ki values for each drug were determined utilizing the Cheng-Prusoff
equation and final data are presented as Ki ± standard deviation of n = 3 experiments run
in triplicate.
4.4.2 Cytotoxicity Assays

Human glioblastoma cells T98G and LN-229 (American Type Culture Collection)
were cultured in supplemented media according to the recommendations of the supplier
at 37°C in an atmosphere of 5% CO2 and 95% air. Cell lines were plated in 96-well
polystyrene flat-bottom plates (7,500 cells/well) at 70% confluency in a 100 µl total
volume of supplemented media as indicated, and incubated overnight at 37°C to allow for
adherence. The media was then replaced with media containing 1% FBS and the cultures
were treated with escalating amounts of drug and cell death was analyzed at 18hr or 72hr,
using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek Instruments,
Inc.). The percentage of viable cells present in the culture at each time point was
calculated by comparing the absorbance value at 450nm from the CCK-8 assay (Dojindo
Molecular Technologies) for each condition with untreated control cells. All assays were
conducted per manufacturer’s protocol. All described values represent the average of
three data points per determination and three independent determinations.
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Figure 4.10: Furanopyrimidine cannabinoids screened against the human glioblastoma
cell line T98G

All compounds were screened at 10µM for 48 hours. * = p < 0.005, ** = p < 0.0005, and
*** = p < 0.00005.
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4.4.3 CB1/CB2 Functional Assays

HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and
either human CB1 or CB2 receptors (BD Biosciences, San Jose, CA USA) were seeded
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well. Plates were
incubated at 37°C in 5% CO2 overnight prior to assay. Plates were then removed from
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and
1µg/ml puromycin) was replaced with 100µL DMEM containing 0.25% BSA. Next,
100µL membrane potential dye loading buffer (Molecular Devices) was added to each
well. The plates were placed back into the incubator for 30 minutes and then the baseline
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm
excitation and 590nm emission filters prior to drug addition. Drugs were added in 50µL
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM
Ro 20-1724. Plates were then incubated at room temperature for 25 minutes and
fluorescence measured again at 540nm excitation and 590nm emission.
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Chapter 5: Cannabinoids as Anti-Inflammatory Agents
5.1 Introduction

Pharmacologically, cannabinoids can be used to affect a variety of targets such as
the central nervous system, the cardiovascular system, the immune system and/or
endocrine system. More particularly, compounds possessing an affinity for either the
CB1 or the CB2 receptor, and potentially GPR55, can act on the central nervous system
or act as immunomodulators. In addition, these compounds are useful as anticancer
agents, antiobesity agents, analgesics, myorelaxation agents and antiglaucoma agents.
Such compounds can also be used for the treatment of thymic disorders, vomiting,
various types of neuropathy, memory disorders, dyskinesia, migraine, multiple sclerosis,
asthma, epilepsy, ischemia, orthostatic hypotension, osteoporosis, liver fibrosis,
inflammation and irritable bowel disease, diabetes, and cardiac insufficiency.
However, certain cannabinoids such as Δ9-THC also affect normal
neurotransmission, producing undesirable side effects such as drowsiness, impairment of
monoamine oxidase function, and impairment of non-receptor mediated brain function.
The addictive and psychotropic properties of some cannabinoids tend to limit their
therapeutic value. The unwanted psychotropic effects are mediated through the CB1
receptor and are not observed upon activation of CB2. Many of the desirable effects
associated with cannabinoids such as antinociception and anti-inflammation are mediated
through the CB2 receptor.
Due to the effects mediated by CB2, it appears to be a promising target for the
treatment of pain, inflammation, and neuro-inflammation. It is therefore no mystery as to
why the current trend in the field is the development of CB2 selective compounds that
will not activate the CB1 receptor and will thus be void of the unwanted psychotropic
effects. The expression of CB2 was at one time thought to be limited to the periphery,
being found mainly in the cells of the immune system.17,43 Recently, however, the CB2
receptor has also been shown to be present in the CNS in both perivascular microglial
cells179 and in brainstem neurons.42b CB2 also appears to be up-regulated in dorsal root
ganglia and peripheral neurons following injury.180
CB2 has been validated as a potential target for the treatment of pain and neuroinflammation based on preclinical data using CB2 selective agonists and receptor
knockout mice. Despite the challenge that lies in developing CB2 selective compounds
that maintain activity and selectivity across species, several compounds have advanced
into clinical development.
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5.2 Evaluation of CB2 Agonists in Preclinical Models
5.2.1 Pain

The ability of Cannabis to attenuate the pain response has been known for
millennia in Asia. The medical use of marijuana was introduced to the West in 1839 by a
physician serving with the British in India named W. B. O’Shaughnessy. He published a
treatise expounding the usefulness of extracts of the plant in a wide variety of conditions
including relieving the pain of rheumatism. The medical use of Cannabis grew rapidly in
the late 19th and early 20th centuries. In the United States, the plant was even included in
the National Formulary and Pharmacopoeia until 1941 when its use was virtually
brought to a halt due to the Marihuana Tax Act of 1937.181 After the discovery of the
cannabinoid receptors type I and II and their ligands, both exogenous and endogenous,
research into the medical use of marijuana and cannabinoids has grown exponentially.
Recently, the putative cannabinoid receptor GPR55 has been proposed as a target for the
treatment of pain and inflammation, especially that of neuropathic origin. The largest
body of work with cannabinoids in the field of antinociception, however, is with ligands
that are selective for the CB2 receptor; therefore, the discussion will be limited to those
compounds.
Several CB2 agonists such as GW405833 (Figure 5.1), a substituted indole
derivative, have shown to be efficacious in preclinical models of neuropathic,
inflammatory, and postoperative pain. GW405833 is a CB2 agonist with binding
affinities of 3.92 (± 1.58)nM for the human CB2 versus 4772 (± 1676)nM for CB1 which
translates into greater than 1000-fold selectivity.182 As with many cannabinoids, binding
affinity constants and selectivity ratios are found to be variable between species. When
assayed against the rat cannabinoid receptors, GW405833 was found to be only 78-fold
selective for CB2. Depending on the type of assay used, the compound appears to be a
partial agonist at the human CB2 receptor182 and has also been reported to be a partial
inverse agonist at both human and rat CB2 receptors.183
In a sciatic nerve partial ligation model of neuropathic pain, GW405833 showed a
63.3% reversal of pain at 1 hour following an i.p. dose of 10mg/kg with an ED50 of
0.077mg/kg. This compound also exhibited a reversal of hyperalgesia with ED50s of
2.58mg/kg and 0.17mg/kg in the hind paw surgical incision model and the Freund’s
complete adjuvant (FCA) model, respectively. The target was confirmed in a CB2
knockout mouse model in which the compound did not reverse inflammatory pain.
GW405833 was also screened in a number of behavioral tests to determine if the
compound would elicit unwanted effects due to interaction with CB1. The well
established catalepsy assay, rotorod assay examining motor function, and tail flick and
hot plate tests which test for acute analgesia were used in these studies. Only the highest
dose tested (100mg/kg) showed any positive results in these assays. This suggests that at
higher doses GW405833 does signal through CB1, but not at lower doses.182
Data has been published by Abbott regarding two CB2 agonists, A-796260183 and
A-836339184 (Figure 5.1). A-796260 is an indole derivative which possesses the same 2162
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Figure 5.1: CB2 selective agonists used in preclinical studies as antinociceptive agents

163

morpholinoethyl substitution as GW405833. It exhibits binding affinities for the human
cannabinoid receptors of 845nM and 4.37nM for CB1 and CB2, respectively, which is a
selectivity ratio of 193-fold for the human CB2. Again, selectivity is lessened when
assayed for affinity to the rat cannabinoid receptors. Assays obtained the values of
395nM and 13nM for rat CB1 and CB2, respectively, which is 30-fold selective for the
rat CB2 receptor. Functional selectivity of A-796260 for the CB2 receptor is greater than
binding affinity selectivity for both the human and rat receptors (1380-fold and 175-fold,
respectively).
Efficacy of A-796260 as an antinociceptive agent has been evaluated in the FCAinduced model of hyperalgesia using thermal stimulus. The compound exhibited dosedependent reduction in hyperalgesia following i.p. administration with an ED50 of
2.8mg/kg. In this particular model, the target was confirmed pharmacologically using the
CB2 selective antagonists SR144528185 and AM630.186 In each case, the analgesic
effects of A-796260 were blocked. The CB1 selective antagonist SR141716A, however,
had no effect on the analgesia produced by the compound. To evaluate the compound’s
ability attenuate postoperative pain, a skin incision model was performed. In this study,
A-796260 was administered i.p. 1.5 hours following surgery; it dose-dependently
lowered mechanical allodynia with an ED50 of 18mg/kg and with a maximum efficacy of
68 (± 7%) without the development of tolerance following repeated administration. In a
study of neuropathic pain, the chronic constriction injury of the sciatic nerve model was
used. In this study, A-796260 also reduced mechanical allodynia with an ED50 of
15mg/kg with maximum efficacy of 66 (± 9%). This compound has also shown efficacy
in an osteoarthritis pain model and performed favorably compared to celecoxib. A796260 displayed 56% efficacy at a dose of 35mg/kg while celecoxib was 62%
efficacious using a 38mg/kg dose. This compound was also screened for CNS effects
and none were found up to a 35mg/kg dose.
A-836339, a dimethylthiazole carboxamide derivative, displays similar binding
affinities to A-796260. The Ki for binding affinity to the human CB2 receptor is 0.64nM
and a selectivity of 425-fold is observed over the human CB1. Affinity for the rat CB2
receptor is very similar to that of the human, Ki = 0.76nM, and again selectivity when
compared to the CB1 receptor is lower than in the human receptors (189-fold). Like A796260, A-836339 is a full agonist at CB2 with an EC50 of 1.6nM. Both compounds
have also been shown to be full agonists at CB1 but, of course, much less potent.
A-836339 has been shown to be efficacious in the FCA-induced inflammatory
pain model with an ED50 of 1.96µmol/kg and has also shown efficacy in the skin incision
model of postoperative pain with an ED50 of 12µmol/kg. The compound has also yielded
promising results in a capsaicin-induced model of hyperalgesia and in the chronic
constriction injury neuropathic pain model with EC50s of 10.4µmol/kg and 12.9µmol/kg,
respectively. A-836339 was shown to have some CB1 mediated effects as determined by
decreased horizontal locomotor activity following both 15µmol/kg and 45µmol/kg doses
which was reversed by SR141716A treatment. Although A-796260 has been shown to
have affinity for the δ-opiod receptor, the antinociceptive effects of A-796260 and A836339 are not due to interaction with the µ-opiod receptor as exemplified by the
inability of naloxone to reverse the analgesic effects of either compound.
164

The phenylamino pyrimidine GW842166X (Figure 5.2) is a clinical candidate
belonging to GlaxoSmithKline which is being studied for its anti-inflammatory potential.
The compound has been reported to be fully selective for CB2, both human and rat, with
EC50s of 63nM and 91nM, respectively. The compound displayed no significant agonist
activity at either human or rat CB1 receptors up to 30µM.187 In the FCA-induced model
of inflammatory pain, the compound was shown to be highly efficacious with an oral
ED50 of 0.1mg/kg with full reversal of hyperalgesia at an oral dose of 0.3mg/kg. As with
A-796260, the development of tolerance was not observed within the timeframe of the
study.
A dihydrobenzofuran developed at the MD Anderson Cancer Center, MDA7
(Figure 5.2), has shown to be another cross-species CB2 selective compound.159 The
compound has a Ki of 422 (± 123)nM for human CB2 with no affinity for the human CB1
up to 10µM. For rat cannabinoid receptors, the Ki values 2565 (± 695)nM for CB1 and
238 (± 143)nM for CB2. The compound was shown to be a weak partial agonist at the
human CB1 at concentrations above 1µM. The compound has produced promising
results in attenuation of mechanical allodynia due to both paclitaxel and spinal nerve
ligation. The authors also reported a transient antinociceptive effect from thermal
stimulus following i.p. administration of a 10mg/kg dose.
Pfizer has reported a dihydrobenzimidazole, PF-03550096 (Figure 5.2), that has
also showed promise in preclinical research.188 The compound performed well in a rat
colonic pain model utilizing 2,4,6-trinitrobenzene sulfonic acid as a gastric irritant. The
authors report that the compound significantly suppressed visceral hypersensitivity in this
model which was reversed by the CB2 antagonist SR144528.
5.2.2 Neuro-Inflammation

CB2 selective compounds have also begun to show promise as possible
therapeutic options for the treatment of neuro-inflammatory diseases such as multiple
sclerosis (MS), Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and
encephalitis. Compounds that do not have CB1 activity would not have been logical
choices for treatment of these disorders before the discovery that CB2 is indeed
expressed in the CNS.
A preclinical model that is used for the study of MS is experimental autoimmune
encephalomyelitis. CB2 was found to be a legitimate target in this model by the fact that
CB2 knockout mice have a more severe disease course upon induction than do wild-type
mice.189 Furthermore, mice at the peak of disease development that are treated with the
CB2 agonist HU-210 (Figure 5.3) are scored much lower on severity rating scales
compared to vehicle treated controls. This efficacy is reported by the authors to be due to
reduced microglia activation and reduction in the infiltration of myeloid cells.189a HU210 is an analog of cannabidiol possessing the dimethyl heptyl side chain. Receptor
binding affinity for the compound at human CB1 and CB2 is > 10µM and 22.7 (±
3.9)nM, respectively.
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5.2.3 Other Indications

CB2 selective agonists have also shown promise for indications other than the
inflammatory conditions mentioned above. GW833972A, another phenylamino
pyrimidine (Figure 5.3), is a1000-fold selective CB2 agonist that has been shown to
reduce citric acid-induced cough in a conscious guinea-pig model.190 The role of CB2 in
the action of GW833972A was verified by pretreatment with antagonists for the CB1 and
CB2 receptors. The antitussive effects were blocked by pretreatment with the CB2
selective antagonist SR144528 while the CB1 selective antagonist SR141716A had no
effect.
HU-210 has been studied in other animal models of disease also. It has been
reported that observed in vitro effects of HU-210 are suppression of trabecular
osteoclastogenesis.191 This effect is reported to be due to inhibition of osteoclast
precursors and also inhibition of receptor activator of NFκB ligand. The authors of this
report also tested this compound in a model of postmenopausal osteoporosis using
ovarectomized mice. HU-210 lessened trabecular bone loss by 66% compared to
untreated controls.
A potential role for CB2 agonists in the treatment of the chronic inflammatory
disease atherosclerosis has also been identified. The presence of CB2 receptors was
verified in both human and mouse atherosclerotic plaques.192 The non-selective
cannabinoid agonist Δ9-THC showed significant inhibition of disease progression in a
murine model of established atherosclerosis using apolipoprotein E knockouts. THC was
dosed at 1mg/kg orally once a day.192 This dose is below that which is usually associated
with the CB1 mediated psychotropic effects of THC. The role of CB2 in this study was
verified by the observation that the CB2 selective antagonist SR144528 blocks the
therapeutic effect of THC. The authors also observed in vitro that THC blocks
macrophage chemotaxis which is crucial for the formation of atherosclerotic plaques, an
effect that was also blocked by SR144528.
5.3 Evaluation of CB2 Agonists in Clinical Trials

To date, there have been reports of three pharmaceutical companies entering
clinical trials with CB2 agonists for the treatment of pain.193 Cannabinor, formerly
known as PRS-211,375 (Figure 5.4) is a fumarate ester derivative of compounds similar
to HU-308. In January 2007, Pharmos Corporation reported the results of a Phase IIa
experimentally induced pain model performed with cannabinor. In this study the
compound failed to meet the primary endpoint which was reduction of capsaicin-induced
pain.194 In this study, however, researchers made the observation that, when compared to
placebo, intravenous (i.v.) administration of cannabinor did have a significant effect in
the reduction of both pressure-induced and heat-induced pain. In April of that same year,
Pharmos reported the results of a separate Phase IIa trial with Cannabinor. The study was
designed to examine the usefulness of i.v. cannabinor to attenuate pain following 3rd
molar dental extraction. The results were difficult to interpret. The lowest dose of 12mg
demonstrated a significant analgesic effect while the higher doses of 24mg and 48mg
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were not statistically efficacious. After this unexpected pattern of results the company
decided to drop further development of i.v. cannabinor as an antinociceptive and
retargeted the research with this compound to other possible indications and later dropped
development all together. One positive note from each of these trials is that cannabinor
was generally well tolerated with no serious adverse events reported. Pharmos currently
has other CB2 selective compounds of undisclosed structure that are currently in preclinical studies for the conditions of neuropathic pain, autoimmune disease, and irritable
bowel syndrome.195 GlaxoSmithKline has completed three Phase II clinical trials with
GW842166.196 One trial was for analgesia following 3rd molar extraction and the other
two trials were examining the efficacy of the compound for treatment of osteoarthritis
pain. The company has not reported the results of these studies and currently lists no
cannabinoids in their list of pipeline drugs.197 In 2009, Glenmark Pharmaceuticals
announced the completion of Phase I studies in Europe of GRC10693 which is a CB2
selective agonist (> 4700-fold) that possesses good oral bioavailability and is well
tolerated. The company plans to pursue the compound for the treatment of neuropathic
pain.198
5.4 Evaluation of Novel Cannabinoids as Anti-Inflammatory Agents
5.4.1 Initial Study

In order to exploit the therapeutic potential of our cannabinoid ligands as possible
anti-inflammatory agents, we designed a preliminary in vitro study to determine what
effects we could observe. We chose to use cytokine and chemokine production as
markers for inflammation. We chose six of our novel synthetic cannabinoids (along with
Δ8-THC) and screened them for anti-inflammatory activity against A-549 cells stimulated
with tumor necrosis factor alpha (TNF-α). The six compounds chosen represented six
different chemical classes (Figure 5.5). The previously described pyrimidine hexahydro
classical cannabinoid 37 was selected along with a similar compound that is a pyridine
hexahydro classical with the same dimethyl heptyl side chain 79 prepared in our
laboratory by Dr. Suni Mustafa. The non-classical triaryl compounds were represented
by HB-I-172, the pyrimidine nonclassical 50, and the equivalent pyridine non-classical
80 also prepared by Dr. Mustafa. The furanopyrimidine cannabinoids had not been
synthesized at this point, but Dr. Mustafa had begun on a series of furanopyridines – one
of which was included in this group 81. Cells were treated with vehicle, drug (at the
toxic EC1 or EC10), TNF-α, or a combination of TNF-α and drug. The cells were allowed
to incubate in the presence of the stimulus or drug for periods of 4 or 18 hours. The
media was then removed from the cells and flash frozen on dry ice. The samples were
then shipped to an independent laboratory for analysis of excreted cytokines and
chemokines.
The results of this preliminary study were quite promising. The efficacies of the
compounds were evaluated by the levels of the excreted cytokines IL-1β, IL-6, IL-8,
granulocyte colony stimulating factor (G-CSF), monocyte chemotactic protein-1 (MCP1), macrophage migration inhibitory factor (MIF), and RANTES (Regulated upon
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Activation, Normal T-cell Expressed, and Secreted). All of the compounds screened
exhibited an attenuation of the inflammatory response manifesting as a reduction in the
excretion of one or more of the pro-inflammatory cytokines assayed for (data not shown).
This positive result prompted the design of a study to pick leads from the various
chemical classes in our library to screen for anti-inflammatory activity. In order to select
leads we first had to define criteria which we would use to make the selections. It was
decided to use functional activity as the criterion with which to narrow the compounds.
We would first screen a vast number of compounds from the library for functional
activity at the CB1 and CB2 receptors. We would then select compounds that matched
the functional profiles of the seven compounds screened in the initial study. The list of
candidates would then be reduced based on solubility and/or toxicity data. We would
then examine the cytokine and chemokine release profiles of human macrophage and
dendritic cell lines challenged with lipopolysaccharide (LPS, to simulate a gram negative
infection) or peptidoglycan (PGN, to simulate a gram positive infection) and human
epithelial and endothelial cell lines challenged with TNF-α or IL-1β. The candidates
would then be screened for their ability to modulate the excretion of cytokines and
chemokines in our in vitro models. The one or two compounds that proved to be most
efficacious would then be moved into an in vivo inflammatory model such as bacteremia
or sepsis. The overall design of the study is summarized in Figure 5.6.
5.4.2 Selection of Compounds to Screen

In order to select lead compounds from our chemically diverse library of
cannabinoid ligands, it was necessary to first develop functional profiles for the initial
seven compounds in order to develop the paradigm used for selection. It was presumed
that since all seven compounds exhibited anti-inflammatory activity that they would each
have similar functional activity patterns. This proved to be an incorrect assumption. To
develop the functional profiles, we screened each compound in our functional assay
platform for the CB1 and CB2 receptors at 10µM. The assay determines a compound’s
ability to affect the alpha-agonist stimulated production of cAMP. Since CB1 and CB2
signal through Gαi, an agonist will decrease the amount of cAMP produced, and agonist
will have no effect, and an inverse agonist will increase the production of cAMP. The
profiles for each of the initial seven compounds are shown in Figure 5.7. The data is
presented as a percentage of the cAMP production compared to a control. Higher agonist
activity presents as a lower percentage. Lesser agonist activity or antagonism presents a
percentage closer to 100 and inverse agonist activity will give percentages greater than
100. The compounds clearly have varied functional activity at CB1 and CB2. Δ8-THC
along with compounds 37 and 79 has greater agonist activity at 10µM at the CB1
receptor than at CB2. In fact, THC appears to be an antagonist and possibly even an
inverse agonist in our assay platform. HB-I-172, as previously described, is an antagonist
at CB1 and an inverse agonist at CB2. The remaining compounds (50, 80, and 81)
exhibited very little if any agonist activity at CB1 and moderate agonist activity at CB2.
The observed differences in the functional profiles of these compounds could point to the
possibility that agonists of either the CB1 or CB2 receptors are efficacious in reducing
the inflammatory response, or that possibly there is another target involved such as
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Figure 5.7: Functional profiles of initial seven compounds screened for antiinflammatory activity

Compounds were screened using the ActOne© whole cell functional assay for the CB1
and CB2 receptors. The assay measures a compound’s ability to alter cAMP production
stimulated by an alpha agonist. The lower the percentage of control, the greater ability of
the compound to suppress the formation of cAMP; therefore, the greater the agonist
activity at the given receptor. Percentages closer to 100 represent lower agonist activity
or antagonist activity. Percentages above 100 represent activity of an inverse agonist.
Data represents a minimum of three experiments run in triplicate.
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GPR55. The fact that HB-I-172 showed preliminary efficacy strengthens the possibility
that CB2 inverse agonists may be viable candidates for the treatment of inflammatory
disorders.
Since there was no clear pattern with which to use as a screening criterion, we
chose to develop functional profiles for a large number of our compounds and select a
number that had a variety of functional activities. Initially, we screened seventy-five
compounds from eight distinct structural classes. The classes were the triaryls, pyridine
triaryls, pyrimidine triaryls, pyridine hexahydros, pyrimidine hexahydros, benzofurans,
furanopyridines, and the furanopyrimidines. Out of the seventy-five screened, forty-four
compounds were carried forward. These compounds were then screened for toxicity
against human dermal fibroblasts at 10, 25, and 50µM (data not shown). The compounds
that exhibited the greatest toxicity at the lowest doses were eliminated. The remaining
compounds were further narrowed based on solubility. The compounds that visibly
precipitated at the 50µM concentration in the cytotoxicity assay were also eliminated.
This narrowed down the field significantly and one compound was chosen from each
class (Figure 5.8) to carry forward into the in vitro inflammation assays.
5.4.3 Cytokine and Chemokine Release Profiles

I initially decided to utilize a total of four cell lines in the anti-inflammatory
study. Two cell lines were used to model cells of the immune system: THP-1 and KG-1.
THP-1 is a human monocytic leukemia cell line that can be differentiated into a
macrophage-like phenotype and KG-1 is a human lymphoblastic leukemia line that can
be differentiated into a dendritic cell phenotype. Cells of the epithelial and endothelial
lineages that also play roles in the inflammatory response were also to be studied. A-549,
a human epithelial lung carcinoma cell line, was chosen to model the epithelial response
and the human vascular endothelial cell line HUV-EC-C was selected to model the
endothelial inflammatory response.
We decided to utilize the previously described MSD® technology to measure the
cytokine and chemokine levels in-house. We selected two types of analysis plates for our
studies. The first was the Human ProInflammatory 9-PlexTissue Culture Kit which
measures the quantitative levels of nine cytokines, namely: IL-1β, Il-2, IL-6, IL-8, IL-10,
IL-12 p70, TNF-α, IFN-γ, and GM-CSF (granulocyte-macrophage colony-stimulating
factor). To measure chemokine production, the Human Chemokine 9-PlexTissue Culture
Kit was chosen which assays for Eotaxin, Eotaxin-3, IL-8, IP-10 (10 kDa interferongamma-induced protein), MCP-1, MCP-4, MDC (macrophage-derived chemokine), MIP1β (macrophage inflammatory protein-1 beta), and TARC (thymus and activation
regulated chemokine).
In order to test the ability of our assay design to detect the levels of excreted
cytokines and chemokines, we initially collected time-course release profiles of each cell
line challenged with two different stimuli. This would also give us information as to the
optimum time point to use for screening our compounds. The THP-1 and KG-1 cell lines
grow in suspension and must be transformed to attach and take on the macrophage and
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dendritic cell phenotypes, respectively. This is accomplished by incubating the cells in
the presence of phorbol 12-myristate 13-acetate (PMA, 10ng/ml) and ionomycin
(500ng/ml) for a minimum of 5 days. The transformed cells, along with non-transformed
THP-1 and KG-1 for comparison, were challenged with LPS or PGN at 1µg/ml and the
supernatant media was assayed at 10 time points from 1 to 24 hours post stimulus for the
levels of the previously mentioned cytokines and chemokines. The same procedure was
performed with A549 and HUV-EC-C stimulated with TNF-α and IL-1β. A
representative graph is shown in Figure 5.9. This data demonstrates the release of IL-6
from transformed and non-transformed THP-1 in response to LPS over the 24 hour
experiment. The entire data set is included in Appendix A. From the time-course
experiments we were able to validate the assay platform and to draw some conclusions
that helped to shape the remainder of the experiments:
1. There is a detectable, time-dependent release of cytokines and chemokines
from the human cell lines THP-1, KG-1, A549, and HUV-EC-C.
2. The cytokines and chemokines reached maximum or near maximum levels at
18 hours post stimulus.
3. THP-1 exhibited a more pronounced response than did KG-1.
4. LPS elicited a greater response from THP-1 and KG-1 than did PGN.
5. The responses elicited from A549 and HUV-EC-C from TNF-α and IL-1β
were comparable.
5.4.4 Screening of Initial Eight Compounds

With the information gained from the cytokine/chemokine release profile
experiments, the screening of the eight selected compounds was planned. Due to the
lesser response of the transformed KG-1 cells, it was decided to use only the THP-1 cell
line to model cells of the immune system and to continue with both A549 and HUV-ECC. Each of the eight compounds was screened for toxicity against the three cell lines, the
EC50s were determined, and the EC10s calculated. The compounds were then screened
for their abilities to attenuate the inflammatory response in THP-1 stimulated with LPS or
PGN and in A549 and HUV-EC-C stimulated with TNF-α or IL-1β. The drugs were
screened at the EC10 or 25µM (whichever was less) and cytokine/chemokine levels were
measured 18 hours post stimulus and drug treatment.
Each compound was capable of attenuating the inflammatory response on
multiple cell lines as manifested by decreases in the levels of multiple secreted cytokines
and chemokines. The entire data set from this series of experiments can be found in
Appendix B. Significant effects were seen in a number of inflammatory markers; for
example, in the transformed THP-1 cell line decreases in the cytokine IFN-γ were
observed for all compounds tested in the PGN group and five of the eight compounds
tested in the LPS group (Figure 5.10). The significance of this effect is that IFN-γ can
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Figure 5.9: Time-dependent release of IL-6 from THP-1 stimulated with LPS
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Figure 5.10: Effects of eight compounds on release of IFN-γ from THP-1 in response to
LPS and PGN

* = p < 0.05, ** = p < 0.01, and *** = p < 0.005.
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further activate macrophages and lead to an increased synthesis and release of proinflammatory cytokines and chemokines.199 Significant results were also seen with THP1 in the levels of IL-12p70 and IL-6 produced in response to both LPS and PGN (Figures
5.11 and 5.12, respectively). IL-12p70 is a cytokine that can further activate
macrophages; however, its main function is the activation of NK cells200 and
differentiation of naïve T cells.201 Upon exposure to IL-12, T and NK cells are
stimulated to produce and release the pro-inflammatory cytokines IFN-γ and TNF-α
which further perpetuate the inflammatory response. IL-6 is a major pro-inflammatory
mediator produced mainly by macrophages that elicits a wide range of responses such as
lymphocyte activation, increased antibody production, fever, and production of acute
phase proteins by hepatocytes. Overproduction of IL-6 has also been implicated in a
number of autoimmune disorders such as rheumatoid arthritis.202 Still further positive
results were seen in the PGN stimulated THP-1 cells as evidenced by reductions in GMCSF, IL-1β, and TNF-α and increases in the anti-inflammatory cytokine IL-10 (Figures
5.13 and 5.14). GM-CSF increases the production of granulocytes and monocytes and
increases monocyte adhesion.203 TNF-α and IL-1β each produce a wide range of
inflammatory responses such as increased expression of adhesion molecules on
endothelial cells and increases in vascular permeability.204 The increased production of
IL-10 following exposure to PGN and five of the eight compounds tested is of interest
due to the anti-inflammatory role of IL-10 which inhibits the synthesis of proinflammatory mediators such as IFN-γ, IL-2, IL-3, TNF-α and GM-CSF.205
Attenuations in the production of cytokines were also observed in the HUV-EC-C
endothelial cell line. Examples are reductions in GM-CSF and IL-6 in response to TNF-α
(Figure 5.15) and reductions in IFN-γ, IL-12p70, and IL-2 in response to IL-1β (Figure
5.16). IL-2 is a cytokine normally produced by activated T cells and stimulates the
growth and differentiation of antigen-selected cytotoxic T cells and is required for the
development of T cell immunologic memory.206 The significance of the lower levels of
IL-2 produced by endothelial cells is not known.
There were also several noteworthy observations in the levels of chemokines
following stimulus and drug exposure. For example, reductions in the production of
MIP-1β were detected following both TNF-α and IL-1β challenge in both A549 (Figure
5.17) and HUV-EC-C (Figure 5.18). MIP-1β has many varied functions in the
inflammatory process. It activates neutrophils, eosinophils, and basophils. It also attracts
NK, T, and dendritic cells to sites of infection.207 It also induces the synthesis and release
of other pro-inflammatory cytokines from fibroblasts and macrophages.208 MIP-1β is
generally produced by macrophages and T cells, and as previously stated in regards to IL2, the significance in the attenuation of the lower levels of MIP-1β produced from
endothelial and epithelial cells cannot be speculated. Interestingly, the production of
MIP-1β from the macrophage-like transformed THP-1 cell line was not significantly
affected by any of the eight compounds tested. Significant reductions in the chemokine
IP-10 were also observed for both A549 and HUV-EC-C after TNF-α challenge (Figure
5.19). IP-10 attracts monocytes/macrophages, NK, T, and dendritic cells to sites of
infection and also promotes T cell adhesion to endothelial cells.209 The triaryl HB-I-172
was also found to decrease the production of IL-8 from HUV-EC-C stimulated with
either TNF-α or IL-1β (Figure 5.20). IL-8 is another major pro-inflammatory mediator.
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Figure 5.11: Effects of eight compounds on release of IL-12p70 from THP-1 in response
to LPS and PGN

* = p < 0.05 and ** = p < 0.01.
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Figure 5.12: Effects of eight compounds on release of IL-6 from THP-1 in response to
LPS and PGN

* = p < 0.05, ** = p < 0.005, *** = p < 0.001, and **** = p < 0.0005.
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Figure 5.13: Effects of eight compounds on release of GM-CSF and IL-1β from THP-1
in response to PGN

* = p < 0.05, ** = p < 0.005, *** = p < 0.0005, and **** = p < 0.0001.
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Figure 5.14: Effects of eight compounds on release of IL-10 and TNF-α from THP-1 in
response to PGN

* = p < 0.05, ** = p < 0.01, *** = p < 0.005, and **** = p < 0.001.
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Figure 5.15: Effects of eight compounds on release of GM-CSF and IL-6 from HUVEC
in response to TNF-α

* = p < 0.05, ** = p < 0.01, and *** = p < 0.005.
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Figure 5.16: Effects of eight compounds on release of IFN-γ, IL-12p70, and IL-2 from
HUVEC in response to IL-1β

* = p < 0.05 and ** = p < 0.005.
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Figure 5.17: Effects of eight compounds on release of MIP-1β from A549 in response to
TNF-α and IL-1β

* = p < 0.05, ** = p < 0.005, and *** = p < 0.001.
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Figure 5.18: Effects of eight compounds on release of MIP-1β from HUVEC in response
to TNF-α and IL-1β

* = p < 0.05 and ** = p < 0.005.
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Figure 5.19: Effects of eight compounds on release of IP-10 from A549 and HUVEC in
response to TNF-α

* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001, and ***** = p < 0.0005.
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Figure 5.20: Effects of eight compounds on release of IL-8 from HUVEC in response to
TNF-α and IL-1β

* = p < 0.05.
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One of its main functions in the inflammatory response is to recruit neutrophils. Upon
exposure to IL-8, neutrophils are mobilized and activated which is necessary for
degranulation and the respiratory burst.210 Reductions in the chemokine MCP-1 were
also observed in THP-1 (Figure 5.21) following LPS stimulation and in HUV-EC-C
(Figure 5.22) following both TNF-α and IL-1β stimulation. MCP-1 activates
macrophages, recruits monocytes, eosinophils, and basophils, and triggers histamine
release from basophils.211 The action of this chemokine has been implicated in allergy,
asthma, and arthritis, and a treatment that could effectively reduce the levels of this
protein could be useful in those conditions.212
5.4.5 Dose Response of Four Lead Compounds

We decided to determine if the observed reductions in cytokines and chemokines
due to the eight cannabinoids screened were dose dependant. The eight compounds were
further narrowed down to four based on the compounds’ overall effects of the cytokine
and chemokine panels. The four that were chosen were the triaryl HB-I-172, the
pyrimidyl and pyridyl hexahydros 37 and 79, and the benzofuran 83 (Figure 5.23). Two
cell lines were chosen for the dose response study: THP-1 and HUV-EC-C and the
compounds were screened in four escalating doses based on each compound’s EC50
against each cell line. The highest concentration for each compound was the EC10 or
25µM, whichever was lower.
Many of the drugs exhibited a dose dependent suppression of cytokine and
chemokine release from THP-1 stimulated with LPS and HUV-EC-C stimulated with
TNF-α. The complete data set from this experiment may be found in Appendix C.
Some examples of the dose dependent reduction are shown in Figures 5.24 and 5.25.
The first graph depicts the dose dependent reduction in synthesis and secretion of Eotaxin
and MCP-4 from THP-1 cells in response to HB-I-172 treatment post LPS exposure. The
second graph shows the dose dependent reduction in Eotaxin-3 and TARC from THP-1
cells in response to treatment with the benzofuran 83. Interestingly, for some cytokines
and chemokines, there was a greater reduction in levels due to the lowest concentration of
certain drugs (see Appendix C).
5.4.6 Further Evaluation of HB-I-172

HB-I-172 was selected out of the four compounds screened due to its broad
spectrum anti-inflammatory activity across the cell lines tested and also due to its novel
inverse-agonist activity at the CB2 receptor coupled with being an antagonist at CB1.
The previously described anti-inflammatory studies, with the exception of HUV-EC-C,
utilized cancerous cell lines. The known abnormalities in the signaling cascades of
cancers can overlap with the inflammatory pathways within the cell. For example the
Akt and ERK pathways have been shown to be one signaling mechanism leading to NFκβ translocation to the nucleus.213
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Figure 5.21: Effects of eight compounds on release of MCP-1 from THP-1 in response to
LPS
* = p < 0.05.
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Figure 5.22: Effects of eight compounds on release of MCP-1 from HUVEC in response
to TNF-α and IL-1β

* = p < 0.05, ** = p < 0.001, and *** = p < 0.0005.
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Figure 5.23: Four compounds chosen for dose response study
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Figure 5.24: Examples of dose dependent reductions in chemokines produced by THP-1
after treatment with HB-I-172
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Figure 5.25: Examples of dose dependent reductions in chemokines produced by THP-1
after treatment with compound 83
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In order to test HB-I-172 in a system that more closely resembles the responses of
an in vivo environment, three human primary cell lines were used. HB-I-172 and the
thiphenyl analog SMM-I-229 (Figure 5.26) were screened against human lung blood
microvasculature endothelial cells (HMVEC-LBI, Lonza, Inc.), human small airway
epithelial cells (SAEC, Lonza, Inc.), and human monocyte derived macrophages (AllCell,
Inc.). SMM-I-229 possesses the same inverse agonist activity at CB2 as HB-I-172 and is
also an antagonist at CB1.
Cytokine and chemokine release profiles were determined for the three cell lines,
as with the initial experiments, and EC50s were then determined for the two compounds
against the cell lines. See Appendix D for the complete set of release profiles. The antiinflammatory assays were then carried out as before. The HMVEC-LBI and SAEC cell
lines were stimulated with TNF-α and the primary macrophages were stimulated with
LPS before drug treatment. The supernatant media was then assayed 18 hours later for
levels of the same cytokines and chemokines. The complete set of graphs can be found
in Appendix E. While the effects of HB-I-172 on the three primary cell lines were
different than in the original cell lines tested, there were reductions in several of the proinflammatory cytokines and chemokines assayed for.
In order to test the possible contributions of cannabinoids in the treatment of
neurological inflammatory disorders such as meningitis, Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, and neuropathic pain, we next tested HB-I172 and the CB1 agonist/CB2 antagonist classical cannabinoid KM-233 primary human
microglia (Clonexpress) challenged with LPS. Again, the first step was to determine
cytokine and chemokine release profiles for the cell line due to LPS exposure (Appendix
F). The EC50s were then determined for the two drugs against the cells and the assay
performed as before. HB-I-172 reduced the levels of a majority of the cytokines and
chemokines assayed including IFN-γ, IL-6, and MCP-1 which have all been found to
play roles in a number of neuro-inflammatory conditions214 (Appendix G). KM-233 also
performed well in this assay. There were, however, differences in the anti-inflammatory
profile of the two drugs, probably due to the different functional activities at the
cannabinoid receptors.
In order to strengthen the case for the use of CB2 inverse agonists as antiinflammatory agents, we chose to compare HB-I-172 to the clinically utilized antiinflammatory drug dexamethasone. HB-I-172 was compared to dexamethasone in the
THP-1 cell line stimulated with LPS and in A549 and HMVEC-LBI stimulated with
TNF-α. In the majority of cytokines and chemokines assayed for, HB-I-172 performed as
well or better than dexamethasone (See Appendix H for complete data set).
In conclusion, we have demonstrated that HB-I-172 is a viable candidate for
development as an anti-inflammatory agent. The compound has exhibited in vitro
reductions in the production and secretion of a wide range of cytokines and chemokines
from a variety of cell types involved in the inflammatory process. Not only have we
demonstrated that the compound is efficacious in standard inflammatory models using
cancerous cell lines (THP-1, KG-1, and A549) but that this activity also translates into
efficacy when normal human primary cells are utilized and when compared to a standard
therapy. A number of future studies are planned to further evaluate the utility of HB-I197
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Figure 5.26: CB2 inverse agonists screened as anti-inflammatory agents against human
primary macrophages, epithelial, and endothelial cells
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172 as an anti-inflammatory agent. These include an experiment to test the compound’s
ability to favorably modulate the immune response of T and B cells by observing the
effects on antigen receptor-dependent activation using murine splenocytes, an in vivo
endotoxemia model, and murine models of Huntington’s disease, multiple sclerosis, and
neuropathic pain. Future studies are also planned to determine the exact molecular target
of HB-I-172 that is responsible for the anti-inflammatory activity and the signaling
pathway that this activates. Knowledge gained from the work with HB-I-172 in the
treatment of glioblastoma (Chapter 3) gives us some clues as to possible signaling
mediators involved. As stated earlier, the Akt and ERK pathways have been shown to be
one signaling mechanism that leads to NF-κβ translocation to the nucleus during the
inflammatory response. The profound effects of HB-I-172 on the PI3K/Akt and
Raf1/MEK/ERK pathways in glioma may also be found in cells treated with the
compound following inflammatory challenge. As observed in glioma, the effects of HBI-172 on STAT3 and GSK-3β may also play a role, as each of these proteins has been
shown to be mediators of inflammation.215 We also believe that the possible interaction
of HB-I-172 with the GPR55 receptor may contribute to its action as RhoA has been
shown to contribute to NF-κβ-dependent proinflammatory gene transcription.216
5.5 Experimental Methods
5.5.1 Transformation of THP-1 and KG-1

Differentiation of Monocytes: To THP-1 human leukemia monocytes (ATCC
#TIB-202) or KG-1 human leukemia myeloblasts (ATCC #CCL-246) in suspension was
added phorbol 12-myristate 13-acetate (PMA Aldrich #P1585) and ionomycin (Aldrich
#I0634), 10 and 500 ng/ml respectively, to induce differentiation into macrophage-like or
dendritic-like cells, respectively. Cells were seeded at 30,000 cells/well in a 96-well
polystyrene dish and allowed to incubate at 37°C in 5% CO2 / 95% air for 5-10 days to
complete transformation. Media was refreshed as needed until assay.
5.5.2 Cytokine and Chemokine Assays

A549 (ATCC #CCL-185), HUV-EC-C (ATCC #CRL-1730), HMVEC-LBI
(Lonza #CC-2815), SAEC (Lonza #CC-2547), monocyte derived macrophages (AllCells
#PB-MDM-001F), microglia (Clonexpress #HMG 030), or differentiated THP-1 or KG-1
cells were maintained according to suppliers recommendations and were seeded on 96well polystyrene plates at a density of 300,000 cells/ml (100μL per well) and incubated at
37°C in 5% CO2 / 95% air for 24 hours to allow cell attachment. Drug solutions were
prepared in DMSO at 100x concentration and mixed 1:100 in media containing 1% FBS
to yield the desired concentration. Plates were then removed from the incubator and the
complete growth media was replaced with 50μL media containing 1% FBS and
lipopolysaccharide or peptidoglycan at 1 μg/ml (for macrophages, microglia, or
differentiated THP-1 or KG-1), or TNF-α (10ng/ml) or IL-1β (1 ng/ml) in the case of
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A549, HUV-EC-C, HMVEC-LBI, or SAEC or without stimulus in the case of control
wells. Cells were returned to the incubator for 1 hour before drug treatments. Drugmedia solutions were prepared at 2x desired final concentration in media containing 1%
FBS and the appropriate stimulus at the previously mentioned concentration. Control
media was also prepared which contained only vehicle (DMSO). 50μL of media
containing drug or vehicle alone was then added to appropriate wells and the plates
returned to the incubator for 18 hours. Media supernatants were then assayed for
cytokines and chemokines using the Human ProInflammatory 9-PlexTissue Culture Kit
(MSD # K15007B-1) and the Human Chemokine 9-PlexTissue Culture Kit (MSD #
K15001B-1) according to the manufacturer’s protocol. The plates were then imaged on
the SECTOR Imager 2400 (Meso Scale Dscovery) according to the manufacturer’s
instructions.
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Appendix A: Cytokine and Chemokine Release Profiles of THP-1, KG-1, A549, and
HUV-EC-C
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Appendix B: Effects of Eight Cannabinoids on Cytokine and Chemokine Release of
THP-1, A549, and HUV-EC-C
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Appendix C: Dose Response of Four Cannabinoids on Cytokine and Chemokine
Release of THP-1 and HUV-EC-C
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Appendix D: Cytokine and Chemokine Release Profiles of HMVEC-LBI, Monocyte
Derived Macrophages, and SAEC
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Appendix E: Effects of HB-I-172 and SMM-I-229 on the Cytokine and Chemokine
Release of HMVEC-LBI, Monocyte Derived Macrophages, and SAEC
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Appendix F: Cytokine and Chemokine Release Profiles of Primary Human
Microglia
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Appendix G: Effects of HB-I-172 and KM-233 on the Cytokine and Chemokine
Release of Primary Human Microglia
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Appendix H: Comparison of the Effects of HB-I-172 to Dexamethasone on the
Cytokine and Chemokine Release of THP-1, A549, and HMVEC-LBI
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